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Chapter 1 
 
 
 
 
General introduction and  
 
Outline of this thesis
General introduction 
LPS 
Endotoxin or lipopolysaccharide (LPS) is a constituent of the outer membrane of Gram-negative  
bacteria and is released in the bloodstream from the cell wall of growing or damaged bacteria. 
When released, it evokes an overwhelming spectrum of biological activities and LPS is considered 
the most powerful microbial stimulant of immune and non-immune cells. As an example for non-
immune cells, vascular endothelial cells become activated in the presence of LPS which result in 
endothelial dysfunction.  
The immune system responds to LPS with a systemic production of pro-inflammatory cytokines, 
such as TNF and IL-6, aimed to eliminate invading pathogens. Although these pro-inflammatory 
cytokines are indispensable for the control of the growth and dissemination of the pathogen, 
overproduction of these cytokines, together with LPS-induced effects on endothelial cells, results 
in the clinical symptoms of systemic inflammatory response syndrome (SIRS), septic shock and 
multiple organ failure. LPS administration to healthy volunteers can produce a controlled and 
profound systemic model of inflammation which is more than suitable for investigational 
purposes. Indeed, administration of endotoxin has been shown to mimic many of the clinical 
symptoms of septic shock1.   
 
Endotoxin tolerance 
Richard Pfeiffer used the term endotoxin for the first time in 1904. His experiments led him to 
formulate the concept that V. cholerae harbored a heat-stable toxic substance that was 
associated with the insoluble part of the bacterial cell. He called this substance endotoxin from 
the Greek word ‘endo’ meaning ‘within’. 
It was observed in the 1960s that animals receiving a low dose pre-exposure of LPS had a 
markedly reduced mortality when challenged with a “lethal” injection of LPS2, a phenomenon 
called “endotoxin tolerance”. However, history shows that this phenomenon was not a new 
finding as Paul Beeson was the first to describe endotoxin tolerance in 19463. When typhoid 
vaccine was administered to patients with neurosyphilis as a pyrogen to induce fever as part of 
therapy, as fever was known to slow the progress of Treponoma pallidum infection. With 
repeated administration the vaccine showed progressive loss of efficacy as a pyrogen, and an 
increase in dose was required to achieve the same fever effect.  
 
Since then many authors described the phenomenon of endotoxin tolerance and called it hyper-
inflammation, compensatory anti-inflammatory response syndrome (CARS), mixed antagonist 
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response syndrome (MARS), SIRS, immunoparalysis, monocyt deactivation, anergy, 
immunodepression and leukocyte reprogramming.  
 
Mechanisms of endotoxin tolerance 
The mechanisms of LPS-induced tolerance are complex and probably involve many signaling 
components. Toll-like receptor-4 (TLR-4), the primary receptor for LPS, was found to be involved 
in LPS signaling transduction and to play a pivotal role in the development of endotoxin 
tolerance. Quantitative, structural and functional changes of receptors, adaptor proteins and 
transcription factors in TLR-4 signaling pathways might have effects on the observed decrease in 
pro-inflammatory cytokines, increased release of anti-inflammatory cytokines and activation of 
alternative signaling pathways as well as some negative regulatory factors during the 
development of endotoxin tolerance.  
 
EXTRACELLULAR SIGNALING PATHWAYS 
Desensitizing agents in plasma 
Twenty-five years ago, Freedman showed that endotoxin tolerance could be transferred by 
administering plasma from endotoxin tolerant donors, suggesting that circulating mediators that 
facilitate tolerance are present and may contribute to the resultant hyporeactivity of circulating 
leukocytes4. Other extracellular mechanisms may also play a role as there is accumulating 
evidence for a strong interaction between components of the nervous and the immune system. 
Various neuromediators have been shown to behave as immunosuppressors, for example, 
catecholamines, alpha-melanocyte-stimulating hormone, glucocorticoids, prostaglandins, heat 
shock proteins, vasoactive intestinal peptide, lipoproteins and pituitary adenylate cyclase-
activating polypeptide are known to limit cytokine production5-11.  
More recently it has been proposed that adenosine di- and tri-phosphate (ADP and ATP) are 
released extracellular in large quantities during sepsis or septic shock and that they also exert 
anti-inflammatory effects12. 
Nitric oxide (NO) is an important signaling molecule in a large variety of physiological processes 
such as thermoregulation and endothelial function. Stimulation of cells with LPS leads to 
production of pro-inflammatory cytokines and upregulation of inducible NO synthase (iNOS), a 
precursor of NO production. Various studies suggest that the protection afforded by endotoxin 
tolerance is mediated by upregulation of NO synthesis based on experiments performed in 
rats13;14, rabbits15 and mice16;17. Inhibition of NO-synthase abrogated the beneficial effects of 
endotoxin tolerance, whereas administration of NO donors induced a tolerance-like state and 
protected against the lethal effect of endotoxin18.  
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Cytokines 
Human in vitro and animal experiments conducted in the past 20 years demonstrated a 
differential response of various cytokines to subsequent LPS exposure characterized by an 
attenuated pro-inflammatory response and an unaltered or even enhanced production of anti-
inflammatory cytokines such as IL-1019;20, TGFß21;22 and IL-1ra21 leading to the “anti-inflammatory 
hypothesis of endotoxin tolerance”.  
IL-10 and TGFß have shown to have synergistic effects for inducing LPS hyporesponsiveness in 
vitro, and when administered during the pretreatment period, both IL-10 and TGFß completely 
obliterated the initial effects of LPS21-23. Furthermore, administration of anti-IL10 and anti-TGFß 
monoclonal antibodies prevented induction of LPS tolerance21. However, the role of IL-10 is 
controversial and eventually IL-10 knock-out mice showed the dispensability of this cytokine in the 
development of endotoxin tolerance24.  
Experiments in which IL-1ra was administered to mice, showed that IL-1 is also an intermediate in 
the development of LPS tolerance as it could reverse the induction of tolerance, however only 
partially25. IL-1 pretreatment protected rabbits against LPS-induced hypotension26. However, IL-1ra 
production appears to be differentially affected as increased production was observed in septic 
patients27 and attenuated levels were found in isolated macrophages from SIRS patients28. 
 
Suppressor of cytokine signaling proteins  
The family of suppressor of cytokine signaling proteins (SOCS) was described originally to provide 
a negative-feedback system by interfering with the Janus tyrosine kinase (JAK)-STAT signaling 
pathway. SOCS-1 protein is one of eight members of the SOCS family that regulates various 
aspects of the innate immunity. SOCS-1 is upregulated by various cytokines and its function is to 
inhibit cytokine signaling activities and is therefore critical for the regulation of LPS tolerance29-31 
as it protects the host from harmful over-responses to LPS32. Furthermore, SOCS-1 knock-out mice 
exhibit increased LPS sensitivity, associated with elevated TNFα production and lack of the 
development of LPS tolerance31. 
 
CD4+CD25+ T-regulatory cells (Treg cells) 
During endotoxin tolerance T-cells become unresponsive in terms of proliferation shown in whole 
blood of septic and trauma patients, which show that all lymphocyte T cell lineages are 
attenuated with the exception of one cell line: the Treg cells, which are actually increased in 
numbers. Human Treg cells have been characterized as suppressor T cells and they are required 
for the maintenance of inflammatory reactions to commensally bacteria and opportunist 
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pathogens. These cells are involved in closing down immune responses after they have 
successfully tackled invading organisms.  
Of the 10 known TLR genes, TLR-4, -5, -7 and –8 are selectively expressed in Treg cells33 and this 
suggests that a rather large universe of inflammation-related endogenous and pathogen-
associated molecules might directly modulate Treg cells activities. 
 
Heat shock proteins  
Besides hyperthermia, it has been shown that various other forms of cellular stress, such as 
ischemia-reperfusion injury and exposure to endotoxin, are capable of inducing the same heat 
shock response. The heat shock response consists of expression of a family of highly conserved 
proteins known as heat shock proteins. It was postulated that the release of HSP70 may serve as 
a danger signal to the innate immune system and increased levels of HSP70 were indeed 
observed in children with septic shock34. HSP70 activates a CD14-dependent mechanism35 and 
TLR-4 is thought to be involved. HSP70 suppresses nuclear factor kappa B (NFκB) via stabilization 
of inhibitor of kinase Bα protein (IκBα) through prevention of inhibitory kinases (IKK)36-38 complex 
activation and inhibition of IκBα degradation38. Pretreatment with HSP-70 induced tolerance to 
LPS in human monocyte11;39 and HSP70 conferred protection during endotoxemia38. 
 
Heme oxygenase  
The microsomal enzyme heme oxygenase (HO) catalyzes the oxidation of heme to bilirubin, 
ferrous iron, and carbon monoxide (CO) and is widely distributed in mammalian tissues. Three 
isoforms have been identified: HO-1 the inducible form (also known as heat shock protein 32), HO-
2 the constitutive form and HO-3. HO-1 expression is extremely sensitive to a variety of agents that 
cause oxidative stress, such as hypoxia and cytokines. HO-2 is a constitutive isoform which is 
expressed under homeostatic conditions. Both HO-1 and HO-2 are ubiquitously expressed and 
catalytically active. HO-3 is not catalytically active, but is thought to work in oxygen sensing.  
HO-1 responds to induction by a wide variety of stimuli associated with oxidative stress, such as 
hypoxia, cytokines, NO, heat shock and shear stress40. The multiplicity of toxic inducers suggests 
that HO-1 may function as a critical cytoprotective molecule. Indeed, increasing experimental 
evidence suggests that in sepsis, the HO pathway is a powerful protective system and the 
transcriptional upregulation of HO-1 is found to limit tissue damage in response to pro-
inflammatory stimuli. The mechanisms by which HO-1 provides protection most likely involves its 
enzymatic reaction products.  
Concerning endotoxin tolerance, administration of a HO-pathway inducer before the final of 3 LPS 
administrations in rats resulted in an enhanced instead of attenuated fever response, with a full 
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reversal of this response after administration of an HO-pathway inhibitor41. Cytokines are thought 
to be responsible as it has been demonstrated that IL-1, IL-6 and TNFα have properties of inducing 
HO activity42-44, most of which are attenuated during endotoxin tolerance.  
 
LPS RECEPTOR 
TLR recognize specific pathogen-associated molecular patterns. Ten members of the so-called 
TLR family have been identified in humans so far, and several of them recognize specific microbial 
products, including LPS. Recognition leads to activation of the intracellular Toll-IL-1R (TIR) domain 
which is essential for signal transduction. 
TLR-1 appears to be expressed predominantly on monocytes, neutrophils, B-cells, and natural 
killer cells. TLR-2 is found in substantial amounts on monocytes and neutrophils, but also on 
dendritic cells. TLR-3 is found almost exclusively on dendritic cells. TLR-4 mRNA is expressed in 
endothelial cells, monocytes, neutrophils, and dendritic cells. Most prominent, the TLR-4 has been 
found to signal for the endotoxin of gram-negative bacteria, whereas the TLR-2 has been shown 
to signal the presence of bacterial lipoproteins and lipoteichoic acids from gram-positive bacteria. 
Regulation of TLR-2 and -4 expressions by LPS is considered to be one of the mechanisms by 
which the overall response of immune cells to bacteria is controlled.  
Upregulation of TLR-4 may play a role in the pro-inflammatory response and pathophysiology of 
polymicrobial sepsis and has been shown in human monocytes in vitro derived from intensive care 
and SIRS patients in response to low dose LPS compared to controls. A decrease in inflammatory 
cytokine production in tolerant macrophages correlated well with downregulation of the surface 
TLR-4 expression, which may explain part of the mechanism for LPS tolerance. However, total 
disruption of the TLR-4 receptor is unlikely during LPS tolerance, since LPS tolerant human 
macrophages can still respond to further LPS challenge and express many other genes and 
proteins. Therefore, impaired function of intracellular signaling is also present, not solely a defect 
or downregulation of the TLR receptor.  
 
INTRACELLULAR SIGNALING PATHWAYS 
LPS induces cellular responses by complexing with circulating LPS-binding protein (LBP) and 
subsequently binding to CD14. The LPS receptor complex consists of two interacting receptors 
CD14 and TLR-4 and an associated protein MD-2.  
Activation of TLR-4 by LPS triggers binding of MyD88 via MyD88 adapter-like (Mal) to the 
intracellular portion of the receptor and initiates intracellular signaling that evolves by 
recruitment of IL-1 receptor-associated kinase 4 (IRAK4) and subsequent association and 
phosphorylation of IRAK1. Binding of TNF receptor-associated factor 6 (TRAF6) to 
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phosphorylated IRAK1 induces the dissociation of IRAK1/TRAF6 from the receptor to form a 
plasma membrane-bound complex with TGFß-activated kinase 1 (TAK1). Subsequent 
phosphorylation of TAK1 and degradation of IRAK1 at plasma membrane triggers release of the 
complex to the cytosol where TRAF6/TAK1 activates mitogen-activated protein kinases (MAPKs) 
and the IκB-kinase (IkK) complex. The IKK complex phosphorylates IκBα which leads to 
ubiquitylation and degradation of this NFκB inhibitor.  
NFκB liberated of its inhibitor translocates to the nucleus to induce the expression of its 
inflammatory target genes. In parallel, the induced MAPK pathway may generate phosphorylated 
p38MAPK involved in RNA stabilization of inflammatory genes and activator protein 1 (AP1) 
dependent transcriptional responses.  
LPS activation of TLR-4 also triggers a MyD88-independent response that is mediated by the TIR 
domain containing adaptor inducing IFNß (TRIF) and TRIF-related adaptor molecule (TRAM) 
complex. TRIF/TRAM-mediated signaling induces IKK-ε- and TBK1-dependent phosphorylation of 
IFN regulatory factor 3 and nuclear translocation of IFN regulatory factor 3 resulting in IFNß 
release and subsequent expression of type I IFN-inducible genes.  
Moreover, whereas TLR-4/MyD88 signaling is found to be responsible for early NFκB activity, TLR-
4/TRIF appears to be involved in late NFκB transcriptional activity after LPS administration45. 
 
Negative regulators of the intracellular signaling 
Various regulators that inhibit LPS signaling have been identified and SHIP22 and IRAK-M are 
potential mediators in LPS-induced tolerance. SHIP is produced in response to TGFß, exerting its 
inhibitory effects primarily through the hydrolysis of PI3K46. IRAK-M prevents the dissociation of 
IRAK1 and -4 from MyD88 and the formation of TRAF6 complexes47. In vitro studies in whole 
blood have shown that IRAK-M upregulation by LPS is largely dependent on TNFα production. 
However, an in vitro study with whole blood from a human endotoxemia model showed that 
IRAK-M levels were increased during LPS tolerance in vitro, as 6-8 hours post-LPS administration 
increased transcript levels of IRAK-M were observed while 24 hours post-LPS administration both 
IRAK-M levels and the presence of LPS tolerance had faded48. In monocytes of sepsis patients, 
IRAK-M is expressed more rapidly upon exposure to LPS compared with those of healthy 
controls49, and IRAK-M has been shown to be crucially involved in the fatal effects of pneumonia 
in mice with abdominal sepsis50.  
 
Nuclear level transcription 
NFκB can translocate into the nucleus an induce the transcription of genes coding for pro-
inflammatory proteins, such as TNFα, and NO. NFκB is therefore critical for expression of many 
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cytokines involved in the pathogenesis of inflammation. The NFκB family is composed of p50, p52, 
p65, reticuloendotheliosis viral oncogene related B (RelB) and c-Rel which can form homo- and 
heterodimers. P65p50 is thought to be the active heterodimer as opposed to p50p50, which is its 
inactive form. NFκB regulation of transcription can be divided into two phases. First, a cytosolic 
phase in which there is IκB kinase ß-dependent activation of IκBα followed by ubiquitine-directed 
IκB degradation that allows translocation of p50 and p65 into the nucleus. The second, or nuclear 
phase, involves events that result in depression of NFκB-dependent promoters, chromatin 
remodelling, and binding of transcriptional active p65 and p50 as a heterodimer to cognate DNA 
on enhancer and promoter elements.  
Activation and regulation of NFκB are tightly controlled by a group of inhibitory proteins (IκB) 
which maintain NFκB in the cytoplasm of effector cells.  
Various studies have demonstrated that, upon in vitro LPS activation, SIRS and septic patients 
show patterns of NFκB expression that resemble those reported during LPS tolerance: a global 
downregulation of NFκB and p65p5051;52 in survivors of sepsis, and the presence of large amounts 
of the p50p50 form in the non-survivors51;53.  
 
Negative regulators on transcriptional level 
ST2 is expressed on a subset of Treg cells54, and is able to inhibit NFκB production. Experiments 
have shown that LPS induces a sustained ST2 expression, and mice lacking ST2 are unable to 
mount endotoxin tolerance55. The ligand for ST2 is unknown, but ST2 cannot bind LPS, therefore it 
appears likely that LPS-activated TLR-4 signals the induction of ST2 in a negative feedback 
manner.  
 
Based upon a number of studies in LPS tolerant cells, the mechanisms behind LPS tolerance 
cannot simply be explained by downregulation of cell surface receptors. Indeed, in recent years, a 
more distinct role for modified intracellular signaling, turned to favor production of anti-
inflammatory molecules, emerged as pathophysiologic mechanism behind the development of 
LPS tolerance, this phenomenon is called ‘leukocyte reprogramming’56;57.  
The concept originates from experiments with isolated leukocytes from septic patients having a 
reduced capacity to produce pro-inflammatory cytokines but not all signaling proteins and 
pathways are suppressed and induction of specific anti-inflammatory proteins and signaling 
pathways may serve important counter inflammatory functions. 
So, although there are species and cellular variations in manifestation of the LPS tolerant 
phenotype, it is clear that the tolerance phenomenon has evolved as a complex orchestrated 
counter regulatory response to inflammation. Control of neutrophil tolerance and function in vivo 
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is thus likely to be a complex sum of actions of LPS and pro-inflammatory cytokines on TLR 
expression and signaling. 
 
Infectious complications? 
There is ongoing debate about the clinical relevance and usefulness of endotoxin tolerance and 
although it attenuates the severity of infections and other type of insults, conversely some 
studies suggest that the induction of endotoxin tolerance might impair resistance to infectious 
processes, in particular to live bacteria58.  
Indeed, a reduced level of IFN was reported in animals pretreated with LPS and further 
challenged with Newcastle disease virus59, a reduced Leishmanicidal activity was observed after 
pre-exposure of macrophages to LPS60 and an impaired lung clearance of Pseudomonas 
aeruginosa was shown after pre-exposure to LPS 61. Also, a subset of septic shock survivors show 
a tolerant-like phenotype manifested by decreased macrophage responses to LPS and increased 
incidence of secondary bacterial infections62.  
This is in contrast to various other studies which show that pretreatment with LPS increases the 
survival rates of animals lethally infected with Staphylococcus aureus, Cryptococcus neoformans63, 
Listeria monocytogenes, Salmonella enteritica64, Candida albicans65 or a human stool suspension 
to induce a multigerm peritonitis, which more closely mimics the physiological situation of the 
septic patient66. Furthermore, experiments combining a TNFα blocker and LPS pretreatment63 
showed that the boost of TNFα, during the first stimulation by LPS, later increased the resistance 
of the animals to the infectious process. This is in agreement with the protective role of 
inflammatory cytokines regularly reported since the 1980s.  
Accordingly, it is difficult to assume that endotoxin tolerance per se is directly linked to the 
increased susceptibility of SIRS patients to nosocomial infections. Indeed, leukocytes from sepsis 
and SIRS patients also display altered antigen presentation, direct microbicidal activity, and 
oxidative burst.  
 
Clinical applicability of endotoxin tolerance 
Cross-tolerance 
Although endotoxin has been used to induce resistance against a subsequent identical stimulus, it 
has also been demonstrated that endotoxin provokes tolerance against other forms of injury, a 
phenomenon called ‘cross tolerance’. 
A vast amount of animal studies demonstrate that pretreatment with endotoxin induced 
protection against hemorrhagic shock67;68, cerebral ischemia69-73, coronary occlusion74-76 and 
hepatic77-80, pancreatic81, lung82;83 and renal ischemia-reperfusion (IR) injury84;85. In the kidney of 
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mice for example, pretreatment with LPS combined with an IR experiment showed that after 
reperfusion, renal injury with elevated serum creatinine levels were more pronounced in the 
control than in the LPS pretreatment group, furthermore, all mice in the control group died of the 
lethal IR experiment compared to survival of all mice in the LPS pretreatment group after the 
same IR experiment85. 
The pathophysiological mechanisms of IR injury are complex and mediated by multiple processes, 
including production of reactive oxygen species, intracellular calcium overload, rapid restoration 
of physiologic pH, metabolic derangements, mitochondrial re-energization, and inflammation and 
complement activation86. Which IR injury pathway is predominantly influenced by LPS tolerance is 
not known. 
In humans in vivo, IR-induced injury can be visualized by use of annexin A5 scintigraphy87. Annexin 
A5 selectively binds to phosphatidylserine molecules, which are exposed on the outer membrane 
leaflet of affected cells immediately after an ischemic insult either as an early sign of apoptosis, or 
as a pathophysiological reversible event88;89. Binding of annexin A5 to these externalized 
molecules allows the detection of IR injury by a gamma camera. 
 
 
It was shown that a relatively short period of forearm exercise during local blockade of the 
circulation increases targeting of annexin A5 in forearm skeletal muscle87. As such, targeting of 
radiolabeled annexin A5 can be used to detect early and reversible IR injury in humans in vivo. By 
using this model of IR injury, it has been shown that the pharmacological modulation of the 
adenosine metabolism appears to be protective, as IR injury is prevented by ischemic 
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preconditioning87, adenosine87, and dipyridamole90 whereas adenosine receptor antagonist 
caffeine prevents protection from ischemic preconditioning in healthy volunteers91.  
LPS-induced cross-tolerance has not been studied in humans whilst protection of IR injury 
through endotoxin tolerance potentially is of clinical importance in elective procedures in which 
episodes of organ ischemia are likely to occur, for example in elective organ transplantation 
procedures and major vascular surgery. 
 
Renal injury 
Renal injury represents a common clinical problem in the critically ill patient and is associated with 
poor outcome92. Recently, 2 large multicentre cohort studies reported the occurrence of renal 
injury in an estimated 30-40% of all patients admitted to the intensive care unit93. Furthermore, 
critically ill patients who develop renal injury and require renal replacement therapy have 
increased mortality rates of 50-80%92. 
Sepsis has been identified as the most common cause of renal injury in intensive care units and 
different pathophysiological mechanisms of renal injury have been proposed. However in the last 
years, the emphasis of the pathophysiological mechanism of renal injury during sepsis has shifted 
from solely caused by altered hemodynamics to a more pronounced immune state, as the direct 
toxic role of cytokines in the kidney has become clear. Indeed, pro-inflammatory cytokines, such 
as TNFα, IL1ß and IL-6, have been implicated in the development of renal injury in septic 
patients94-101. Nevertheless, clinical studies using anti-cytokine therapies failed to show a survival 
benefit in patients with sepsis94;101-103.   
Therefore, despite many advances in therapeutic and research techniques in the past 20 years 
fundamental changes in the outcome of patients with renal injury have not occurred. This limited 
progress may be related to many factors, including the lack of early diagnostic tests that indicate 
the onset of renal injury and our restricted understanding of the pathophysiology of 
inflammation-induced renal injury.  
Currently, the diagnosis of renal injury is based on measuring surrogates of renal function such as 
serum creatinine and urea. However, these markers are insensitive and non-specific for detecting 
renal injury. They also increase late in the injury process and as a consequence, they may not 
detect an acute insult or potentially ongoing injury to the kidney. On the other hand, several novel 
biomarkers (i.e. antigens, peptides, enzymes, cytokines) have been detected in the urine in acute 
renal injury and have been characterized as potential early, non-invasive, and more sensitive 
indicators of renal injury104.  
Interestingly, endotoxin tolerance provokes “cross-tolerance” against other forms of injury, for 
example renal IR injury84;85. However, results on whether LPS tolerance provides protection 
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against inflammation-induced renal injury or whether the kidney acquires tolerance are matter of 
debate. Animal studies have shown that renal injury attenuates during LPS tolerance85, although 
the kidney fails to participate in the LPS tolerant state. It was observed that instead of 
manifesting attenuated levels of renal TNFα concentrations upon a LPS re-challenge, the post-LPS 
renal TNFα concentrations were about twice as high in the LPS preconditioned group compared 
to the LPS challenged naive controls but still with less kidney injury85;105. 
 
Microcirculation and regulation of vascular tone 
The endothelium is source of many vasoconstrictive and vasodilating substances involved in the 
regulation of vascular tone. One vasodilating substance is considered pivotal and was initially 
termed endothelium-derived relaxing factor106 and later identified as NO. It is a simple molecule 
with broad and diverse effects in human biology. 
NO exert many effects such as vasodilation and maintenance of vascular tone and is formed 
either by production through endothelial NO synthase (eNOS), which is physiologically necessary 
or via the induction of an inducible form of NO synthase (iNOS), which is not expressed in the 
vasculature under normal physiological conditions. 
Over the past years, with the use of new techniques, the human microcirculation has been 
examined in a large variety of clinical settings. One of the most striking findings is the pathological 
heterogeneity of microcirculatory flow during disease. In septic patients some vascular beds 
show a preserved functional capillary density whereas others have a sluggish blood flow and 
some display no flow at all. It is thought that the endothelium is an important determinant of this 
focal response in sepsis as there is an excessive, sustained and generalized activation of the 
endothelium which results in arterial and venous dilatation and blunted vascular responses to 
vasoactive drugs. A potential trigger for the observed endothelial dysfunction in sepsis is 
cytokines of which receptors have been found on endothelial cells107. 
Exposure of endothelial cells to these pro-inflammatory cytokines leads to expression of iNOS in 
the vessel wall with consequently enormous amounts of iNOS-derived NO108-111. This excessive 
production of NO causes downregulation of eNOS leading to an attenuated endothelium-
dependent vasodilatory response112-114.  
However, the role of circulating cytokines and upregulation of iNOS in endothelial dysfunction is 
controversial, as endothelial dysfunction during experimental endotoxemia in humans was not 
associated with an increase in iNOS expression in circulating macrophages115, therefore arguing 
against involvement of iNOS in the observed systemic vasodilation and endothelial dysfunction 
following the administration of LPS.  
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Whereas the endothelium was once regarded as an inert cell layer, it is now clear that the total 
opposite is true. During critical illness, e.g. sepsis, the endothelial cell plays a central role in the 
regulation of vascular tone integrating systemic changes in inflammation and coagulation in ways 
that differ in time and from organ to organ.  
So, ‘stabilizing’ the vascular tone by use of endotoxin tolerance as an attenuated cytokine state, 
or by use of a selective iNOS inhibitor, may be key to correct the inflammation-induced vascular 
dysfunction, halting disease progression and reducing mortality in sepsis.  
 
Reference List 
 
 1.  Suffredini AF, Fromm RE, Parker MM et al. The cardiovascular response of normal humans to the administration of 
endotoxin. N Engl J Med 1989;321:280-7. 
 2.  Berger FM. The effect of endotoxin on resistance to infection and disease. Adv Pharmacol 1967;5:19-46. 
 3.  Beeson P. Tolerance to bacterial pyrogens. I. Factors influencing its development. J Exp Med 1947;29. 
 4.  FreedmanHH. Passive transfer of tolerance to pyrogenicity of bacterial endotoxin. J Exp Med 1960;111:453-63. 
 5.  Jones SB, Westfall MV, Sayeed MM. Plasma catecholamines during E. coli bacteremia in conscious rats. Am J Physiol 
1988;254:R470-R477. 
 6.  Luger TA, Kalden D, Scholzen TE, Brzoska T. alpha-melanocyte-stimulating hormone as a mediator of tolerance induction. 
Pathobiology 1999;67:318-21. 
 7.  Delgado M, Pozo D, Martinez C et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide 
inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. J Immunol 1999;162:2358-67. 
 8.  Annane D, Cavaillon JM. Corticosteroids in sepsis: from bench to bedside? Shock 2003;20:197-207. 
 9.  Choudhry MA, Ahmad S, Ahmed Z, Sayeed MM. Prostaglandin E2 down-regulation of T cell IL-2 production is independent of 
IL-10 during gram-negative sepsis. Immunol Lett 1999;67:125-30. 
 10.  Njemini R, Lambert M, Demanet C, Mets T. Elevated serum heat-shock protein 70 levels in patients with acute infection: use 
of an optimized enzyme-linked immunosorbent assay. Scand J Immunol 2003;58:664-9. 
 11.  Ding XZ, Fernandez-Prada CM, Bhattacharjee AK, Hoover DL. Over-expression of hsp-70 inhibits bacterial lipopolysaccharide-
induced production of cytokines in human monocyte-derived macrophages. Cytokine 2001;16:210-9. 
 12.  Nalos M, Huang S, Sluyter R et al. "Host tissue damage" signal ATP impairs IL-12 and IFNgamma secretion in LPS stimulated 
whole human blood. Intensive Care Med 2008;34:1891-7. 
 13.  Almeida MC, Trevisan FN, Barros RC, Carnio EC, Branco LG. Tolerance to lipopolysaccharide is related to the nitric oxide 
pathway. Neuroreport 1999;10:3061-5. 
 14.  Soszynski D. Inhibition of nitric oxide synthase delays the development of tolerance to LPS in rats. Physiol Behav 
2002;76:159-69. 
 15.  Gourine AV. Pharmacological evidence that nitric oxide can act as an endogenous antipyretic factor in endotoxin-induced 
fever in rabbits. Gen Pharmacol 1995;26:835-41. 
 16.  Fahmi H, Charon D, Mondange M, Chaby R. Endotoxin-induced desensitization of mouse macrophages is mediated in part 
by nitric oxide production. Infect Immun 1995;63:1863-9. 
 17.  Dias MB, Almeida MC, Carnio EC, Branco LG. Role of nitric oxide in tolerance to lipopolysaccharide in mice. J Appl Physiol 
2005;98:1322-7. 
 18.  Zingarelli B, Halushka PV, Caputi AP, Cook JA. Increased nitric oxide synthesis during the development of endotoxin 
tolerance. Shock 1995;3:102-8. 
 19.  Shimauchi H, Ogawa T, Okuda K, Kusumoto Y, Okada H. Autoregulatory effect of interleukin-10 on proinflammatory 
cytokine production by Porphyromonas gingivalis lipopolysaccharide-tolerant human monocytes. Infect Immun 
1999;67:2153-9. 
 20.  Frankenberger M, Pechumer H, Ziegler-Heitbrock HW. Interleukin-10 is upregulated in LPS tolerance. J Inflamm 1995;45:56-
63. 
 21.  Randow F, Syrbe U, Meisel C et al. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming 
growth factor beta. J Exp Med 1995;181:1887-92. 
 22.  Sly LM, Rauh MJ, Kalesnikoff J, Song CH, Krystal G. LPS-induced upregulation of SHIP is essential for endotoxin tolerance. 
Immunity 2004;21:227-39. 
 23.  Cavaillon JM, Pitton C, Fitting C. Endotoxin tolerance is not a LPS-specific phenomenon: partial mimecry with IL-1, IL-10 and 
TGFb. J Endotoxin Research 1994;21-9. 
 24.  Berg DJ, Kuhn R, Rajewsky K et al. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic 
shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest 1995;96:2339-47. 
 25.  Henricson BE, Neta R, Vogel SN. An interleukin-1 receptor antagonist blocks lipopolysaccharide-induced colony-stimulating 
factor production and early endotoxin tolerance. Infect Immun 1991;59:1188-91. 
 26.  Kaplan E, Dinarello CA, Wakabayashi G, Burke JF, Connolly RS, Gelfand JA. Interleukin-1 pretreatment protects against 
endotoxin-induced hypotension in rabbits: association with decreased tumor necrosis factor levels. J Infect Dis 
1993;167:244-7. 
 27.  van Deuren M., van der Ven, Demacker PN et al. Differential expression of proinflammatory cytokines and their inhibitors 
during the course of meningococcal infections. J Infect Dis 1994;169:157-61. 
21
 28.  Marie C, Muret J, Fitting C, Payen D, Cavaillon JM. Interleukin-1 receptor antagonist production during infectious and 
noninfectious systemic inflammatory response syndrome. Crit Care Med 2000;28:2277-82. 
 29.  Kinjyo I, Hanada T, Inagaki-Ohara K et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity 
2002;17:583-91. 
 30.  Kubo M, Hanada T, Yoshimura A. Suppressors of cytokine signaling and immunity. Nat Immunol 2003;4:1169-76. 
 31.  Nakagawa R, Naka T, Tsutsui H et al. SOCS-1 participates in negative regulation of LPS responses. Immunity 2002;17:677-87. 
 32.  Starr R, Willson TA, Viney EM et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997;387:917-21. 
 33.  Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G. Human CD4(+)CD25(+) regulatory, contact-dependent T cells 
induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med 2002;196:247-53. 
 34.  Wheeler DS, Fisher LE, Jr., Catravas JD, Jacobs BR, Carcillo JA, Wong HR. Extracellular hsp70 levels in children with septic 
shock. Pediatr Crit Care Med 2005;6:308-11. 
 35.  Asea A, Kraeft SK, Kurt-Jones EA et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, 
demonstrating its dual role as a chaperone and cytokine. Nat Med 2000;6:435-42. 
 36.  Kohn G, Wong HR, Bshesh K et al. Heat shock inhibits tnf-induced ICAM-1 expression in human endothelial cells via I kappa 
kinase inhibition. Shock 2002;17:91-7. 
 37.  Yoo CG, Lee S, Lee CT, Kim YW, Han SK, Shim YS. Anti-inflammatory effect of heat shock protein induction is related to 
stabilization of I kappa B alpha through preventing I kappa B kinase activation in respiratory epithelial cells. J Immunol 
2000;164:5416-23. 
 38.  Chan JY, Ou CC, Wang LL, Chan SH. Heat shock protein 70 confers cardiovascular protection during endotoxemia via 
inhibition of nuclear factor-kappaB activation and inducible nitric oxide synthase expression in the rostral ventrolateral 
medulla. Circulation 2004;110:3560-6. 
 39.  Aneja R, Odoms K, Dunsmore K, Shanley TP, Wong HR. Extracellular heat shock protein-70 induces endotoxin tolerance in 
THP-1 cells. J Immunol 2006;177:7184-92. 
 40.  Ryter SW, Otterbein LE, Morse D, Choi AM. Heme oxygenase/carbon monoxide signaling pathways: regulation and 
functional significance. Mol Cell Biochem 2002;234-235:249-63. 
 41.  Raffaini MS, Dias MB, Branco LG. Central heme oxygenase-carbon monoxide pathway participates in the lipopolysaccharide-
induced tolerance in rats. Brain Res 2006;1111:83-9. 
 42.  Helqvist S, Sehested HB, Johannesen J, Ullits AH, Hoiriis NJ, Nerup J. Interleukin 1 induces new protein formation in isolated 
rat islets of Langerhans. Acta Endocrinol (Copenh) 1989;121:136-40. 
 43.  Mitani K, Fujita H, Kappas A, Sassa S. Heme oxygenase is a positive acute-phase reactant in human Hep3B hepatoma cells. 
Blood 1992;79:1255-9. 
 44.  Rizzardini M, Terao M, Falciani F, Cantoni L. Cytokine induction of haem oxygenase mRNA in mouse liver. Interleukin 1 
transcriptionally activates the haem oxygenase gene. Biochem J 1993;290 ( Pt 2):343-7. 
 45.  Dobrovolskaia MA, Vogel SN. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect 
2002;4:903-14. 
 46.  Rauh MJ, Sly LM, Kalesnikoff J et al. The role of SHIP1 in macrophage programming and activation. Biochem Soc Trans 
2004;32:785-8. 
 47.  Kobayashi K, Hernandez LD, Galan JE, Janeway CA, Jr., Medzhitov R, Flavell RA. IRAK-M is a negative regulator of Toll-like 
receptor signaling. Cell 2002;110:191-202. 
 48.  van 't Veer C, van den Pangaart PS, van Zoelen MA et al. Induction of IRAK-M is associated with lipopolysaccharide tolerance 
in a human endotoxemia model. J Immunol 2007;179:7110-20. 
 49.  Escoll P, del FC, Garcia L et al. Rapid up-regulation of IRAK-M expression following a second endotoxin challenge in human 
monocytes and in monocytes isolated from septic patients. Biochem Biophys Res Commun 2003;311:465-72. 
 50.  Deng JC, Cheng G, Newstead MW et al. Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M. J Clin 
Invest 2006;116:2532-42. 
 51.  Ziegler-Heitbrock HW, Wedel A, Schraut W et al. Tolerance to lipopolysaccharide involves mobilization of nuclear factor 
kappa B with predominance of p50 homodimers. J Biol Chem 1994;269:17001-4. 
 52.  Blackwell TS, Blackwell TR, Christman JW. Induction of endotoxin tolerance depletes nuclear factor-kappaB and suppresses 
its activation in rat alveolar macrophages. J Leukoc Biol 1997;62:885-91. 
 53.  Adib-Conquy M, Asehnoune K, Moine P, Cavaillon JM. Long-term-impaired expression of nuclear factor-kappa B and I kappa 
B alpha in peripheral blood mononuclear cells of trauma patients. J Leukoc Biol 2001;70:30-8. 
 54.  McGuirk P, Mills KH. Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious 
diseases. Trends Immunol 2002;23:450-5. 
 55.  Brint EK, Xu D, Liu H et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains 
endotoxin tolerance. Nat Immunol 2004;5:373-9. 
 56.  Cavaillon JM, Adib-Conquy M. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in 
sepsis. Crit Care 2006;10:233. 
 57.  Zhang X, Morrison DC. Lipopolysaccharide structure-function relationship in activation versus reprogramming of mouse 
peritoneal macrophages. J Leukoc Biol 1993;54:444-50. 
 58.  Cavaillon JM, Adrie C, Fitting C, dib-Conquy M. Endotoxin tolerance: is there a clinical relevance? J Endotox Res 2003;9:101-7. 
 59.  Youngner JS, Stinebring WR. Interferon appearance stimulated by endotoxin, bacteria, or viruses in mice pre-treated with 
Escherichia coli endotoxin or infected with Mycobacterium tuberculosis. Nature 1965;208:456-8. 
 60.  Severn A, Xu D, Doyle J et al. Pre-exposure of murine macrophages to lipopolysaccharide inhibits the induction of nitric 
oxide synthase and reduces leishmanicidal activity. Eur J Immunol 1993;23:1711-4. 
 61.  Mason CM, Dobard E, Summer WR, Nelson S. Intraportal lipopolysaccharide suppresses pulmonary antibacterial defense 
mechanisms. J Infect Dis 1997;176:1293-302. 
 62.  Wilhelm W, Grundmann U, Rensing H et al. Monocyte deactivation in severe human sepsis or following cardiopulmonary 
bypass. Shock 2002;17:354-60. 
 63.  Rayhane N, Fitting C, Lortholary O, Dromer F, Cavaillon JM. Administration of endotoxin associated with lipopolysaccharide 
tolerance protects mice against fungal infection. Infect Immun 2000;68:3748-53. 
22
 64.  Lehner MD, Ittner J, Bundschuh DS, van RN, Wendel A, Hartung T. Improved innate immunity of endotoxin-tolerant mice 
increases resistance to Salmonella enterica serovar typhimurium infection despite attenuated cytokine response. Infect 
Immun 2001;69:463-71. 
 65.  Leon P, Redmond HP, Shou J, Daly JM. Interleukin 1 and its relationship to endotoxin tolerance. Arch Surg 1992;127:146-51. 
 66.  Wheeler DS, Lahni PM, Denenberg AG et al. Induction of endotoxin tolerance enhances bacterial clearance and survival in 
murine polymicrobial sepsis. Shock 2008;30:267-73. 
 67.  Ackermann M, Reuter M, Flohe S, Bahrami S, Redl H, Schade FU. Cytokine synthesis in the liver of endotoxin-tolerant and 
normal rats during hemorrhagic shock. J Endotoxin Res 2001;7:105-12. 
 68.  Barroso-Aranda J, Chavez-Chavez RH, Mathison JC, Suematsu M, Schmid-Schonbein GW. Circulating neutrophil kinetics 
during tolerance in hemorrhagic shock using bacterial lipopolysaccharide. Am J Physiol 1994;266:H415-H421. 
 69.  Ahmed SH, He YY, Nassief A et al. Effects of lipopolysaccharide priming on acute ischemic brain injury. Stroke 2000;31:193-9. 
 70.  Bordet R, Deplanque D, Maboudou P et al. Increase in endogenous brain superoxide dismutase as a potential mechanism of 
lipopolysaccharide-induced brain ischemic tolerance. J Cereb Blood Flow Metab 2000;20:1190-6. 
 71.  Dawson DA, Furuya K, Gotoh J, Nakao Y, Hallenbeck JM. Cerebrovascular hemodynamics and ischemic tolerance: 
lipopolysaccharide-induced resistance to focal cerebral ischemia is not due to changes in severity of the initial ischemic 
insult, but is associated with preservation of microvascular perfusion. J Cereb Blood Flow Metab 1999;19:616-23. 
 72.  Rosenzweig HL, Lessov NS, Henshall DC, Minami M, Simon RP, Stenzel-Poore MP. Endotoxin preconditioning prevents 
cellular inflammatory response during ischemic neuroprotection in mice. Stroke 2004;35:2576-81. 
 73.  Tasaki K, Ruetzler CA, Ohtsuki T, Martin D, Nawashiro H, Hallenbeck JM. Lipopolysaccharide pre-treatment induces 
resistance against subsequent focal cerebral ischemic damage in spontaneously hypertensive rats. Brain Res 1997;748:267-
70. 
 74.  Brown JM, Grosso MA, Terada LS et al. Endotoxin pretreatment increases endogenous myocardial catalase activity and 
decreases ischemia-reperfusion injury of isolated rat hearts. Proc Natl Acad Sci U S A 1989;86:2516-20. 
 75.  Eising GP, Mao L, Schmid-Schonbein GW, Engler RL, Ross J. Effects of induced tolerance to bacterial lipopolysaccharide on 
myocardial infarct size in rats. Cardiovasc Res 1996;31:73-81. 
 76.  Yao Z, Auchampach JA, Pieper GM, Gross GJ. Cardioprotective effects of monophosphoryl lipid A, a novel endotoxin 
analogue, in the dog. Cardiovasc Res 1993;27:832-8. 
 77.  Colletti LM, Remick DG, Campbell DA, Jr. LPS pretreatment protects from hepatic ischemia/reperfusion. J Surg Res 
1994;57:337-43. 
 78.  Dominguez FE, Siemers F, Flohe S, Nau M, Schade FU. Effects of endotoxin tolerance on liver function after hepatic 
ischemia/reperfusion injury in the rat. Crit Care Med 2002;30:165-70. 
 79.  Fernandez ED, Flohe S, Siemers F et al. Endotoxin tolerance protects against local hepatic ischemia/reperfusion injury in the 
rat. J Endotoxin Res 2000;6:321-8. 
 80.  Yoshidome H, Kato A, Edwards MJ, Lentsch AB. Interleukin-10 suppresses hepatic ischemia/reperfusion injury in mice: 
implications of a central role for nuclear factor kappaB. Hepatology 1999;30:203-8. 
 81.  Obermaier R, Drognitz O, Grub A et al. Endotoxin preconditioning in pancreatic ischemia/reperfusion injury. Pancreas 
2003;27:e51-e56. 
 82.  Friedrich I, Spillner J, Lu EX et al. Induction of endotoxin tolerance improves lung function after warm ischemia in dogs 
2. Am J Physiol Lung Cell Mol Physiol 2003;284:L224-L231. 
 83.  Markart P, Schmidt R, Ruppert C et al. Ischemic and endotoxin pre-conditioning reduce lung reperfusion injury-induced 
surfactant alterations. J Heart Lung Transplant 2005;24:1680-9. 
 84.  Godet C, Goujon JM, Petit I et al. Endotoxin tolerance enhances interleukin-10 renal expression and decreases ischemia-
reperfusion renal injury in rats. Shock 2006;25:384-8. 
 85.  Heemann U, Szabo A, Hamar P et al. Lipopolysaccharide pretreatment protects from renal ischemia/reperfusion injury : 
possible connection to an interleukin-6-dependent pathway. Am J Pathol 2000;156:287-93. 
 86.  Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357:1121-35. 
 87.  Rongen GA, Oyen WJ, Ramakers BP et al. Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle 
preconditioning in humans. Circulation 2005;111:173-8. 
 88.  Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection 
of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994;84:1415-20. 
 89.  Hammill AK, Uhr JW, Scheuermann RH. Annexin V staining due to loss of membrane asymmetry can be reversible and 
precede commitment to apoptotic death. Exp Cell Res 1999;251:16-21. 
 90.  Riksen NP, Oyen WJ, Ramakers BP et al. Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. Clin 
Pharmacol Ther 2005;78:52-9. 
 91.  Riksen NP, Zhou Z, Oyen WJ et al. Caffeine prevents protection in two human models of ischemic preconditioning. J Am Coll 
Cardiol 2006;48:700-7. 
 92.  Uchino S, Kellum JA, Bellomo R et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 
2005;294:813-8. 
 93.  Bagshaw SM, George C, Dinu I, Bellomo R. A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in 
critically ill patients. Nephrol Dial Transplant 2008;23:1203-10. 
 94.  Abraham E, Anzueto A, Gutierrez G et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour 
necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998;351:929-33. 
 95.  Baud L, Oudinet JP, Bens M et al. Production of tumor necrosis factor by rat mesangial cells in response to bacterial 
lipopolysaccharide. Kidney Int 1989;35:1111-8. 
 96.  Cunningham PN, Dyanov HM, Park P, Wang J, Newell KA, Quigg RJ. Acute renal failure in endotoxemia is caused by TNF 
acting directly on TNF receptor-1 in kidney. J Immunol 2002;168:5817-23. 
 97.  Iglesias J, Marik PE, Levine JS. Elevated serum levels of the type I and type II receptors for tumor necrosis factor-alpha as 
predictive factors for ARF in patients with septic shock. Am J Kidney Dis 2003;41:62-75. 
 98.  Jaber BL, Rao M, Guo D et al. Cytokine gene promoter polymorphisms and mortality in acute renal failure. Cytokine 
2004;25:212-9. 
23
 99.  Jo SK, Cha DR, Cho WY et al. Inflammatory cytokines and lipopolysaccharide induce Fas-mediated apoptosis in renal tubular 
cells. Nephron 2002;91:406-15. 
 100.  Knotek M, Rogachev B, Wang W et al. Endotoxemic renal failure in mice: Role of tumor necrosis factor independent of 
inducible nitric oxide synthase. Kidney Int 2001;59:2243-9. 
 101.  Messmer UK, Briner VA, Pfeilschifter J. Tumor necrosis factor-alpha and lipopolysaccharide induce apoptotic cell death in 
bovine glomerular endothelial cells. Kidney Int 1999;55:2322-37. 
 102.  Opal SM, Fisher CJ, Jr., Dhainaut JF et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, 
randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator 
Group. Crit Care Med 1997;25:1115-24. 
 103.  Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care 
Med 2001;29:S121-S125. 
 104.  Parikh CR, Devarajan P. New biomarkers of acute kidney injury. Crit Care Med 2008;36:S159-S165. 
 105.  Zager RA, Johnson AC, Lund S. 'Endotoxin tolerance': TNF-alpha hyper-reactivity and tubular cytoresistance in a renal 
cholesterol loading state. Kidney Int 2007;71:496-503. 
 106.  Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by 
acetylcholine. Nature 1980;288:373-6. 
 107.  Faure E, Thomas L, Xu H, Medvedev A, Equils O, Arditi M. Bacterial lipopolysaccharide and IFN-gamma induce Toll-like 
receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol 
2001;166:2018-24. 
 108.  Wang P, Ba ZF, Chaudry IH. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent 
relaxation. Am J Physiol 1994;266:H2535-H2541. 
 109.  Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 
1997;96:3042-7. 
 110.  Clapp BR, Hingorani AD, Kharbanda RK et al. Inflammation-induced endothelial dysfunction involves reduced nitric oxide 
bioavailability and increased oxidant stress. Cardiovasc Res 2004;64:172-8. 
 111.  Pickkers P, Netea MG, van der Meer JW, Smits P. TNFalpha and IL-1beta exert no direct vasoactivity in human isolated 
resistance arteries. Cytokine 2002;20:244-6. 
 112.  Wang P, Ba ZF, Chaudry IH. Endothelium-dependent relaxation is depressed at the macro- and microcirculatory levels during 
sepsis. Am J Physiol 1995;269:R988-R994. 
 113.  Pleiner J, Mittermayer F, Schaller G, MacAllister RJ, Wolzt M. High doses of vitamin C reverse Escherichia coli endotoxin-
induced hyporeactivity to acetylcholine in the human forearm. Circulation 2002;106:1460-4. 
 114.  Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular 
events in patients with coronary artery disease. Circulation 2001;104:2673-8. 
 115.  Pleiner J, Heere-Ress E, Langenberger H et al. Adrenoceptor hyporeactivity is responsible for Escherichia coli endotoxin-
induced acute vascular dysfunction in humans. Arterioscler Thromb Vasc Biol 2002;22:95-100. 
 
  
 
 
 
 
 
 
 
 
 
 
         
24
Outline of this thesis 
 
In this thesis various aspects of endotoxemia and endotoxin tolerance in humans in vivo are 
investigated with special emphasis on circulating cytokine balance, the role of nitric oxide (NO) as 
a mediator of action, the effects on vasculature, the kidney and the presence of cross-tolerance. 
The thesis is divided in 5 parts, including an Introduction and a general overview of all performed 
experiments with future perspectives in the last part.  
 
Introduction 
Chapter 1 mainly focuses on LPS and the development of endotoxin tolerance in vivo with regard 
to the abovementioned areas of interest in studies performed before start of the present PhD 
project. 
 
Part A Pathophysiology of endotoxin tolerance 
Chapter 2 describes the in vitro experiments in which whole blood from healthy volunteers is 
stimulated with various Toll-like receptor (TLR) agonists, including LPS, prior and after the 
administration of LPS in vivo. To examine the role of NO in the development of endotoxin 
tolerance in vitro, subjects that received the inducible NO synthase (iNOS) inhibitor 
aminoguanidine in vivo were compared to subjects who received LPS without concomitant 
aminoguanidine with regard to whole blood stimulation with different TLR agonists. 
 
Chapter 3 describes the in vivo experiments in which LPS is administered to the healthy 
volunteers during 5 consecutive days to examine whether or not endotoxin tolerance develops in 
humans in vivo and to investigate whether this tolerance is caused by an attenuated pro-
inflammatory response only, with an enhanced or suppressed anti-inflammatory response.  
 
Part B Microcirculation and Endothelial function 
Chapter 4 examines the effects of sequential LPS administrations on a vascular level measured by 
3 different methods. First, it describes the effect on baseline microvascular flow measured by 
sidestream darkfield imaging, second, the effect on endothelium-dependent ischemia-mediated 
tissue oxygenation determined by use of near infrared spectroscopy, and finally the effect on the 
pharmacologically-induced endothelium-dependent vasodilatory response by use of intrabrachial 
administration of acetylcholine and venous occlusion plethysmography prior and during 
endotoxemia, and after the development of LPS tolerance.  
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Endothelial dysfunction, as cause of the blunted vascular response to vasoactive drugs, is 
observed during sepsis and the upregulation of cytokines or iNOS may play a pivotal role. 
In chapter 5, the role of inflammation-induced cytokines and the NO metabolism in human 
endotoxemia-induced endothelial dysfunction in vivo is investigated by use of 2 different models. 
In the first model LPS tolerance is induced to achieve attenuated cytokine levels on the fifth day 
of repeated LPS administrations, while in the second model the vascular effect of co-
administration of the selective iNOS inhibitor aminoguanidine during human endotoxemia was 
investigated.  
 
Part C Cross tolerance  
Pretreatment with LPS has been shown to protect animals from hepatic, pancreatic, lung and 
renal ischemia-reperfusion injury through a phenomenon known as “cross tolerance”.  
Chapter 6 describes whether endotoxin tolerance in humans is associated with protection against 
ischemia-reperfusion (IR) injury in humans in vivo. The forearm circulation of one arm is occluded 
for 10 minutes to induce transient ischemia. After reperfusion, radiolabeled annexin A5 is injected 
intravenously to detect phosphatidylserine expression as an early marker of ischemia-reperfusion 
injury. The scintigraphy of both arms is done prior to the first LPS administration and when LPS 
tolerance developed after 5 days of repeated LPS administrations.  
In addition, measurements of complement activation following the ischemic insult is addressed to 
establish the possible role of the IR-induced inflammatory pathway, and to determine whether 
the beneficial effect of LPS tolerance is mediated through this pathway.  
 
Also in this Chapter, two different protocols regarding the development of endotoxin tolerance 
are compared. In the first protocol 2 ng/kg/day LPS is administered while in the second protocol 
incremental dosages of LPS are administered during 5 consecutive days in order to develop 
endotoxin tolerance. Several clinical and inflammatory parameters are compared to establish the 
best clinical application protocol with the least of symptoms but resulting in the same level of LPS 
tolerance.  
 
Chapter 7 addresses the existence and the ability to detect subclinical renal injury during repeated 
experimental endotoxemia in humans in vivo at an early stage by urinary proteome investigations. 
The Surface-enhanced laser desorption/ionization Time-of-Flight Mass Spectrometry (Seldi-TOF-
MS) technology enables rapid urinary protein profiling in search of new potential biomarkers to 
detect inflammation-induced renal injury at an early stage. Markers on day 1 that had predictive 
26
value for the increase in serum creatinine levels later on were sought, and the presence of 
endotoxin tolerance on a renal level was examined. 
 
Part D Review 
Chapter 8 summarizes the literature with relevance to, and the results obtained during the 
present PhD project.  
 
Future perspectives 
In view of all pertained results in this thesis and what is known in literature, the end of this thesis 
harbors a future perspective to establish the possible clinical potential of endotoxin tolerance in 
humans in vivo. 
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PART A 
 
Pathophysiology of endotoxin tolerance 
 
 
 
Chapter 2 
 
 
 
 
“The effect of systemic iNOS inhibition during human endotoxemia on the 
development of tolerance to different TLR-stimuli” 
Draisma A, Dorresteijn M, Pickkers P, van der Hoeven JG 
Innate Immunity 2008, Jun;14(3):153-9. 
 
 
 
 
 
 
 
 
 
Abstract 
The phenomenon of repeated exposure to endotoxin resulting in diminished release of 
proinflammatory cytokines is called endotoxin tolerance, in which there is a putative role for nitric 
oxide (NO). We investigated the effect of selective inducible NO-synthase (iNOS) inhibition during 
experimental human endotoxemia on the development of tolerance to various Toll-like receptor 
(TLR) agonists ex vivo.  
Volunteers received 2 ng/kg Escherichia coli endotoxin in the absence (n=7) or presence (n=7) of 
the selective iNOS inhibitor aminoguanidine (bolus 5mM followed by a continuous infusion of 1.5 
mmol/hr). At t=0, 2 and 4 hrs blood samples were drawn for ex vivo stimulation with different TLR 
agonists.  
Experimental endotoxemia did not induce tolerance to TLR-2 and -7 stimulation. In TLR-3, -4 and -5 
stimulated whole blood, the pro and anti-inflammatory cytokine release was attenuated at t= 4 
hrs, indicating that endotoxin-induced tolerance is not confined to subsequent TLR-4 stimulation 
alone. Aminoguanidine treated subjects also developed tolerance to TLR-4 stimulation. In 
contrast, tolerance to TLR-3 stimulation did not occur for IL-10, and tolerance in TLR-5 stimulated 
blood did not develop for both pro and anti-inflammatory cytokines. The role of NO in the 
development of tolerance is different for the various TLRs stimulated and pro- and anti-
inflammatory cytokines measured. 
 
Introduction 
Animals pretreated with a low-dose endotoxin (lipopolysaccharide, LPS), survive a subsequent 
challenge with a normally lethal dose of endotoxin1;2. Similarly, whole blood of human volunteers 
after experimental endotoxemia 3-5 and of septic patients6-11 stimulated with LPS in vitro 
demonstrates an attenuated cytokine response. This phenomenon of repeated exposure to 
endotoxin associated with a diminished release of proinflammatory cytokines and improved 
survival is called ‘endotoxin tolerance’. Although endotoxin has been used to induce resistance 
against a subsequent identical insult, it has also been demonstrated that endotoxin tolerance 
provokes “cross-tolerance” against other forms of injury, such as ischemia-reperfusion injury.  
Various Toll-like receptors (TLRs) are involved in the recognition of different microbial products. 
Although TLRs do not exhibit specificity for a single microbial product, they are individually 
responsive to a limited group of molecules. Besides stimulation of TLR-4 with endotoxin, derived 
from the cell wall of Gram-negative bacteria, a wide variety of bacterial products, DNA and RNA 
viruses, fungi and protozoa play an important role through stimulation of other TLRs. For 
example, LPS and heat shock protein signal via TLR-4, Gram positive peptidoglycan via TLR-1 and -
2, TLR-3 is implicated in the recognition of viral double-stranded RNA, TLR-5 recognizes bacterial 
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flagellin and single-stranded RNA viruses signal via TLR-7. The development of tolerance after 
repeated exposure to LPS results not only in tolerance to subsequent TLR-4 stimulation, both in 
vivo as well as in vitro, but also results in a diminished cytokine response after TLR-212-14, -315 and -
516 stimulation ex vivo. Since the discovery of the various TLRs it is becoming more obvious that 
they act in concert in the signaling cascade following a specific stimulus. To what extent in vivo 
pretreatment with LPS influences the cytokine response evoked by stimulation of other TLRs is 
only sparsely studied in humans17;18. Also, the pathophysiological knowledge including the 
underlying mechanisms is still very limited. 
Nitric oxide (NO) is an important signaling molecule in a large variety of physiological processes. 
Moreover, NO has an important role in thermoregulation and fever19 and was found to be 
involved in the development of tolerance to LPS both in rabbits20 and rats21. Stimulation of cells 
with LPS leads to production of proinflammatory cytokines and upregulation of iNOS. Recent 
evidence suggests that the protection afforded by endotoxin tolerance is indeed mediated by 
upregulation of NO synthesis based on experiments performed in rats21;22, rabbits20 and mice23;24. 
Inhibition of NO-synthase abrogates the beneficial effects of endotoxin tolerance, whereas 
administration of NO donors induces a tolerance-like condition and protects against the lethal 
effect of endotoxin25.  
In the present study we examined the putative role of iNOS on the development of endotoxin 
tolerance. The study addresses two main questions: Does pretreatment with LPS in vivo result in 
an attenuated cytokine response to, not only TLR-4, but also other TLR-stimuli ex vivo?  And 
second, does co-administration of the selective iNOS inhibitor aminoguanidine during human 
endotoxemia in vivo influence the subsequent development of tolerance to various TLR-stimuli ex 
vivo?  
 
Materials and methods 
Subjects. 
Fourteen non-smoking volunteers (6 females, 8 males, aged 21.52.0 yrs) participated in the 
experiments that were part of a larger open-label endotoxin trial (NCT 00184990). The study 
protocol was approved by the Ethics Committee of the Radboud University Nijmegen Medical 
Centre and complies with the Declaration of Helsinki including current revisions and the Good 
Clinical Practice guidelines. Written informed consent was obtained from all study participants. 
 
Study design:  
Seven subjects received an iv bolus injection of 2 ng/kg Escherichia coli O:113 LPS (United States 
Pharmacopia, Rockville, MD, USA) in the absence and seven subjects in the presence of the 
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selective iNOS-inhibitor aminoguanidine (Clinalfa, Switzerland). Apart from the administration of 
aminoguanidine, subjects were sham treated. Based on the pharmacokinetics of aminoguanidine 
the bolus injection (5mM) was administered one hour after the LPS administration followed by a 
continuous infusion of 1.5 mmol/hr during the first four hours of the experiment aiming at a 
plasma concentration 3 times the EC50 of aminoguanidine26. The calculated dose was based on 
the pharmacodynamics of aminoguanidine26 and taken the IC50 of aminoguanidine (31μM)27 to 
inhibit iNOS into consideration. With this intervention, aminoguanidine-induced inhibition of 
inducible NO-synthase was adequately reached as described in our previous experiments, which 
showed activation of renal iNOS in humans in vivo during experimental endotoxemia, as 
demonstrated by a 34±15 fold induction of iNOS mRNA expression in cells isolated from urine of 
subjects treated with endotoxin compared to controls not treated with endotoxin. 
Aminoguanidine significantly inhibited the LPS-induced increase in renal iNOS mRNA expression 
(induction: 6±2 fold, p<0.05 compared to LPS alone) and attenuated the urinary excretion of NO 
metabolites by 38±9% compared to endotoxemia in the absence of aminoguanidine (p<0.01)28. 
 
Laboratory tests:  
Arterial blood samples were collected throughout the experiment. Total leukocytes and CRP 
values were measured before LPS administration and at 1, 6, 12 and 22 hours after the 
administration of LPS. Leukocyte numbers were determined using flow-cytometry (Sysmex XE-
2100, Goffin Meyvis, Etten Leur, the Netherlands) and CRP was measured using immunologic 
detection according to the instructions of the manufacturer (Aeroset, Abbott Laboratories, 
Abbott Park, IL, U.S.A.). Circulating cytokines were measured at 0, 15, 30, 60, 90 min and 2, 3, 4, 6 
and 22 hrs after LPS administration. Heparinized blood for whole blood stimulation with five TLR 
agonists ex vivo was performed immediately before, 2 hrs and 4 hrs after the in vivo LPS 
challenge.  
 
Whole blood stimulation and cytokine measurements.  
Whole blood (200 μl) anticoagulated with LPS-free heparin and diluted in sterile and pyrogen-free 
RPMI 1640 medium (700 μl, Dutch modification by Gibco) was stimulated with different TLR 
agonists (100 μl) in sterile polypropylene tubes. The TLR agonists used were Pam3Cys 1 μg/ml 
(stimulates both TLR-1 and TLR-2, further referred to as TLR-1-2, EMC Microcollections, Tubingen, 
Germany), Poly I:C 50 μg/ml (TLR-3, InvivoGen, San Diego, California, USA), E.coli LPS 1 ng/ml (TLR-
4, Sigma, St. Louis, Missouri, USA), Flagellin 10 ng/ml (TLR-5, InvivoGen, San Diego, California, 
USA) and Loxoribine 50 μg/ml (TLR-7, InvivoGen, San Diego, California, USA). The samples were 
incubated in the presence of 5% CO2 at 37ºC for 24 hrs. After the incubation, cell-free supernatant 
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was obtained after centrifugation (2000g at 4˚C for 15 minutes) and stored at –80ºC until ELISAs 
were performed. The ex vivo released pro- and anti-inflammatory cytokines TNFα, IL-1β, IL-6, IL10, 
IL-12, IFNγ were measured by use of the Luminex Assay (Bioplex-kits: BioRad Laboratories, 
Hercules, California USA) in accordance with manufacturers’ instructions. The lower limits of 
detection were: IL-6: 125 pg/ml; IL-10 and IL-12: 2 pg/ml; IFNγ: 8 pg/ml; TNFα and IL-1β: 2 pg/ml.  
 
Statistical analysis.  
The cytokine response to stimulation with the different TLR-agonists ex vivo in whole blood 
drawn prior to the LPS administration in vivo is expressed in pg/ml. Thereafter, these baseline 
measurements were set at 100% to correct for inter-individual variation and subsequent responses 
at t=2 and 4 hrs after the in vivo administration of LPS expressed as % of baseline response. Data 
was tested for significance using ANOVA with repeated measures. All data are expressed as 
meanSEM unless specified otherwise. A P <0.05 was considered statistically significant.  
 
Results         
Baseline characteristics of the volunteers:  
Baseline characteristics of both study groups showed no significant differences between groups. 
The age, weight, height and blood pressure were, respectively, 21.02.0 years, 75.912.0 kg, 1768 
cm and 13113/727 mmHg for the control group and 22.32.0 years, 7214.6 kg, 17911 cm, and 
12811/7513 mmHg for the aminoguanidine group.  
Changes in clinical, inflammatory and hemodynamic parameters after the administration of LPS 
LPS administration induced the expected and transient influenza-like symptoms with no 
difference between the two groups. Body temperature increased from 36.40.4 to 38.20.6 oC  in 
the control group and from 36.40.2 to 37.70.2 oC in the aminoguanidine group at t= 4 hr (p= 
0.48 between groups). WBC decreased from 6.01.2 to 2.00.6 109/L in the control group and 
from 5.00.4 to 2.20.3 109/L in the aminoguanidine group at t=1 hr after LPS administration, after 
which there was an increase to 12.92.2 and 13.93.5 109/L in the control group and to 12.01.0 and 
12.71.0 109/L in the aminoguanidine group at t=6 and t=12 hrs, respectively (p=0.88 between 
groups). CRP was below the detection limit (<5 mg/dL) at baseline in both groups, increasing to 
25.99.7 mg/dL in the control group and to 20.31.7 in the aminoguanidine group at t=12 hrs and 
to 39.912.3 mg/dL and 33.63.1 mg/dL in the control group and aminoguanidine group at 22 hrs 
after the injection of LPS (p=0.4 between groups). In the control group LPS administration 
resulted in a decrease in the mean arterial blood pressure from 979 to 8710 mmHg (p<0.0001) 
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at 4 hrs associated with an increase in heart rate from 6210 to 9110 bpm (p<0.0001) at 4 hrs. In 
the aminoguanidine group, LPS administration led to a decrease in the mean arterial blood 
pressure from 915 to 828 mmHg (p<0.0001) at 4 hrs and an increase in heart rate from 619 to 
8713 bpm (p<0.0001) at 4 hrs. There were no significant differences in the LPS-induced 
hemodynamic effects between the control and aminoguanidine group.  
In all subjects, circulating cytokines increased significantly after the administration of LPS (Figure 
1), with no significant differences between the two groups.  
 
TNFα 
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Figure 1. In vivo concentrations of circulating TNFα, IL-6 and IL-10  after LPS administration in vivo 
in the absence (straight line) and presence (dotted line) of in vivo treatment with selective iNOS 
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inhibitor aminoguanidine. Data are expressed as meanSEM. Changes were tested by one-way 
ANOVA and significant for all cytokines. 
 
Ex vivo experiments 
Blood samples drawn 2 and 4 hours after human endotoxemia demonstrated an attenuated 
cytokine response (IL-10 and IL-6) after stimulation ex vivo with TLR-3, –4 and –5 agonists, 
compared to stimulated cytokine levels prior to experimental endotoxemia. In contrast, in vitro 
incubation with TLR-7 agonist stimulation resulted in increased levels of IL-10 and IL-6 after in vivo 
administration of LPS. In vitro incubation with TLR-2 agonist stimulated whole blood resulted in 
attenuation of IL-6 and IL-10 after endotoxemia.  
The response to TLR-2 stimulation was not significantly influenced by the in vivo administration of 
aminoguanidine (figure 2).  
The attenuated pro-inflammatory response (IL-6) after TLR-3 stimulation was also not influenced 
by aminoguanidine, however, tolerance of the anti-inflammatory IL-10 was significantly inhibited 
after the administration of aminoguanidine. The observed attenuated TLR-4 agonist-induced 
response at t=2 and 4 hrs after experimental endotoxemia was not influenced by the 
administration of aminoguanidine (Figure 2). The endotoxemia-induced tolerance to TLR-5 
agonist ex vivo was completely abolished by aminoguanidine administration for both pro- and 
anti-inflammatory cytokines. Finally, the absence of endotoxemia-induced tolerance to TLR-7 
agonism described above was not influenced by aminoguanidine.  
The effects of stimulation of the various TLR-agonists before and during endotoxemia in vivo and 
in the absence and presence of aminoguanidine on the ex vivo release of the other measured 
cytokines are depicted in table 1.  
Four hours after experimental endotoxemia ex vivo cytokine production was attenuated after 
stimulation with all TLR-agonists, except TLR-2 agonist for IL-12 and TLR-7 agonist for IL-1β and 
IFNγ levels. Aminoguanidine did not influence the development of tolerance to TLR-2, -3, -4, and –
7 or the measured cytokines, whereas TLR-5 agonist-induced tolerance was significantly inhibited 
by aminoguanidine for the all of the measured cytokines.   
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Figure 2. IL-6 and IL-10 response to TLR-1-2, -3, -4, -5 and -7 agonist stimulation in vitro before, and 
2 and 4 hours after LPS administration in the absence (straight line) and presence (dotted line) of 
in vivo treatment with iNOS inhibitor aminoguanidine. Data are expressed as meanSEM. 
Differences between groups were determined by two-way ANOVA with repeated measures.  
* indicates p<0.05.  
 
36
  
Table 1. The change in cytokine production 4 hrs after LPS administration compared to cytokine 
production prior to LPS administration in vivo, after stimulation with various TLRagonists in vitro. 
The left upper corner shows the change in cytokine production in the absence of iNOS inhibitor 
aminoguanidine and the right corner in the presence of aminoguanidine. The statistical 
significance of the difference between groups as tested by ANOVA repeated measures are 
illustrated in the left down corner. All data are expressed as meanSEM. Baseline cytokine 
measurements (100% values) were in pg/ml. 
 
Discussion 
Our study has two main findings: First, we confirm previous studies that show that selective TLR-4 
stimulation in humans by endotoxin results in the development of tolerance after stimulation ex 
vivo not only with a TLR-4 agonist (LPS), but also with other, but not all, TLR agonists12-16. Second, 
we found that in vivo administration of the selective iNOS inhibitor aminoguanidine during 
endotoxemia results in different effects on the development of tolerance to TLR stimulation: The 
observed tolerance to TLR-4 stimulation is not influenced by selective iNOS inhibition, whereas 
TLR-3 stimulation after iNOS inhibition resulted in a restored IL-10 response and tolerance to TLR-
5 agonist does not develop at all in the presence of aminoguanidine. These results indicate that 
37
the role of nitric oxide in the development of tolerance is different for the various TLRs 
stimulated and pro- and anti-inflammatory cytokines measured.  
Endotoxin tolerance is not specific to the action of LPS, and cross reactivity with other exogenous 
stimuli occurs. Our study confirms the previously reported observations concerning TLR-3, and -5. 
It was previously demonstrated that TLR-3 activation induced by poly I:C prevented LPS-induced 
fulminant hepatitis by downregulation of macrophage TLR-4 expression in mice15. Furthermore, it 
was shown that LPS treatment of monocytes resulted in flagellin cross tolerance16. The effect of 
TLR-2 agonism is not consistent: Macrophages pretreated with TLR-2 agonist showed reduced 
production of TNFα in response to LPS, demonstrating that tolerance occurs. However, in our 
experiments tolerance did not occur in the TLR-2 agonist stimulated samples after LPS 
administration in vivo, in contrast, there was an enhanced response of TNFα release to TLR-2 
stimulation 2 and 4 hrs after endotoxemia. Our data is in concordance with animal studies, in 
which there was an unaltered or increased cytokine production upon stimulation with muramyl 
dipeptide or whole S. aureus after LPS tolerance induction29;30.  
It is known that NO has an important role in the thermoregulation and development of fever 
during systemic inflammation19. In the central nervous system, NO has been shown to decrease 
baseline temperature and act as an antipyretic molecule31. In contrast, inhibition of NO-synthase 
inhibits LPS-induced fever32, an effect that may be related to its direct effect on peripheral 
thermoregulatory tissues (humoral pathway) rather than the febrigenic signaling to the brain33 
(neuronal pathway). Indeed, NO reduces the sympathetic input and attenuates the 
norepinephrine-induced increase in blood flow to brown adipose tissue34-36. So, NO synthase 
inhibition may result in a higher or lower temperature and fever response to LPS depending on its 
central or peripheral effects, respectively. Since NO synthase inhibition in the central nervous 
system causes an increase in baseline temperature19;21;24;37;38, it has been proposed that the main 
site of action of NO-synthase inhibition is the central nervous system. 
 
One study demonstrated that the selective iNOS inhibitor aminoguanidine inhibits LPS-induced 
fever32 supporting the hypothesis that NO has a propyretic effect during the development of LPS-
tolerance. However, others showed that aminoguanidine had no effect on LPS-induced fever in 
guinea pigs39 , rats40 and pigs41. It appears that the antipyretic activity of this inhibitor is species-
dependent, as inhibition of peripheral NO-synthesis enhanced the febrile response of rabbits, and 
is possibly caused by different thermal strategies employed by animals to generate fever. Up to 
now, no human data concerning the role of NO in the development of LPS tolerance was 
available. Although our study shows that the systemic administration of iNOS inhibitor 
aminoguanidine to volunteers challenged with endotoxin does not result in pronounced changes 
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in circulating cytokines and fever, it does show a trend to a diminished release of circulating 
cytokines and LPS-induced fever. Additionally, since the tolerance experiments with different TLR-
agonist were performed ex vivo, our results show that inhibition of NO-synthase exerts a direct 
effect on the release of cytokines in stimulated whole blood, independent of its effect in the 
central nervous system. In our experiments however, it cannot be excluded that aminoguanidine 
itself may alter some TLRs-mediated signaling, independent of its iNOS inhibiting properties. 
In conclusion, our results indicate that nitric oxide has a role in the development of endotoxin 
tolerance. Our study adds notion to the fact that the modulation of these responses is extremely 
complex and differentially dependent on the specific TLR that is stimulated and cytokine that is 
measured.  
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PART A 
 
Pathophysiology of endotoxin tolerance 
 
 
 
Chapter 3 
 
 
 
 
“The development of endotoxin tolerance in humans in vivo” 
Draisma A, Pickkers P, Bouw PJWM, van der Hoeven JG 
Critical Care Medicine 2009, apr;37(4):1261-7. 
 
Abstract: 
Objective:  Endotoxin (lipopolysaccharide, LPS) tolerance is characterized by a reduced 
responsiveness to a subsequent LPS challenge. In animal and human in vitro experiments, LPS 
tolerance is associated with an attenuated response of pro-inflammatory cytokines and an 
enhanced production of anti-inflammatory cytokines. It is unclear if this mechanism accounts for 
the development of LPS tolerance in humans in vivo.  
Design: Clinical experimental study. 
Setting: Intensive care research unit. 
Patients: Fourteen healthy male volunteers. 
Interventions: Intravenous injections of 2 ng/kg/day Escherichia coli LPS on 5 consecutive days.  
Measurements: Symptom scores, vital signs, leukocyte (elastase) and endothelial cell activation 
(von Willebrand factor, vWF) and circulating cytokine levels. 
Main results: On day 1, the symptom score increased to 6.13.1, temperature to 37.80.4 oC, heart 
rate to 1036/min (p<0.0001 for all parameters) compared to 0.30.6, 36.20.5 oC, 794/min on day 
5, respectively (p<0.0001 between day 1 and 5). On day 1, Elastase, vWF and all cytokine levels 
increased significantly (p<0.001 for all, except TGFß p=0.02), whereas on day 5 this increase was 
significantly attenuated (p<0.001) for elastase (61±6%), vWF (68±5%), TNF (973%), IL-6 (888%), 
IL-10 (877%) and IL-1ra (939% p=0.018) but not for TGFß (5±22% p=0.22). the TNFα/IL-10 ratio to 
showed an initial pro-inflammatory phase, followed by an anti-inflammatory phase on the first 
day. The pro-inflammatory phase was attenuated with 952% whereas the reduction of the anti-
inflammatory phase, without TGFß levels, was 991% on day 5 (p= 0.13 between phases).  
Conclusions: Endotoxin tolerance developed during 5 consecutive LPS administrations as 
demonstrated by the attenuated release of pro-inflammatory cytokines on the fifth day and was 
associated with less leukocyte and endothelial activation. In contrast to animal and human in vitro 
data, the attenuated response was not limited to the pro-inflammatory response, as a similar 
reduction in the anti-inflammatory cytokines was observed, with the exception of TGFß. 
 
Introduction: 
LPS, a membrane glycolipid of Gram-negative bacteria, induces a strong inflammatory response in 
monocytes, macrophages and neutrophils, associated with endothelial cell activation151;152. 
Animals pretreated with a low dose of endotoxin have a markedly reduced mortality when 
rechallenged with a normally “lethal” dose of endotoxin153-159, a phenomenon termed ‘endotoxin 
tolerance’. Interestingly, endotoxin tolerance provokes “cross-tolerance” against other forms of 
injury, such as ischemia-reperfusion77-80;82-85, which may represent a new clinical application in 
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procedures with a high chance of organ ischemia, for example in elective organ transplant 
patients or during major vascular surgery.  
Endotoxin tolerance is usually assessed by a dramatically reduced production of the pro-
inflammatory cytokines such as TNFα and IL-6 following a LPS challenge in tolerant animals. The 
mechanism by which endotoxin tolerance develops remains unclear however. It was proposed 
that endotoxin tolerance does not attenuate the release of different cytokines similarly and this 
may account for the observed tolerance. It has previously been reported that LPS tolerance is 
associated with an increased expression of anti-inflammatory cytokines such as IL-1019;20 Il-1ra21 or 
TGFß21;22, nevertheless, the differential effect on pro- and anti-inflammatory cytokines is 
controversial as other studies were unable to detect any IL-10 differences in vitro21,, stimulated 
whole blood160 or in animal studies161;162. Finally, experiments using IL-10 knock-out mice showed 
the dispensability of this cytokine in the development of endotoxin tolerance24.  
Human in vivo data on endotoxin tolerance is sparse163 and data on the role of anti-inflammatory 
cytokines in LPS tolerance in humans is not available. Therefore, the aim of this study was to test 
whether endotoxin administration during 5 consecutive days leads to LPS tolerance in humans in 
vivo and whether this is mediated by an attenuated pro-inflammatory response with an enhanced 
anti-inflammatory response or a more general suppression of the innate immune response. 
Furthermore, we were interested in the endothelial and leukocyte activation during endotoxemia 
and the development of LPS tolerance.  
 
Materials and methods: 
Subjects:  
The study protocol was approved by the Ethics Committee of the Radboud University Nijmegen 
Medical Centre and complies with the Declaration of Helsinki including current revisions and the 
Good Clinical Practice guidelines. Written informed consent was obtained from all study 
participants. Fourteen male volunteers participated in the experiments. All volunteers had normal 
physical examinations, electrocardiography and routine laboratory studies before the start of the 
experiment. Volunteers were not taking any prescription medications and they were negative for 
hepatitis B surface antigen and human immunodeficiency virus (HIV) infection. Experiments were 
performed in our intensive care research unit. 
 
Study design:  
Fourteen subjects received iv bolus injections of 2 ng/kg/day Escherichia coli LPS for 5 consecutive 
days, with a 24 hour observation period on day 1 followed by a 6 hour period of observation on 
day 2 to 5. The subjects refrained from food and beverages 8 hours prior to and 4 hours after the 
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LPS administration. Before each LPS administration the subjects were prehydrated with 1500 ml 
glucose/saline infusion164 and after LPS administration a continuous intravenous drip was started 
at 150 ml/hr during 6 hours.  
 
Endotoxin: 
U.S. Reference E.coli endotoxin (lot Ec-5, Center for Biologic Evaluation and Research, Food and 
Drug Administration, Bethesda, MD) was used in this study. Ec-5 endotoxin, supplied as a 
lypophilized powder, was reconstituted in 5 ml saline 0.9% for injection and vortex mixed for at 
least 10 minutes after reconstitution. The endotoxin solution was administered as a single 
intravenous bolus injection during 1 minute at a dose of 2 ng/kg of body weight. This dose of Ec-5 
endotoxin was pyrogenic and elicited subjective side effects in healthy male volunteers in our 
previous studies165-167.  
 
Clinical and hemodynamic parameters and toxicity:  
Symptom scores and vital signs (including tympanic temperature, heart rate and blood pressure) 
were obtained before LPS administration and during 6 hrs after the administration of LPS. The 
symptom score consisted of backache, shivering, nausea, headache and muscle ache. The 
volunteers were asked to score each of these complaints every 30 minutes after LPS 
administration from day 1 until 5 ranging from “not present” (score 0) up to “most severe ever” 
(score 5). Each time point represents a cumulative score of all complaints. Temperature 
measurements were obtained every 30 minutes after LPS administration from day 1 until day 5 
using a tympanic thermometer (oC). Heart rate (ECG) and mean arterial pressure were 
continuously monitored on day 1 and day 5 with the use of an arterial catheter and non-invasively 
on day 2-4. 
Liver and renal functions were measured daily during the experiment for toxicity screening. 
 
Inflammatory parameters and cytokines:  
White blood cell counts with cell differentiation were measured before (t=0) and after (t=1, 4 and 
6 hrs) administration of LPS on day 1 and 5, and before each LPS administration on day 2-4 by 
flow-cytometry (Sysmex XE-2100, Goffin Meyvis, Etten Leur, the Netherlands). C-reactive protein 
levels were measured before each LPS gift (t=0 day 1-5) and after 12 hours on the first day of the 
experiment also by use of standard laboratory techniques. 
Blood samples to determine in vivo circulating levels of elastase and von Willebrand factor were 
drawn before (t=0) and after (t=1, 2, 4 and 6 hrs) administration of LPS on day 1 and 5. TNFα, IL-6 
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and IL-1ß (pro-inflammatory cytokines), IL-10, IL-1ra and TGFß (anti-inflammatory cytokines) were 
drawn before (t=0) and after (t=30, 60, 90 min, 2, 4, and 6 hrs) administration of LPS on day 1 and 
5. The ratio of TNFα and IL-10 was calculated to obtain a measure of the pro/anti-inflammatory 
balance. Elastase levels were measured by use of ELISA-duoset (Hycult biotechnology, Uden, The 
Netherlands), vWF by use of ELISA-duoset (Sanbio, Uden, the Netherlands). Circulating cytokine 
levels (TNFα, IL-6 and IL-10) were measured by use of the Luminex Assay (Bioplex-kits: BioRad 
Laboratories, Hercules, California USA) in accordance with manufacturer’s instructions. IL-1ra, IL-
1ß and TGFß levels were determined using the ELISA-duoset of R&D systems. The lower limits of 
detection were: Elastase: 29 ng/ml, vWF: 0.07 U/ml, TNFα: 36 pg/ml, IL-6: 8 pg/ml, IL-1ß: 8 pg/ml, 
IL-10: 8 pg/ml, IL-1ra: 0.2 pg/ml and TGFß: 32 pg/ml.  
 
Statistical analysis:  
Power-analysis was based on a presumed standard deviation of 50% of the peak cytokine values 
(TNFα). LPS tolerance-induced reduction of 40% was considered clinically relevant. With an 
α=0.05, we calculated that a sample size of 13-17 would be needed to achieve a power of 90-95%. 
Therefore, 14 subjects were included. LPS-induced changes between different time points were 
tested for significance using ANOVA with repeated measures. These data are expressed as 
mean±SD. Circulating cytokine, elastase and von Willebrand factor levels were not normally 
distributed so median levels with 25th and 75th quartile ranges were given. Maximum levels of 
cytokines and baseline levels of von Willebrand factor were tested for significance by use of the 
Wilcoxon’s signed rank test for non-parametric data. A p <0.05 was considered statistically 
significant.  
 
Results: 
Baseline characteristics of the volunteers:  
The age, weight, height, heart rate and blood pressure of the volunteers were 222 years, 718 
kg, 1817 cm, 6516/min and 12718/7310 mmHg, respectively. 
Changes in clinical and hemodynamic parameters and toxicity:  
LPS administration induced the expected and transient flu-like symptoms. The response to LPS is 
characterized by a rise in symptom score, temperature and heart rate, and a decrease in blood 
pressure. During repeated LPS administrations, changes in symptom score, temperature, heart 
rate and blood pressure were significantly less pronounced (Figure 1 and Table 1).  
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Figure 1: Clinical, hemodynamic and inflammatory parameters before and after LPS administration 
on day 1 compared to day 5. Differences between days were determined by two-way ANOVA with 
repeated measures. Data are expressed as meanSD. *indicates p<0.05.  
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 Day 1 Day 2 Day 3 Day 4 Day 5 
Differences 
between days 
ΔSymptom score +6.1  3.1* +4.6  2.7* +1.8  2.8 +0.4  0.6 +0.3  0.6 p<0.001 
ΔTemperature 
(oC) 
+1.8  0.7* +1.9  0.5* +0.8  0.9 +0.3  0.6 +1.0  0.5 p<0.001 
ΔHeart 
rate (/min) 
+35  7* +20  10 +15  14 +10  9 +13 0 p<0.001 
ΔMean arterial     
pressure (mmHg) 
-20  9*    -14  13* p=0.015 
ΔWhite blood cell 
count (*109/L) 
+6.4  1.9*    +3.0  1.2 p<0.001 
 
Table 1:  Changes in clinical, hemodynamic and inflammatory parameters on 5 consecutive days of 
LPS administrations to healthy volunteers. Differences between days were tested for significance 
by use of the student t-test. Data are expressed as meanSD. *indicates p<0.05. 
 
Symptom scores reached maximum levels on day 1 of 6.1±3.1, with a gradual decline on day 2 to 
4.6±2.7, day 3 to 1.8±2.8, day 4 to 0.4±0.6 and on day 5 to 0.3±0.6 (Figure 2). Temperature levels 
also decreased gradually with maximum levels on the first and second day of 37.2±0.1 and 
37.5±0.7 oC, with a gradual decline from day 3 to 36.7±0.2 oC, day 4 to 36.6±0oC, and on day 5 to 
36.2±0.5 oC (Figure 2). Heart rate levels increased on the first day with a gradual attenuation of 
the increase the following days. The mean arterial pressure levels dropped the first day, which 
attenuated the following days when tolerance developed (Table 1).  
Liver functions and haemoglobin levels remained stable during the experiment. Creatinine levels 
increased slightly, but significantly, during the repeated LPS administrations with peak levels at 
day 3 that returned to baseline values at day 5 (Table 2).  
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Figure 2: Symptom scores and temperature levels (oC) before and after LPS administrations on 5 
consecutive days. The symptom score consisted of backache, shivering, nausea, headache and 
muscle ache. The volunteers were asked to score each of these complaints every 30 minutes after 
LPS administration from day 1 until 5 ranging from “not present” (score 0) up to “most severe 
ever” (score 5). Each time point represents a cumulative score of all complaints. Temperature 
levels were obtained every 30 minutes after LPS administration from day 1 until day 5 using a 
tympanic thermometer (oC). Differences between days were determined by use of ANOVA with 
repeated measures. * indicates p<0.05 and ‘ns’ indicates no significant difference. 
 
 
 
 
 
 
 
 
48
 Day 1   Day 2  Day 3  Day 4  Day 5  
 t=0  t=12  t=0  t=0  t=0  t=0  
Hb (mmol/L)  8.20.5   7.80.5  7.80.5  7.90.4  7.60.5  
White blood cell  
count (*109/L)  
6.31.3  10.73  6.71.6  4.60.8  4.20.6  4.61  
C-reactive 
protein (mg/mL)  
50  206  286  3310  308  246  
Creatinine (μmol/L)  6910   7311*  7912*  7810  6812  
ASAT (U/L)  165   146  165  156  134  
ALAT (U/L)  155   157  179  1710  1610  
 
Table 2:  Laboratory measurements on 5 consecutive days for toxicity screening for the in vivo LPS 
administration. Liver function and hemoglobin levels were not affected by the repeated LPS 
administrations. Creatinine levels were significantly increased during the course of the 
experiment, with peak levels on day 3 and return to baseline levels when tolerance was present 
on day 5. Differences between days were determined by one-way ANOVA with repeated 
measures. Data are expressed as meanSD. * indicates p<0.05. 
 
Changes in inflammatory parameters and cytokines: 
Total white blood cell counts decreased at t=1 hour (-4126%) after the first LPS administration, 
followed by an increase with maximum levels at t=6 hrs (+338212%). Both the decrease (t=1hr) as 
well as the increase (t=6hrs) were significantly attenuated on day 5 (016% and +7236%, 
respectively, p<0.001 between day 1 and 5), illustrated in figure 1. Leukocyte differentiation 
showed predominantly neutrophil proliferation on the first day with attenuation when tolerance 
developed. Monocytes, however showed higher levels 4 hours after LPS administration on day 5. 
C-reactive protein levels showed peak levels at day 3 of 33±2.8 mg/mL with gradual decline to 
30±2.1 mg/mL on day 4 and 24±1.6 mg/mL on day 5.  
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Figure 3: In vivo concentrations of circulating white blood cells before and after LPS 
administration in vivo on day 1 and 5.  Leukocyte differentiation showed predominantly neutrophil 
proliferation on day 1 with a significant attenuation when tolerance was present (p<0.001), 
whereas monocytes exerted higher levels 4 hours after LPS administration on day 5 (p=0.055). 
Lymphocyte levels are also significantly attenuated on day 5 (p=0.001) after LPS administration in 
vivo. Eosinophil counts were negligible. * indicates p<0.05 and ‘ns’ indicates no significant 
difference. 
          
Figure 4: Circulating levels of 
elastase (neutrophil 
degranulation) and von 
Willebrand factor (endothelial cell 
activation) after LPS 
administration in vivo on day 1 and 
after LPS tolerance developed on 
day 5. Differences were tested by 
use of the Wilcoxon’s signed 
ranks test (baseline differences) 
and ANOVA with repeated 
measures. Data are expressed as 
median levels with interquartile 
ranges. * indicates p<0.05. 
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LPS administration induced endothelial cell activation with a peak vWF level of 3.52 [3.13-4.08] 
U/mL 6 hours after the first LPS administration on day 1 and 1.67 [1.0-2.11] U/mL on day 5 (p<0.001 
between days, Figure 4). Baseline levels of vWF were significantly higher on day 5 compared to 
the first day (p=0.01). Neutrophil degranulation, as expressed by elastase levels, showed a peak 
level of 775 [481-950] ng/mL 4 hours after the first LPS administration on day 1 and 384 [205-481] 
ng/mL on day 5 (p<0.001 between days, Figure 4).  
All, except IL-1ß, plasma cytokines concentrations increased significantly after the administration 
of LPS (p<0.001 for all cytokines except TGFß p=0.02). TNFα showed the expected fast peak at 90 
minutes after LPS administration on day 1 followed by circulating peak levels of IL-6, IL-10, TGFß 
and IL-1ra. During the 5 days of the experiment all measured cytokines, both pro- and anti-
inflammatory, were significantly attenuated with peak levels of TNFα of 13 [8-38] pg/mL, IL-6 138 
[119-275] pg/mL, IL-10 18 [11-26] pg/mL, IL-1ra 6 [2-8] pg/mL and TGFß 2388 [1788-2646] pg/mL 
(Figure 5). IL-1ß levels did not show a response to LPS administration neither on day 1 and 5. On 
day 1 the pro/anti-inflammatory ratio, represented by TNFα/IL-10 levels, showed an initial phase of 
proinflammation after LPS administration (t=0-2 hr) which was followed by an anti-inflammatory 
phase at t=2-4 hrs (Figure 5). On day 5, both pro- and anti-inflammatory phases were significantly 
attenuated (Figure 5). The reduction of the pro-inflammatory phase was 952% whereas the anti-
inflammatory phase was attenuated by 991% (Difference in the reduction of the pro- and anti-
inflammatory response: p=0.13). 
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Figure 5:  In vivo concentrations of circulating TNFα, IL-6 (pro-inflammatory cytokines) and IL-10, 
IL-1ra and TGFß (anti-inflammatory cytokines) after LPS administration in vivo on day 1 and 5. The 
ratio is shown between pro- (TNFα) and anti- (IL-10) inflammatory cytokines after 1 and 5 LPS 
administrations to illustrate the distinct pro- and anti-inflammatory phases. Differences were 
tested by use of the Wilcoxon’s signed ranks test and ANOVA with repeated measures. Data are 
expressed as median levels with interquartile ranges. AU means arbitrary unit, * indicates p<0.05 
and ‘ns’ indicates no significant difference. 
 
Discussion:  
Our experiments demonstrate that with daily administrations of LPS we were able to induce 
endotoxin tolerance in humans in vivo mediated through a diminished response of pro- and anti-
inflammatory cytokines, with the exception of TGFß levels. After the first LPS administration, the 
TNFα/IL-10 ratio showed the expected pro-inflammatory phase followed by an anti-inflammatory 
phase. These two phases were also present on day 5 and both the pro- and the anti-inflammatory 
phase were attenuated to the same extent. This effect was associated with less leukocyte and 
endothelial cell activation. 
52
In 1942 Favorite and Morgan administered endotoxin to humans for the first time and described 
tolerance after repeated injections168;169. Since then many authors described the phenomenon of 
endotoxin tolerance and called it anergy, immunodepression, or immunoparalysis. In vitro 
experiments conducted in the past 20 years demonstrated a differential response of various 
cytokines to subsequent exposure to LPS with an attenuated pro-inflammatory response and an 
unaltered or even enhanced production of anti-inflammatory cytokines such as IL-10, IL-1ra and 
TGFß leading to the conclusion that immune dysregulation analyzed in terms of ex vivo cytokine 
production is not a global effect. Importantly, most of these studies were performed in isolated 
cells ex vivo/in vitro. Our results indicate that a general attenuated innate immune response 
accounts for the observed LPS tolerance in humans in vivo as the production of most pro- and 
anti-inflammatory cytokines were attenuated, with the exception of anti-inflammatory cytokine 
TGFß, after 5 days of LPS administration. Apparently, regulation of the inflammatory response is 
differently mediated in human in vivo models compared to in vitro models possibly due to the 
complexity of other mediators involved, such as neuroprotective peptides and glucocorticoid 
hormones present in vivo.  
TGFß was found to be involved in the development of LPS tolerance in previous in vitro and 
animal sepsis studies by downregulation of the inflammatory cascade21;170. It was observed that 
after administration of TGFß animals became LPS tolerant, whereas in animals that were infused 
with antibodies aimed to neutralize TGFß, no tolerance to LPS developed at all21. These data 
indicate that TGFß administration is an essential factor in the development of LPS tolerance. 
Interestingly, in our experiments, an identical response of TGFß occurred after the administration 
of LPS on day 5 when all other measured cytokines were downregulated. Our study does not 
enable us to make statements about the cause-effect relationship between the persistent release 
of TGFß and the observed downregulation of the other cytokines. Also, the absence of an 
attenuated TGFß response during the 5 days of LPS treatment demonstrates that LPS tolerance 
observed in vivo in humans is not generalized to all anti-inflammatory cytokines.   
In the recent years, a more distinct role for modified intracellular signaling emerged as 
pathophysiologic mechanism behind the development of LPS tolerance to attenuate the 
production of pro-inflammatory cytokines, this phenomenon is called ‘leukocyte 
reprogramming’56;57. Now that we have demonstrated that repetitive LPS administrations to 
humans is feasible and results in LPS tolerance, further research into the cellular changes during 
tolerance, using RT PCR, microarrays, and proteomic approaches, is possible and will give more 
insight into the pathophysiological processes leading to LPS tolerance. Indeed, our results show 
that similar leukocyte counts and differentiation at baseline on day 1 and 5 exert a different 
cytokine response. This observation suggests that intracellular signaling is affected during the 
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development of LPS tolerance or different subpopulations become more important. Interestingly, 
following LPS administration, leukocyte differentiation showed predominantly neutrophil 
proliferation on day 1 which was significantly attenuated during the development of tolerance, 
whereas monocytes showed higher levels 4 hours after LPS administration on day 5, indicating 
that cytokine production originates from other cells involved. This finding suggests that not only 
intracellular changes are responsible for the different cytokine response, but also that the 
different leukocyte subpopulations may play a role.  
Endothelial cell activation, measured by the release of von Willebrand factor, is one of the first 
events that occur after the administration of endotoxin or pro-inflammatory cytokines. The 
present study confirms previous data152;171-173 that show that LPS administration results in 
increased levels of TNFα and vWF. In addition, we report that the reduced TNFα levels in LPS 
tolerant subjects are associated with less endothelial cell activation. It is likely that these 
observations represent a cause-effect relationship between TNFα and vWF173 although we did not 
find a significant correlation between TNF and vWF concentrations (data not shown). Baseline 
levels of vWF on day 5 were significantly higher than those on the first day, probably due to the 
kinetics and longer half time of the vWF in blood compared to the other parameters measured. 
The neutrophil has been implicated as an important mediator of vascular injury, especially after 
endotoxemia as illustrated in previous studies174;175. Our present study showed that neutrophil 
degranulation occurs during endotoxemia but was absent once LPS tolerance developed. 
Our experiments with administration of LPS on 5 consecutive days demonstrate for the first time 
the effect of endotoxin tolerance on various circulating cytokines, endothelial cell and leukocyte 
activation in humans in vivo. Repeated administrations of LPS were well tolerated by our 
volunteers as illustrated by attenuation of symptoms, increase in temperature and change in vital 
parameters during the course of the experiment. Although there were no indications for 
hepatotoxicity, some renal injury may occur as plasma creatinine levels increased slightly on day 2 
and 3 despite adequate fluid resuscitation. In a previous set of experiments we showed increased 
urinary excretion of markers for proximal tubule damage after a single administration of LPS176. 
Subclinical renal injury correlated with the urinary excretion of nitric oxide (NO) metabolites and 
could be inhibited by aminoguanidine, a selective blocker of inducible NO synthase. It is unknown 
if this pathophysiology is also responsible for the observed rise in plasma creatinine on day 2 and 
3 during the LPS tolerance experiments. Once tolerance developed in our present experiments, 
creatinine levels returned to baseline indicating that LPS-mediated renal injury is also 
‘downregulated’ during endotoxin tolerance. The clinical relevance of endotoxin tolerance stems 
from the potential induction of cross tolerance resulting in protection against other forms of 
tissue damage such as infected thermal injury177, hemorrhagic shock162;178, or ischemia-reperfusion 
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injury of the liver77-80, lung82;83, heart74-76;179, pancreas180, brain70-73;181 and kidney84;85. In the heart for 
example, pretreatment with LPS resulted in up to 40% reduction of infarct size in the area at risk 
following coronary occlusion74-76;179. Also, animals pretreated with LPS showed no increase in 
creatinine levels after renal ischemia-reperfusion injury, indicating a protective role associated 
with the development of endotoxin tolerance resulting in 100% prevention of mortality85. 
Especially in clinical interventions with a high risk of an ischemic insult for example elective 
transplantation procedures or major vascular surgery, pretreatment of the patient with LPS to 
induce cross tolerance may lead to less ischemia-reperfusion injury of the organs at risk. Although 
it is tempting to speculate that kidney function after elective transplantation may be improved by 
LPS-pretreatment and induction of cross tolerance of the donor, the phenomenon of cross 
tolerance needs first to be confirmed in humans in vivo. 
In conclusion, endotoxin tolerance develops in humans in vivo, mediated by an attenuated release 
of both pro- and anti-inflammatory cytokines, with the exception of TGFß and is associated with 
less leukocyte and endothelial cell activation. During our 5 day experiment, we found that 
endotoxin tolerance is a gradual occurring phenomenon, as all measured parameters showed a 
gradual decline starting at day 2-3. All volunteers tolerated the frequent administrations of 
endotoxin well and our human in vivo model can be useful in further unravelling of the 
pathophysiological pathways of LPS tolerance and exploring the beneficial effects of endotoxin 
tolerance in the prevention of ischemia-reperfusion injury.  
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Abstract 
Purpose: To investigate microcirculation and vascular reactivity during experimental endotoxemia 
and endotoxin tolerance in humans by comparing different methods of approach.  
Methods : Endotoxin tolerance was induced in 9 healthy volunteers by intravenous injection of 
2ng/kg/day lipopolysaccharide (LPS) on 5 consecutive days. Microcirculation and vascular 
reactivity were monitored before and after LPS administrations on day 1 and 5 by Near Infrared 
Spectroscopy (NIRS), Sidestream darkfield (SDF) imaging and forearm blood flow (FBF) by 
venous occlusion strain-gauge plethysmography during local intra-arterially infusion of 
endothelial-dependent vasodilator acetylcholine (0.5, 2 and 8 µg.min-1.dL-1).  
Results: LPS administration induced a significant rise in all measured cytokines. During repeated 
LPS administrations, the increase in cytokine levels was almost completely abolished, indicating 
the development of tolerance. NIRS showed a 79[62-92]% attenuation of recovery slope after 
ischemia 2 hours after LPS administration on day 1 (p= 0.04) which was absent on day 5 (p=0.72). 
SDF imaging showed a 33[14-40]% and 30[10-33]% diminished flow in medium and large sized 
microvessels respectively 2 hours after LPS administration on day 1 (p=0.07 and 0.04 respectively) 
which was absent on day 5 (p=0.47 for both vessels). FBF measurements showed an attenuation 
of acetylcholine-induced vasodilatory response with 67[45-72]% 4 hours after the first LPS 
administration (p=0.01), but not when tolerance was present on day 5 (p=0.61).  
Conclusions: Human endotoxemia results in endothelial dysfunction which can be adequately 
detected with different methods and was restored with development of LPS tolerance.  
 
Introduction 
The syndrome of sepsis is associated with a high mortality rate ranging from 27% in patients with 
sepsis and >50% in those progressing to septic shock182. Despite improved intensive care 
therapies, prognosis has improved little during the past decades. The microcirculation, which is a 
complex network of resistance vessels, plays an important role in the pathophysiology of the 
ongoing insult in sepsis183-185. In these resistance vessels, perfusion is dependent on various 
factors, such as arterial oxygen saturation, oxygen consumption, blood viscosity, red and white 
blood cell deformability186;187. Many of the abovementioned components of the microcirculation 
are affected in sepsis, resulting in a regional mismatch of oxygen supply and demand. Flow is 
shunted away from the susceptible microcirculation188 as injured endothelial cells fail to relax and 
release potent vasoconstrictors with ensuing cellular swelling. Furthermore, permeability is 
increased and leukocytes and platelets are trapped in the microcirculation resulting in progressive 
loss of perfusion and further organ injury.  
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Over the past years, with the use of new techniques, the human microcirculation has been 
examined in a large variety of clinical settings. One of the most striking findings was the 
pathological heterogeneity of microcirculatory flow. Some vascular beds show a preserved 
functional capillary density whereas others have a sluggish blood flow and some display no flow 
at all. Near infrared spectroscopy (NIRS)189-193 and sidestream darkfield imaging (SDF)183;184;194-196 
are noninvasive bedside techniques for continuous, real time monitoring of tissue oxygenation 
and microcirculatory flow, whereas forearm plethysmography has been used to investigate 
vascular reactivity in the resistance vessels of the forearm166;197-199. Endothelial dysfunction has 
been demonstrated by attenuated vasodilatory response to the infusion of acetylcholine into the 
brachial artery, and venous occlusion plethysmography measurements of FBF, in various vascular 
diseases and sepsis200. 
Endotoxin administration to humans is a model to study the pathophysiology of inflammation, 
coagulation and cardiovascular effects of sepsis. We previously demonstrated that LPS 
administrations on 5 consecutive days resulted in development of LPS tolerance201. The present 
study was undertaken to determine the effect of endotoxin administration and the development 
of LPS-tolerance on the microcirculation and vascular reactivity measured by 3 different methods 
of approach. In this study we measure baseline microvascular flow (SDF imaging) in addition to 
endothelium-dependent ischemia-mediated tissue oxygenation (NIRS) and pharmacologically-
induced endothelium-dependent vasodilatory response to acetylcholine (venous occlusion 
plethysmography) during endotoxemia, and after the development of LPS tolerance.  
 
Material and methods 
Subjects 
The study protocol was approved by the Ethics Committee of the Radboud University Nijmegen 
Medical Centre and complies with the Declaration of Helsinki including current revisions and the 
Good Clinical Practice guidelines. Nine healthy male volunteers gave written informed consent to 
participate in the experiments which were part of a larger endotoxin tolerance trial 
(NCT00246714). Subjects taking prescription drugs were excluded. Screening of the subjects prior 
to the experiment revealed no abnormalities in medical history and physical examination. Routine 
laboratory tests and ECG were normal. All subjects tested HIV and Hepatitis B negative. Eight 
hours prior to the experiment, subjects refrained from beverages and food.  
 
 
Endotoxin  
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U.S. Reference E.coli endotoxin (lot Ec-5, Centre for Biologic Evaluation and Research, Food and 
Drug Administration, Bethesda, MD) was used in this study. Ec-5 endotoxin, supplied as a 
lypophilized powder, was reconstituted in 5 ml saline 0.9% for injection and vortex mixed for at 
least 5 minutes after reconstitution. The endotoxin solution was administered as a single 
intravenous bolus injection during 1 minute at t=0.  
 
Study design 
LPS 2 ng/kg/day was administered intravenously on 5 consecutive days to induce endotoxin 
tolerance. Before every LPS administration the subjects were prehydrated with 1500 ml 
glucose/saline infusion164 and a continuous intravenous drip was started at 150 ml/hr for six hours 
after LPS administration. Symptom scores, temperature (tympanic thermometer, oC), heart rate 
(ECG), blood pressure (arteria brachialis) and circulating cytokines were obtained before LPS 
administration and serially during 6 hrs after the administration of LPS on day 1 and 5. The 
symptom score consisted of backache, shivering, nausea, headache and muscle ache. The 
volunteers were asked to score each of these complaints ranging from “not present” (score 0) up 
to “most severe ever” (score 5). Each time point represents a cumulative symptom score. TNFα, 
IL-6 and IL-10 were measured by use of the Luminex Assay (Bioplex-kits: BioRad Laboratories, 
Hercules, California USA) in accordance with manufacturer’s instructions. IL-1ra levels were 
determined using the ELISA-duoset of R&D systems. The lower detection limits were: TNFα: 36 
pg/ml; IL-6: 8 pg/ml; IL-10: 8 pg/ml; and IL-1ra: 0.2 pg/ml. Before and after LPS administration on 
day 1 and 5 microvascular changes and vascular reactivity were measured with NIRS, SDF imaging 
(at t= 0, 2 and 4 hrs, n=6) and forearm plethysmography (t=0 and 4 hrs).  
 
Tissue oxygenation measurements protocol 
NIRS protocol: 
The Beer-Lambert law states that the transmission of light through a solution of a coloured 
compound decreases exponentially as the concentration of the compound increases202. Near-
infrared (NIR) light transmits through tissues such as skin, adipose tissue and muscle without 
attenuation and allows for detection of changes in specific light-absorbing chromophores (e.g. 
haemoglobin) in humans in vivo. Because the absorption spectra of oxy- and deoxyhaemoglobin 
differ, their relative concentrations within tissue can be determined. The tissue probe used on 
skeletal muscle emits NIR light and collects light returning from tissue of an approximate depth of 
23 millimetres. The NIRS signal from skeletal muscle is hence a quantification of the tissue 
haemoglobin oxygen saturation specifically in the microcirculation. Muscle tissue oxygen 
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saturation (StO2) readings were obtained noninvasively using a NIRS probe (InSpectra Tissue 
Spectrometer, Hutchinson Technology, USA) placed over the skin of the thenar eminence. The 
positioning of the probe was chosen because of relatively low adiposity and consistency with 
other studies. StO2 values were continuously monitored and stored into a computer using 
InSpectra software analysis Program version 2.0 (Hutchinson Technology, USA) running in 
MatLab 7.0 (Math Works, USA). Baseline StO2 was recorded for 5 minutes, sample measurements 
signals were updated every 3.5s, after which ischemia was induced by inflating an upper arm cuff 
placed above the elbow to 50 mmHg above systolic blood pressure. After a 90-second period of 
ischemia, the occluding cuff was rapidly deflated to 0 mmHg. The slope of increase was defined as 
the utmost rate of StO2 increase 1 second after cuff deflation (%/s) and is thought to be 
representative for endothelial function191. 
 
SDF imaging protocol 
SDF imaging was performed using a handheld device that illuminates an area of interest with light 
emitted by a circle of light-emitting diodes (LEDs). The reflected light is returned through the 
inner image conducting core, which is optically isolated from the LEDs and caught on camera. 
Therefore, in SDF imaging, the illumination and reflectance light paths do not travel down and 
back the same pathway, which improves contrast and lowers surface reflectance and blurring. If a 
wavelength within the haemoglobin absorption spectrum is chosen (e.g. 548 nm), erythrocytes 
will appear dark and leukocytes may be visible as refringent bodies. The vessel walls itself are not 
visualized directly, although faint contours can be identified depending on the presence of 
intravascular erythrocytes. SDF imaging and semi quantitative analyses were performed as 
described in detail elsewhere195;196;203-205. In short, video images (microscan™, microvision Medical, 
Amsterdam, the Netherlands) were captured through fire-wire connection to a Toshiba laptop 
computer with fire-wire capturing. Clips of 20 seconds duration were used206 and each image was 
divided into four equal quadrants. Quantification of flow (MFI, microvascular flow index) was 
scored per quadrant, for each cohort of microvessel diameter. The vessel type diameters were 
small (10-25μm), medium (25-50μm) and large sized (50-100μm) microvessels with quantification 
of flow (0 no flow, 1 intermittent flow, 2 sluggish flow, and 3 continuous flow). SDF images were 
analyzed off line and in a blinded fashion by one of the investigators (PS) unaware of the applied 
protocol.  
 
 
Forearm venous occlusion plethysmography protocol 
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Forearm blood flow (FBF) was determined in both forearms with venous occlusion 
plethysmography (Filtrass Angio, Domed, Munich, Germany) as previously described198. In short, 
the brachial artery of the non-dominant arm was cannulated and 30 minute supine rest was taken 
before the start of the experiment in a temperature stable room. Venous occlusion was achieved 
by inflating the upper arm cuffs to 45 mmHg. Strain gauges were placed on the forearms and 
connected to plethysmograph to measure changes in forearm volume in response to inflation of 
the venous-congesting cuffs. FBF measurements were adjusted for systemic changes unrelated to 
the local stimulus by expressing flow in the experimental arm as a ratio of concurrent flow in the 
non-infused (control) arm (FBF ratio). The effect of acetylcholine infusion is expressed as ratio 
flow change compared to baseline flow. FBF data are the mean of measurements obtained during 
the last 3 minutes of each infusion (steady state). FBF and acetylcholine dose were normalized for 
forearm volume as measured with the water displacement method and expressed in millilitres per 
minute per decilitre forearm volume (mL.min-1.dL-1). After instrumentation of both arms and an 
equilibration period of 15 minutes, the vasodilator response to infusion of acetylcholine into the 
brachial artery was quantified. Each dose-response curve started with a 5-minute period of 
baseline FBF measurements, followed by 5 minutes intra-arterial acetylcholine infusion at 0.5, 2 
and 8 µg.min-1.dL-1. Four hours after LPS administration, the acetylcholine dose-response curve 
was repeated to determine the LPS-induced effects on acetylcholine-mediated vasodilation. On 
day 5 the measurements were repeated to determine the effects of endotoxin tolerance on 
endothelium-dependent vasodilation. 
Statistics 
LPS-induced changes on different time points were tested for significance using repeated 
measures ANOVA with the use of SPSS 14.0.1 for Windows (SPSS Inc. Chicago, IL, USA). The 
results of NIRS and SDF imaging and the effect of acetylcholine infusion in the forearm were 
tested for significance with repeated-measures ANOVA and paired data with the use of the 
Wilcoxon’s signed rank test for non-parametric data. Normally distributed data are expressed as 
mean±SE and not normally distributed data as median [interquartile range]. A p-value<0.05 was 
considered statistically significant. 
 
Results 
Baseline characteristics of the volunteers  
The age, weight, height, heart rate and blood pressure of the 9 volunteers were 222 years, 718 
kg, 1817 cm, 6516/min and 12718/7310 mmHg, respectively. 
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Endotoxin tolerance  
LPS administration induced the expected and transient flu-like symptoms, characterized by a 
significant rise in symptom score, temperature and heart rate, and a decrease in blood pressure 
(p<0.001 for all parameters). During repeated LPS administrations, changes in temperature, heart 
rate and blood pressure were significantly less pronounced indicating the development of 
endotoxin tolerance (p<0.001 for all parameters but blood pressure p=0.015, Table 1). During the 5 
days of the experiment all measured cytokines, both pro- and anti-inflammatory, were 
significantly attenuated also indicating the presence of tolerance (p<0.001 for all measured 
cytokines, Table 1). 
 
  Day 1  Day 5  
Differences 
between days  
 ΔSymptom score  +6.1  0.2  +0.3  0.0*  p<0.001  
 ΔTemperature (oC)  +1.8  0.1  +1.0  0.0*  p<0.001  
 ΔHeart rate (/min)   +35  1   +13 0*  p<0.001  
 ΔMean arterial  blood 
pressure (mmHg)  
 -20  1*    -14  1*  p=0.015  
 ΔTNFα (pg/mL)  +927  182  +31  9*  p<0.001 
  
 ΔIL-6 (pg/mL)  
+1785  230  +201  38*  p<0.001 
  
 ΔIL-10 (pg/mL)  
+155  28  +20  3*  p<0.001  
  
 ΔIL-1ra (pg/mL)  
+215  18  +14  7*  p<0.001  
 
 
Table 1: Clinical, inflammatory and hemodynamic parameters before and after LPS administration 
on day 1 (endotoxemia) and 5 when LPS tolerance developed, together with levels of circulating 
cytokines TNFα, IL-6 (pro-inflammatory cytokines) and  IL-10, IL-1ra (anti-inflammatory cytokines) 
in vivo. Differences between days were determined by ANOVA with repeated measures and 
significant for all parameters and measured cytokines. Data are expressed as mean deltaSEM. 
*indicates p<0.05.  
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Tissue oxygenation during endotoxemia  
NIRS  
To assess endothelial function, the slope of increase of StO2 after reperfusion was measured. 
Two hours after the first administration of LPS, the slope of increase was significantly attenuated 
with 79[62-92]% (p=0.04) and restored to levels above baseline 2 hours later. On day 5 the slope of 
increase after reperfusion showed no difference between time points after LPS administration 
when endotoxin tolerance was present (p=0.72, Figure 2).  
 
 
 
 
Figure 2: Near infrared spectroscopy (NIRS) data is shown as StO2 level of increase 1 second after 
reperfusion (slope of increase in %/s) after ischemia induced in the forearm 2 and 4 hours after LPS 
administration on day 1 and 5. The slope of increase was attenuated 2 hours after LPS 
administration, indicative for endothelial dysfunction. This attenuation was not present 4 hours 
after LPS administration or when LPS developed on day 5. Differences between days were 
determined by two-way ANOVA with repeated measures and differences within subjects by the 
Wilcoxon’s signed rank test. Data are expressed as median but the interquartile range was left 
out for sake of clarity. *indicates p<0.05. 
 
SDF imaging 
On day 1, the microvascular flow of the medium and large sized microvessels were attenuated 
(33[14-40]% and 30[10-33]% respectively) 2 hours after the first administration of LPS (p=0.07 and 
0.04 respectively). Two hours later the response was restored to levels above baseline for the 
medium-sized microvessels. On day 5 no statistically significant changes in flow were observed 
64
following the administration of LPS (p=0.47 for both medium and large sized microvessels). Two 
and 4 hours after the induction of endotoxemia and endotoxin tolerance, sublingual flow in small 
microvessels did not differ from baseline values (p=0.50 and 0.22 respectively at t=2 and 4 hrs, 
Figure 3).  
 
 
 
 
Figure 3: Sidestream darkfield (SDF) imaging data is expressed as microvascular flow index (MFI) 
for the 3 types of microvessels investigated before, 2 and 4 hours after LPS administration on day 
1 and 5. The vessel type diameters were small (10-25μm), medium (25-50μm) and large sized (50-
100μm) microvessels with quantification of flow (0 no flow, 1 intermittent flow, 2 sluggish flow, 
and 3 continuous flow). Microvascular flow was diminished in medium and large size microvessels 
2 hours after LPS administration but not 2 hours later or when LPS tolerance developed on day 5. 
Differences between days were determined by two-way ANOVA with repeated measures and 
differences within subjects by the Wilcoxon’s signed rank test. Data are expressed as median but 
the interquartile range was left out for sake of clarity. *indicates p<0.05. 
 
Forearm plethysmography  
On day 1 the acetylcholine-induced vasodilatory response was significantly attenuated during 
endotoxemia compared to baseline (67[45-72]% p=0.01 ANOVA repeated measures over the 
complete dose-response curve). On day 5 this LPS-induced attenuated vasodilatory effect of 
acetylcholine infusion into the forearm circulation was not observed (p=0.25, Figure 1).  
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Figure 1: Forearm plethysmography shows attenuation of the vasodilatory effect of intra-arterial 
infusion of increasing dose endothelium-dependent vasodilator acetylcholine 4 hours after LPS 
administration on day 1. This attenuation after LPS administration was not present on day 5 when 
LPS tolerance developed. The ratio is shown between the experimental arm en control arm. 
Differences between days were determined by two-way ANOVA with repeated measures and 
differences within subjects by the Wilcoxon’s signed rank test. Data are expressed as median but 
the interquartile range was left out for sake of clarity. *indicates p<0.05. 
 
Discussion 
Our study shows that systemic inflammation in humans induced by experimental endotoxemia 
results in microvascular and endothelial dysfunction that can be detected by 3 different methods 
of approach currently employed in (micro)vascular studies. We demonstrate that during acute 
endotoxemia baseline microvascular flow is decreased (SDF imaging), and endothelial 
dysfunction is present which can be detected either by an attenuated endothelium-dependent 
ischemia-mediated increase in tissue oxygenation (NIRS) or by and an attenuated 
pharmacologically-induced endothelium-dependent vasodilatory response to acetylcholine 
(venous occlusion plethysmography). Furthermore, we show a restored flow pattern when LPS 
tolerance develops and a restored endothelial function after repeated LPS administrations related 
to the development of LPS tolerance. 
Altered microvascular blood flow occurs frequently in patients with sepsis and may also play a 
role in the evolution from sepsis to septic shock. In addition, its presence is associated with 
outcome, as several studies have shown that microvascular blood flow was more severely altered 
in nonsurvivors than in survivors183;184;207. Indeed, microcirculatory alterations improved rapidly in 
septic shock survivors but not in patients dying of multiple organ failure regardless of whether 
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shock had resolved or not. Different patterns of microvascular alterations in septic shock could 
therefore characterize outcome185. Interestingly, the severity of the endothelial dysfunction 
detected by NIRS was related to the severity of the septic state and related to outcome in a 
previous study, as the slope of increase following ischemia was lower in septic shock patients 
compared to septic patients191.The pathophysiological mechanism by which endothelial 
dysfunction is sustained in septic patients is not clear, but since our study shows that endothelial 
function is restored during repeated administrations of LPS, it appears likely that the presence of 
circulating LPS itself does not account for this persistent dysfunction.  
A consistent feature of the pathology in severe sepsis and multiple organ dysfunction is 
the focal nature of their distribution. It is thought that the endothelium is an important 
determinant of this focal response in sepsis. Typically, patients only develop dysfunction in a 
limited number of organs. Furthermore distribution within organs is non-homogeneous. In 
accordance, the endothelium displays remarkable heterogeneity in health and disease states, 
integrating systemic changes in inflammation and coagulation in ways that differ in time and from 
organ to organ. This may be an explanation for the observed normalized endothelial function and 
flow with NIRS and SDF imaging 4 hours after LPS administration on day 1, whereas it is known 
that endothelial dysfunction is still present at that time in other vascular beds1, as adequately 
shown with the occlusion plethysmography in previous studies208 and confirmed in the present 
experiment. More research is needed to further unravel the mediators and kinetics of endothelial 
dysfunction during systemic inflammation.  
Because of the presence of LPS receptors on the endothelium209, it was thought that endotoxin 
may exert a direct effect on endothelial function. Indeed, after LPS administration an 
upregulation of the TLR-4 receptor is observed with subsequent increased production of various 
cytokines. However, during endotoxin tolerance, when an identical dose of LPS is administered 
on day 5, endothelial dysfunction does not occur this can either be due to downregulation of the 
TLR-4 receptor as the endothelial cell becomes tolerant or due to intracellular changes with 
normal regulated TLR expression on the endothelial cell. The other hypothesis, that LPS-induced 
cytokines or other inflammatory mediators are primarily responsible for endothelial dysfunction, 
is supported by the fact that in humans Salmonella typhi vaccination is associated with short-term 
impairment of endothelium-dependent dilation in conduit and resistance vessels that parallels the 
inflammatory response210.  
Several limitations to our study should be acknowledged. Due to the LPS-induced burden for the 
subjects and laborious and invasive nature of the experiments, LPS studies are usually performed 
in small groups of subjects. Nevertheless, in the 9 subjects studied, we were able to demonstrate 
the effects of systemic inflammation on various aspects of endothelial function by use of 3 
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methods currently employed in microcirculation research. Second, NIRS and SDF are limited by 
the semi-quantitative approach, the intra-user variability, movement artifacts and the indirect way 
of measurements that can all influence the obtained results. These limitations are, at least 
partially, obviated by the fact that serial observations per subject were obtained and analyzed in a 
blinded fashion. Although we demonstrated that the used methods were able to detect 
endothelial dysfunction during systemic inflammation, and the kinetics of endothelial function 
may be of importance in the critically ill patient, the clinical applicability of these methods is not 
yet established. Despite advances in our understanding of endothelial cell biology, this has not 
been translated into effective clinical therapies, although stabilizing the endothelium may be key 
to halting disease progression. It appears that organ dysfunction is often preceded by one unseen 
failing organ, the endothelium. Our study shows that bedside tests to identify endothelial 
dysfunction during systemic inflammation are possible, but whether or not endothelial 
dysfunction could become a treatment goal is not clear.  
In conclusion, systemic inflammation in humans induced by experimental endotoxemia results in 
microvascular and endothelial dysfunction, which can be detected by NIRS, SDF imaging, and 
venous occlusion plethysmography. These microcirculatory alterations were no longer present 
after repeated administrations of LPS, indicating that endothelial cells develop LPS tolerance 
either by downregulation of the LPS receptor or by modification of the TLR-4 signaling pathway, 
or that the LPS-induced cytokine response is responsible for the endothelial dysfunction. Studies 
focusing on surface receptor expression and analysis of markers for the intracellular pathways 
need to be conducted to differentiate between these putative pathophysiological mechanisms.   
An increased understanding of endothelial dysfunction during sepsis may result in novel effective 
treatment regimes. Whether or not induction of endotoxin tolerance prior to elective 
interventions associated with a high risk of developing endothelial dysfunction improves patient 
outcome is worth investigating and needs to be established. 
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“The role of cytokines and inducible nitric oxide synthase activation in 
endotoxemia-induced endothelial dysfunction” 
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Journal of cardiovascular pharmacology, submitted 
Abstract 
Sepsis is characterized by a blunted vascular responses due to impairment of endothelial function. 
The aim of our study was to assess endothelial function and the role of cytokines and nitric oxide 
(NO). Endotoxin tolerance was induced in 14 healthy volunteers by intravenous injection of 
2ng/kg/day LPS on 5 consecutive days. Forearm blood flow (FBF) was measured by strain-gauge 
plethysmography during dose-response curves of endothelial-dependent vasodilator 
acetylcholine  and endothelium-independent vasodilator sodium nitroprusside before and 4 hours 
after LPS administration on day 1 and 5. In another study, 7 healthy volunteers were given 
selective inducible NO synthase (iNOS) inhibitor aminoguanidine intravenous continuously from 1 
hour after a single LPS administration until 5 hours later. FBF showed an attenuation of ACh-
induced vasodilatory response with 67[45-72]% 4 hours after the first LPS administration (p=0.01) 
with an unchanged dose-response curve to SNP. This attenuation to ACh infusion did not occur in 
the presence of aminoguanidine (p= 0.21) and also did not occur when tolerance was present on 
day 5 (p=0.45).  
Our data demonstrate that endothelial dysfunction caused by endotoxemia does not occur when 
endotoxin tolerance develops, indicated by the absence of cytokine production and during 
administration of selective iNOS inhibitor aminoguanidine in vivo.  
 
Introduction 
Sepsis is characterized by arterial and venous dilatation and blunted vascular responses to 
vasoactive drugs. The endothelium plays a central role in the regulation of vascular tone, but the 
precise mechanism resulting in inflammation induced endothelial dysfunction in humans is not 
completely understood. A variety of mediators and substances is released by endothelial cells 
during sepsis, of which the excess formation of nitric oxide (NO) through the production of 
inducible NO synthase (iNOS) is thought to be mainly responsible for the loss of vascular tone.  
Exposure of endothelial cells to pro-inflammatory cytokines leads to expression of iNOS in the 
vessel wall resulting in the production of vast amounts NO.1-4 This excessive production of NO 
causes downregulation of endothelial NOS (eNOS) leading to an attenuated endothelium-
dependent vasodilatory response.5-7 However, in humans the role of circulating cytokines and 
activation of iNOS in endothelial dysfunction is controversial, as endothelial dysfunction during 
experimental endotoxemia in humans was not associated with an increase in iNOS expression in 
circulating macrophages, therefore arguing against involvement of iNOS in the observed systemic 
vasodilation and endothelial dysfunction.8  
72
 LPS, a membrane glycolipid of gram-negative bacteria, has been administered to healthy 
volunteers for many years to produce a model of systemic inflammation.  Endothelial function can 
be assessed by venous occlusion plethysmography, comparing the vasodilatory response of 
endothelium-dependent acetylcholine with the endothelium-independent vasodilator glyceryl 
trinitrate. 6;8-15 Repeated administrations of LPS in humans results in a phenomenon called 
‘endotoxin tolerance’,16 characterized by attenuated levels of cytokines. It is therefore a suitable 
model to investigate the role of cytokines in inflammation-mediated endothelial dysfunction. In 
addition, we have demonstrated that administration of the selective iNOS inhibitor 
aminoguanidine results in an attenuated release of NO during experimental endotoxemia.17  
The aim of the present study is to address endothelial dysfunction with regard to the 
pathophysiological role of inflammation-induced cytokine production and upregulation of iNOS. 
 
Material and methods 
Study population 
The study protocol was approved by the Ethics Committee of the Radboud University Nijmegen 
Medical Centre and complies with the Declaration of Helsinki including current revisions and the 
Good Clinical Practice guidelines. Written informed consent was obtained and 21 healthy non-
smoking volunteers (3 females, 18 males) participate in the experiments (LPS tolerance study: 
NCT00246714 and aminoguanidine study: NCT00184990). Subjects taking prescription drugs 
(except for oral contraceptives) were excluded. Screening of the subjects prior to the experiment 
revealed no abnormalities in medical history, physical examination, routine laboratory tests and 
ECG. All subjects tested HIV and Hepatitis B negative. Eight hours prior to the experiment, 
subjects refrained from beverages and food. Subjects laid supine in a temperature-controlled 
research facility on our intensive care unit with both forearms resting slightly above heart level.  
 
Study design 
After local anaesthesia (lidocaine HCL 20 mg/mL), the brachial artery was cannulated using a 20-
gauge catheter connected to an arterial pressure monitoring line (Siemens SC 9000, The Hague, 
The Netherlands). The arterial cannula was used for the administration of drugs (acetylcholine 
ACh and sodium nitroprusside SNP), monitoring of blood pressure and blood sampling. The heart 
rate was continuously monitored through ECG wires. A second cannula was placed in a deep 
antecubital vein for prehydration (1500 ml glucose/saline infusion 1 hour before LPS 
administration18) and the administration of LPS and aminoguanidine. LPS 2 ng/kg/day was 
administered in 14 subjects on 5 consecutive days to induce endotoxin tolerance and 7 subjects 
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received 1 gift of LPS followed 1 hour later by administration of the selective iNOS inhibitor 
aminoguanidine. A continuous intravenous drip was started at 150 ml/hr during six hours after 
each LPS administration. Vascular reactivity was measured by use of venous occlusion 
plethysmography of the forearm during dose-response curves of ACh en SNP infusions. Data on 
the development of LPS tolerance is partially similar to a previous published manuscript by our 
research group.16 
 
Drugs 
U.S. Reference E.coli endotoxin (lot Ec-5, Centre for Biologics Evaluation and Research, Food and 
Drug Administration, Bethesda, MD) was used in this study. Ec-5 endotoxin, supplied as a 
lypophilized powder, was reconstituted in 5 ml saline 0.9% for injection and vortex mixed for at 
least 5 minutes after reconstitution. The endotoxin solution was administered as a single 
intravenous bolus injection during 1 minute at t=0. One hour later the iNOS inhibitor 
aminoguanidine (Clinalfa, Laufelfingen, Switzerland) was co-administered as a single bolus 
injection (5mM) followed by a continuous infusion of 1.5 mmol/hr during 5 hours aiming at a 
plasma concentration 3 times the EC50 of aminoguanidine.19 The calculated dose was based on 
the pharmacodynamics of aminoguanidine19 and taken the IC50 of aminoguanidine (31μM)20 to 
inhibit iNOS into consideration. With this intervention, aminoguanidine-induced inhibition of iNOS 
was adequately reached as described in our previous experiments.17  
Intra-arterial infusion of acetylcholine 0.5-2-8µg/mL/dL (Clinalfa, Laufelfingen, Switzerland) and 
sodium nitroprusside 0.2-2-6µg/mL/dL (Clinical pharmacy, Radboud University Nijmegen Medical 
Centre, Nijmegen, the Netherlands) were used in incremental dosages and freshly prepared 
before each experiment.  
 
Clinical, hemodynamic and inflammatory responses to LPS administration  
On day 1 we measured clinical subjective (symptom score), hemodynamic (heart rate and blood 
pressure) and inflammatory parameters (temperature, white blood cell count, C-reactive protein 
levels and circulating cytokines) before and during 6 hrs after the administration of LPS. The 
symptom score consisted of backache, shivering, nausea, headache and muscle ache. All subjects 
were asked to score each of these complaints every 30 minutes after LPS administration ranging 
from “not present” (score 0) up to “most severe ever” (score 5). Each time point represents a 
cumulative score of all complaints. Temperature measurements were obtained every 30 minutes 
after LPS administration using a tympanic thermometer (oC). White blood cell counts were 
measured before (t=0) and after (t=1, 4 and 6 hrs) administration of LPS by flow-cytometry 
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(Sysmex XE-2100, Goffin Meyvis, Etten Leur, the Netherlands). C-reactive protein levels were 
measured before each LPS administration and 12 hrs after the first gift by use of routine 
laboratory test. Circulating levels of TNFα, IL-6 (pro-inflammatory cytokines) and IL-10 (anti-
inflammatory cytokine) were measured before (t=0) and after (t=30, 60, 90 min, 2, 4, and 6 hrs) 
administration of LPS by use of the Luminex Assay (Bioplex-kits: BioRad Laboratories, Hercules, 
California USA) in accordance with manufacturer’s instructions. The lower limits of detection 
were: TNFα: 36 pg/ml; IL-6: 8 pg/ml; IL-10: 8 pg/ml.  
In the LPS tolerance group we repeated the described measurements on day 5 to determine the 
effect of endotoxin tolerance on abovementioned parameters. 
 
Venous occlusion plethysmography 
FBF was determined in both forearms with venous occlusion plethysmography (Filtrass Angio, 
Domed, Munich, Germany) as previously described.10;14 Briefly, venous occlusion was achieved by 
inflating the upper arm cuffs to 45 mmHg. Strain gauges were placed on the forearms and 
connected to plethysmograph to measure changes in forearm volume in response to inflation of 
the venous-congesting cuffs. FBF and drug infusions were normalized for forearm volume as 
measured with the water displacement method and expressed in millilitres per minute per 
decilitre forearm volume (mL.min-1.dL-1). After instrumentation of both arms and an equilibration 
period of 15 minutes, the response to infusion of ACh and SNP into the brachial artery was 
quantified by measuring FBF. Each dose-response curve started with a 5-minute period of baseline 
measurements, followed by 5 minutes intra-arterial infusion and 5 minutes of recording FBF. FBF 
data are the mean of measurements obtained during the last 3 minutes of each infusion (steady 
state). Four hours after LPS administration, the vascular reactivity was measured again in the 
absence (n=14) or presence (n=7) of aminoguanidine to determine the role of NO on LPS-induced 
effects on vascular sensitivity. In addition, in the LPS tolerance group we repeated the 
measurements on day 5 to determine endothelium-dependent and –independent vasoactivity in 
the presence of endotoxin tolerance.  
 
Data analysis, calculations and statistics 
Restoring the endotoxemia-induced attenuation of the vasodilatory response to acetylcholine 
infusion during LPS tolerance or administration of aminoguanidine by 45% was considered 
clinically relevant. This is based on our previous studies with regard to LPS tolerance and the 
observed effect of aminoguanidine.17,21 Based on our LPS tolerance study, we used a standard 
deviation of 50% with an α=0.05 in the LPS tolerance group resulting in a sample size of 13.4 to 
achieve a power of 95%. Therefore, 14 subjects were included in the LPS tolerance group. In the 
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LPS with aminoguanidine group we previously found a standard deviation of 35% with an α=0.05, 
we calculated that a sample size of 6.6 would be sufficient to achieve a power of 95%, therefore, 7 
subjects were included in the aminoguanidine group.  
FBF measurements were adjusted for systemic changes unrelated to the local stimulus by 
expressing flow in the experimental arm as a ratio of concurrent flow in the non-infused (control) 
arm (FBF ratio). The FBF ratio is the optimal approach to analyse data from this kind of research.11 
The effect of ACh and SNP infusion in the forearm and the course of cytokine levels after LPS 
administrations on day 1 and 5 were tested for significance with an ANOVA for repeated measures 
by use of SPSS 14.0.1 for Windows (SPSS Inc. Chicago, IL, USA). Cytokine data were not normally 
distributed, therefore differences within subjects data were assessed the Wilcoxon signed rank 
test and expressed as median [25th-75th interquartile range]. The remaining data was normally 
distributed and therefore the paired student t-test was used and data is expressed as mean±SEM. 
A p-value<0.05 was considered statistically significant.  
 
Results 
Baseline characteristics  
The age, weight, height and blood pressure of the LPS tolerance group were 222 years, 718 kg, 
1817 cm, and 12718/7310 mmHg, respectively, and for the aminoguanidine group 222 years, 
7215 kg, 17911 cm, and 12811/7513 mmHg, respectively. No differences were observed 
between groups.  
 
Clinical, hemodynamic and inflammatory response to LPS 
Endotoxemia resulted in the expected and transient flu-like symptoms with an increase in 
symptom score, temperature, heart rate, white blood cell count, C-reactive protein, pro-
inflammatory cytokines (TNFα and IL-6) and anti-inflammatory cytokine IL-10 (p<0.001 for all 
parameters). In addition, a decrease in mean arterial pressure was observed (Table 1).  
After 5 consecutive days of LPS administrations to induce LPS tolerance, the changes in all 
parameters measured were significantly attenuated indicating the development of LPS tolerance 
(p<0.001 for all parameters except mean arterial pressure p=0.015, Table 1).  
Co-administration of aminoguanidine did not affect the LPS-induced changes in vital parameters 
compared to the first day of the LPS tolerance group (p=0.12 for heart rate and p=0.62 for mean 
arterial pressure between groups, Table 1). However, during the course of the endotoxemia 
experiments significant higher C-reactive protein levels (p=0.001) and lower levels of circulating 
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IL-6 (p=0.04) were observed in the presence of aminoguanidine compared to the results of day 1 
in the LPS tolerance group (Table 1).  
  
Table 1: Delta levels of clinical and inflammatory parameters with circulating cytokines (pro-
inflammatory TNFα and IL-6, anti-inflammatory IL-10) in both the LPS tolerance group (day 1 and 
5) and in the LPS+ aminoguanidine group.  The LPS-induced effect on different parameters was 
tested for significance by use of ANOVA for repeated measures. Clinical and inflammatory data is 
expressed as mean±SEM.  
 
Venous occlusion plethysmography 
FBF ratio during the dose response curve of ACh infusion increased from 0.9±0.1 to 5.5±0.8 before 
and from 1.0±0.1 to 2.6±0.4 four hours after LPS administration. The FBF ratio during SNP infusion 
increased from 0.8±0.1 to 4.9±0.9 before and from 1.0±0.1 to 3.3±1.0 four hours after LPS 
administration. Therefore endotoxemia resulted in a significant attenuation of the dose-response 
curve of endothelium-dependent vasodilator ACh with 59±6% 4 hours after administration of LPS 
(ANOVA with repeated measures, p=0.006) but not during infusion of endothelium-independent 
vasodilator SNP (p=0.24, Figure 1A).  
After 5 consecutive days of LPS administrations to induce LPS tolerance, FBF ratio during ACh 
infusion increased from 0.8±0.1 to 6.4±0.8 before and from 1.3±0.3 to 5.6±1.4 four hours after the 
5th LPS administration. FBF ratio during SNP infusion increased from 1.0±0.1 to 5.3±1.0 before and 
from 1.3±0.3 to 4.7±1.1 four hours after the 5th LPS administration. Therefore, the endotoxemia-
induced attenuated effect on the vasodilatory response during infusion of ACh (p=0.45) did no 
longer occur after 5 days of LPS administration (Figure 1A).  
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There was an increase in FBF ratio during ACh infusion from 0.9±0.1 to 3.9±1.2 before and from 
1.3±0.3 to 4.5±1.5 four hours after the LPS administration in the presence of aminoguanidine. FBF 
ratio during SNP infusion increased from 0.9±0.1 to 6.3±1.4 before and from 1.1±0.2 to 3.4±0.9 four 
hours after LPS administration in the presence of aminoguanidine. Therefore, during 
endotoxemia no attenuation of the vasodilatory response to ACh infusion (p=0.79) was observed, 
however, the dose-response curve of SNP infusion showed a significant attenuation of 
vasodilator properties in the presence of aminoguanidine (p=0.03, Figure 1B).  
 
 
 
Figure 1A: Increase in ratio of the FBF in the infused versus the non-infused arms (FBF ratio) 
during graded acetylcholine and sodium nitroprusside infusion before and 4 hours after the first 
LPS administration to induce endotoxemia (day 1) and on day 5 after repeated LPS 
administrations to induce LPS tolerance. FBF curves show attenuation of the vasodilatory effect 
of intra-arterial infusion of increasing dose endothelium-dependent vasodilator acetylcholine 4 
hours after LPS administration (t=4 hrs) compared to before (t=0) on day 1 without this 
attenuation present on day 5 when LPS tolerance developed. The dose-response curves were 
tested for significance by use of ANOVA for repeated measures. Data is expressed as mean±SEM 
and * indicates p<0.05.  
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 Figure 1B: Increase in ratio of the FBF in the infused versus the non-infused arms (FBF ratio) during 
graded acetylcholine and sodium nitroprusside infusion before and 4 hours after induction of 
endotoxemia in the presence of selective iNOS inhibitor aminoguanidine. FBF curves show no 
attenuation of the vasodilatory effect of intra-arterial infusion of increasing dose endothelium-
dependent vasodilator acetylcholine 4 hours after LPS administration however, FBF measurement 
after intra-arterial infusion of endothelium-independent vasodilator sodium nitroprusside show 
an attenuation of vasodilator properties in the presence of aminoguanidine. The dose-response 
curves were tested for significance by use of ANOVA for repeated measures. Data is expressed as 
mean±SEM and * indicates p<0.05. 
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Figure 2: Time line of peak levels of pro-inflammatory cytokine TNFα in the absence and presence 
of selective iNOS inhibitor aminoguanidine compared to the absolute forearm blood flow values 
in the absence and presence of aminoguanidine during endotoxemia (day 1). Data is expressed as 
median[interquartile range].  
Discussion  
In the present study we used 2 models to elucidate the role of cytokines and iNOS in human 
endotoxemia-induced endothelial dysfunction. In the first model LPS tolerance is induced to 
achieve attenuated cytokine levels, while in the second model administration of the selective 
iNOS inhibitor aminoguanidine was used. Both these models show that endothelial dysfunction in 
humans no longer occur when cytokines are attenuated or when an iNOS inhibitor is given, 
suggesting cytokine-mediated upregulation of iNOS as the main contributor in endothelial 
dysfunction in humans in vivo.  
The endothelium, once regarded as an inert cell layer, can be viewed both as a victim as well as a 
perpetrator of the inflammatory response as it plays a central role in the regulation and 
dysregulation of vascular tone. For instance, in sepsis there is an excessive, sustained and 
generalized activation of the endothelium, which results in arterial and venous dilatation and 
blunted vascular responses to vasoactive drugs. A potential trigger for the observed endothelial 
dysfunction in sepsis is the release of cytokines of which receptors have been found on 
endothelial cells.22 Whether cytokines exert their effect on the endothelial cell directly through 
their receptor or indirectly through upregulation of other mediators first, such as iNOS, is a 
matter of debate. The results of the present study are in line with previous studies which show a 
pivotal role of iNOS in various models of endotoxemia and septic shock.17;23-26 Furthermore, a link 
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was demonstrated between plasma concentrations of nitrite/nitrate (iNOS degradation products) 
and either mean arterial pressure or systemic vascular resistance.27 In contrast, a study performed 
in septic patients failed to show endothelial dysfunction to occur as acetylcholine-induced 
vasodilation was preserved28 and animal studies which show that cytokines induce vasodilation 
within 5 minutes29;30 while this was not confirmed in human isolated vessels.4 Of importance, 
cytokine-induced iNOS upregulation exhibits a 6- to 8-hour lag in cultured macrophages and 
endothelial cells.31 Indeed, the results of the present study underline this finding as persistent 
increased baseline FBF levels are observed 4-6 hours after LPS administration, while cytokines 
levels peak at an average of 110 minutes (Figure 2). The presence of a lag time can indicate that 
the direct effect of cytokines through their receptor is marginal. Our study also indicates the 
dominant role of iNOS over any kind of cytokine, since endothelial dysfunction does not occur in 
the presence of selective iNOS inhibitor aminoguanidine while the LPS-induced increase in 
cytokine levels is still present.  
Previous human studies show a raise in blood pressure and less need for vasopressor therapy in 
septic shock patients treated with the non-selective NOS inhibitor L-NMMA. 32;33 However, a 
subsequent randomized controlled multicenter phase III trial was stopped when interim analysis 
showed increased mortality in the L-NMMA group compared to placebo.34  The non-selective 
inhibition of both eNOS and iNOS may be responsible for this detrimental effect. However, these 
negative results do not imply that selective inhibition of iNOS is not a viable therapeutic 
opportunity in septic patients, as several animal studies have demonstrated that inhibition of 
iNOS versus inhibition of both iNOS and eNOS is of essential importance with regard to outcome. 
These studies have shown less hypotension35, full reversal of vascular hyporeactivity36, less liver37-
39, kidney37 and pancreas37;39 dysfunction and improvement of the microcirculation40 and finally 
survival39;41 by co-administration of  a selective iNOS inhibitor with LPS in isolated vessels and 
animal experiments. In humans, data concerning aminoguanidine treatment is sparse, but in 
accordance with the above, we have demonstrated that selective iNOS inhibition with 
aminoguanidine can abolish the inflammation-mediated renal injury17. 
As is shown in our experiment, inhibition of iNOS prevents endothelial dysfunction and the 
concomitant downregulation of physiologically essential eNOS 42;43 is thought to account for this 
observed loss of vascular tone.  Whether selective inhibition of iNOS to restore endothelial 
function can be a target for therapy in humans remains to be elucidated. Up to now, 
administration of aminoguanidine has been applied intravenously as an inhibitor of glycation end 
products in diabetic (n=454)44 and as NO inhibitor in heart failure patients45 and by nebulization in 
asthma patients,46 studies in which no serious side effects have been reported. Therefore it 
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appears feasible to further investigate aminoguanidine as a selective iNOS inhibitor in septic 
patients.  
The present study reveals 2 unexpected findings that need further elucidation. First, the lower 
levels of circulating cytokine IL-6 together with higher C-reactive protein levels in the 
aminoguanidine-treated group. This is unusual as IL-6 is strongly related to C-reactive protein 
levels,47 and we therefore argue that this finding is probably due to a type 1 error. Second, at 
baseline, intra-arterial SNP should increase FBF ratio to a similar extent in both study groups. 
However, in the aminoguanidine group the increase was higher than expected as one of the 
volunteers expressed very high ratios. When this volunteer is excluded in the statistical analysis 
the LPS-induced effect on the SNP-mediated vasodilatory response is no longer statistically 
significant. Therefore, it may partially explain the ‘attenuated’ vasodilatory response to increasing 
SNP infusions in the presence of aminoguanidine.  
In conclusion, ‘stabilizing’ the vascular tone may be a key to correct the inflammation-induced 
vascular dysfunction, halting disease progression and reducing mortality in sepsis. However, the 
need for a better knowledge of the NO pathway in humans is crucial if we are to make further 
progress in the field of sepsis. Our present study shows that endothelial dysfunction induced by 
LPS administration can be attenuated either by development of endotoxin tolerance or after 
administration of selective iNOS inhibitor aminoguanidine. The next step to explore the potential 
therapeutic properties of selective inhibition of iNOS would be systemic administration of 
aminoguanidine in septic patients. 
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“Endotoxin tolerance does not limit mild ischemia-reperfusion injury in 
humans in vivo” 
Draisma A, de Goeij M, Wouters CW, Riksen NP, Oyen WJG, Rongen GA, Boerman OC, 
van Deuren M, van der Hoeven JG, Pickkers P. 
Innate Immunity 2009, Aug 26 
Abstract 
Animal studies have shown that previous exposure to lipopolysaccharide (LPS) can limit ischemia- 
reperfusion (IR) injury, a phenomenon known as cross-tolerance. We tested whether 
pretreatment with LPS also protects against IR injury in humans in vivo.  
Interventions: 14 volunteers received bolus injections of incremental dosages of LPS (0.2 to 2 
ng/kg) on 5 consecutive days (LPS group). Before the first and 1 day after the last LPS 
administration, the forearm circulation of the nondominant arm was occluded for 10 minutes, 
with concomitant intermittent handgripping to induce transient ischemia. After reperfusion, 
blood was drawn to measure complement activation and 0.1 mg of 99mTc-labeled annexin A5 
(400 MBq) was injected intravenously to detect phosphatidylserine expression as an early marker 
of ischemia-reperfusion injury. Similarly, the control group (n=10) underwent the ischemic 
exercise twice, but without pretreatment with LPS.  
Measurements: Both hands were imaged with a gamma camera 1 and 4 hours after reperfusion, 
to measure the radioactivity in the thenar muscles. Annexin A5 targeting was expressed as the 
percentage difference in radioactivity between both hands. 
Main results:  Endotoxin tolerance developed during 5 consecutive days of LPS administrations. 
Annexin A5 targeting was 12.1±2.2% and 10.4±2.1% before LPS treatment at 1 and 4 hours after 
reperfusion, compared to 12.2±2.4% and 8.9±2.1% at 1 and 4 hours after reperfusion on day 5 (p=1.0 
and 0.6, respectively). Also, no significant changes in annexin A5 targeting were found in the 
control group. So, in this model, LPS-tolerance does not protect against I/R injury in humans in 
vivo. 
 
Introduction 
Lipopolysaccharide (LPS) is a glycolipid that constitutes the major portion of the outer membrane 
of Gram-negative bacteria. Through a Toll-like receptor-4 (TLR-4) mediated pathway the immune 
system responds to LPS administration with the production of pro- and anti-inflammatory 
cytokines, such as TNF, IL-6 and IL-10. After low-dose pretreatment with endotoxin, animals 
survive a subsequent challenge with a normally ‘lethal’ dose of endotoxin243-249, a phenomenon 
designated as endotoxin tolerance. We recently demonstrated that repeated administration of a 
similar dose of LPS on 5 consecutive days in healthy volunteers results in endotoxin tolerance in 
vivo, characterized by a total absence of symptoms and fever, and an almost abolished release of 
both pro-and anti-inflammatory cytokines201. Animal studies have shown that endotoxin also 
provokes “cross-tolerance” against other types of injury, such as ischemia-reperfusion (IR) injury. 
Pretreatment with endotoxin induced protection against hemorrhagic shock67;68, cerebral 
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ischemia69-73, coronary occlusion74-76 and hepatic77-80, pancreatic81, lung82;83 and renal ischemia-
reperfusion injury84;85.  
The pathophysiological mechanisms of IR injury are complex and mediated by multiple 
processes86, including production of reactive oxygen species (ROS), intracellular calcium 
overload, rapid restoration of physiologic pH, metabolic derangements, mitochondrial 
reenergization, and  inflammation and complement activation. Which IR injury pathway is 
predominantly influenced after LPS tolerance is not known. We hypothesized that LPS tolerance 
attenuates IR injury by limiting the degree of complement activation. 
IR injury in humans in vivo can be monitored by 99mTc annexin A5 scintigraphy87. Annexin A5 binds 
to negatively charged phosphatidylserine residues, which are exposed on the outer membrane 
leaflet shortly after an ischemic insult, as an early marker of IR injury88. We have previously shown 
that a relatively short period of forearm exercise during local blockade of the circulation increases 
targeting of annexin A5 in forearm skeletal muscle87. As such, targeting of radiolabeled annexin 
A5 can be used to detect early and reversible IR injury in humans in vivo, and modulation of IR 
injury90;91.  
Up to now, cross-tolerance has not been studied in humans whilst protection of IR injury through 
endotoxin tolerance potentially is of clinical importance in elective procedures in which episodes 
of organ ischemia are likely to occur, for example in elective organ transplantation procedures 
and major vascular surgery.  
In the current study, we aim to determine whether endotoxin tolerance is associated with 
protection against IR injury in humans in vivo.  In addition, measurements of complement 
activation following the ischemic insult will enable us to establish the possible role of the IR-
induced inflammatory pathway, and to determine whether or not the putative beneficial effect of 
LPS tolerance is mediated through this pathway.  
 
Materials and methods 
Subjects 
The study protocol was approved by the Ethics Committee of the Radboud University Nijmegen 
Medical Centre and complies with the Declaration of Helsinki including current revisions and the 
Good Clinical Practice guidelines. Written informed consent was obtained from all study 
participants. A total of 24 normotensive, medication free, non-smoking male volunteers 
participated in the experiments. Screening of the volunteers prior to the tests revealed no 
abnormalities in medical history and physical examination and routine laboratory tests and ECG 
were normal. All subjects were HIV and Hepatitis B negative. Twelve hours prior to the 
experiments, subjects refrained from alcohol and food, and because caffeine is a potent 
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adenosine receptor antagonist and can therefore block ischemic preconditioning91, subjects were 
also asked to abstain from caffeine containing beverages 24 hours before start of the experiment.  
Study design 
Fourteen subjects received incremental dosages of LPS intravenously on 5 consecutive days (0.2-
0.5-1.0-2.0-2.0 ng/kg/day). The clinical and inflammatory response after the LPS administration 
was monitored throughout the experiment and compared to a historical group of volunteers who 
were exposed to a different LPS tolerance protocol (2 ng/kg/day for 5 consecutive days)201. Before 
administration of each dose of LPS, the subjects were prehydrated with 1500 ml glucose/saline 
infusion164 and after LPS administration a continuous intravenous drip was started at 150 ml/hr 
during 6 hours. Before and after 5 days of LPS administrations subjects underwent an ischemia-
reperfusion (IR) experiment as described in one of the next sections. Ten subjects served as time 
controls (control group) for the IR experiments and performed the ischemic exercise twice 
without any administrations of LPS.  
 
Preparation of endotoxin and radiolabeled annexin A5 
U.S. Reference E.coli LPS (lot Ec-5, Center for Biologic Evaluation and Research, Food and Drug 
Administration, Bethesda, MD) was used in this study. LPS, supplied as a lypophilized powder, 
was reconstituted in 5 ml saline 0.9% for injection and vortex mixed for at least 5 minutes after 
reconstitution. LPS solution was administered as a single intravenous bolus injection during 1 
minute at t=0 hour. In subjects not tolerant to LPS, this dose of LPS is pyrogenic and elicits 
subjective side effects in our previous human endotoxemia studies166;167;250-252.  
99mTc-labeled annexin A5 was freshly prepared before each experiment as previously described87. 
Briefly, 0.1 mg of hydrazinonicotinamide-derivatized (HYNIC) recombinant human annexin A5, 
radiolabeled with 400 MBq 99mTc was administered. The recombinant human annexin A5 was 
provided to our centre by Theseus Imaging Corporation (NAS 2020) and derivitized with HYNIC at 
the department of Clinical Pharmacy of our hospital as described previously91.  
 
Clinical and inflammatory parameters during the experiment 
Symptom scores and body temperature were measured during the 5-day LPS administrations. The 
symptom score included scores for backache, shivering, nausea, headache and muscle ache. The 
volunteers were asked to score each of these symptoms every 30 minutes after LPS 
administration from day 1 until 5 ranging from “not present” (score 0) up to “most severe ever” 
(score 5). Each time point represents a mean cumulative score. Temperature measurements were 
obtained every 30 minutes after LPS administration from day 1 until day 5 using a tympanic 
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thermometer (oC). Arterial blood was sampled for white blood cell count (at t=0, 1, 4 and 6 hours 
after LPS infusion on day 1 and 5) and circulating cytokine levels (t=0, 0.5, 1, 1.5, 2, 4 and 6 hours 
after LPS infusion on day 1 and 5). 
Blood samples  
White blood cell counts were measured by flow-cytometry (Sysmex XE-2100, Goffin Meyvis, Etten 
Leur, the Netherlands). Circulating cytokine levels (TNFα, IL-6 and IL-10) were measured by use of 
the Luminex Assay (Bioplex-kits: BioRad Laboratories, Hercules, California USA) in accordance 
with manufacturer’s instructions. The lower limits of detection were: TNFα: 15 pg/ml, IL-6: 8 pg/ml 
and IL-10: 12 pg/ml. Plasma caffeine concentrations were determined by use of reversed-phase 
HPLC with ultraviolet detection set at 273 nm according to Schreiber-Deturmeny and 
Bruguerolle253.  
 
Complement activation 
C3bc and soluble terminal complement complex (TCC) levels before and immediately after IR 
were measured in EDTA anticoagulated blood samples that were immediately put on melting ice 
and after centrifugation, stored at -80 oC. Blood samples were drawn from the experimental arm, 
during the first experiment, to assess the effect of IR on complement activation. C3bc was 
quantified by using the monoclonal antibody bH6 specific for a neo-epitope expressed in C3bc as 
described previously254. TCC was measured as described previously by Mollnes255, using an ELISA 
(Rikshospitalet University Hospital, Oslo, Norway). Values are expressed as arbitrary units (AU) 
per ml, related to a standard of human serum activated with zymosan, defined to contain 1000 
AU/ml. 
Ischemia-reperfusion experiment 
In all volunteers the antecubital vein of the non-dominant arm was cannulated for blood sampling 
and administration of the 99mTc-annexin A5. Maximal voluntary contractile force was determined 
in the non-dominant arm with a dynamometer. The circulation of the non-dominant forearm was 
occluded for 10 minutes by inflation of an upper arm cuff to 200 mmHg. Immediately after 
occlusion of the forearm circulation, ischemia was combined with isometric contractions of the 
finger flexors at 50% of maximum contractile force. These contractions were performed 
rhythmically: 5-second contraction followed by 5-second relaxation until exhaustion. The total 
duration of ischemia was 10 minutes independent of the duration of contractions.  
Subsequently, radiolabeled annexin A5 was administered intravenously within 5 minutes after 
reperfusion following blood sampling in order to evaluate ischemia-reperfusion-induced 
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complement activation in the experimental arm. For each volunteer, the time interval between 
reperfusion and annexin A5 injection was kept constant for both experiments. Both hands were 
imaged 1 and 4 hours after the start of reperfusion by positioning them on the gamma camera 
(Siemens Orbiter camera equipped with low-energy, high resolution collimators) in a pronated 
position and scanned simultaneously until 150.000 counts were recorded or a maximal scanning 
period of 20 minutes had passed.  
 
Data analysis, calculation and statistics 
Baseline characteristics between groups were compared with an unpaired-sample two-sided t 
test. LPS-induced changes in symptom score, temperature, white blood cell counts and circulating 
cytokine levels were compared with a historical group of 14 volunteers who were exposed to a 
different LPS tolerance protocol (2 ng/kg/day for 5 consecutive days)201. Statistical analysis was 
performed using repeated measures ANOVA.   
Power analysis was based on data from previous studies with the annexin A5 method and an 
estimation of the protective effect of LPS tolerance. A decrease in percentage difference in 
targeting between both hands of 10% was considered clinically relevant. With an estimated SD of 
11% obtained from previous experiments and a significance level  of 0.05, a sample size of 13.1 
person was calculated to reach a power of 95%. We included 14 volunteers in the endotoxin group 
and 10 volunteers in the control group. All 92 digitalized gamma camera images were analyzed 
offline by the same investigator (W.J.G.O), in a blinded fashion, by use of Hermes Gold software. 
The predefined regions of interest were drawn in each hand representing the thenar muscles. The 
major veins and arteries were avoided in this region of interest. Radioactivity was expressed as 
counts per pixel. Annexin A5 targeting was expressed as the percentage difference in the region 
of interest (ROI) between the experimental (non-dominant) hand and the control hand (ROI 
experimental hand – ROI control hand) x 100% ROI control hand. 
Statistical analysis was performed for the LPS-exposed and control group separately using an 
ANOVA for repeated measures with the experimental day (IR experiment before and after the 
development of LPS tolerance) and time after reperfusion (1 and 4 hours) as within subject 
factors and workload (product of contractile force and duration of exercise) as a co-variate87. In 
addition, we performed a post-hoc analysis of subjects with 99mTc-annexin A5 targeting of >10 % 
and a covariate analysis with the lag time between reperfusion and annexin A5 injection. As we 
are interested in the change in annexin A5 targeting before and after LPS treatment and to 
correct for possible baseline differences between groups, data on targeting is also expressed as 
delta change on both 1 and 4 hours post-reperfusion. All data are expressed as mean±SEM unless 
specified otherwise. A p<0.05 was considered statistically significant.  
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Results 
Subjects: 
The baseline characteristics of both groups are depicted in Table 1. Groups were similar with 
respect to age, height, weight and blood pressure. Also, no baseline differences in workload and 
plasma caffeine concentrations were found between groups (table 1). One subject in the LPS 
group was excluded on day 2 of the LPS treatment due to symptoms suspicious of a viral 
infection.  
 
 
Table 1: Baseline characteristics of the volunteers. 
Baseline characteristics of the LPS group (n=14) and the control group (n=10). Groups were similar 
with respect to the mentioned parameters. Baseline characteristics between groups were 
compared using the unpaired-sample two-sided t test. Data are expressed as mean±SD. 
Clinical and inflammatory parameters during the experiment 
The first LPS administration (0.2 ng/kg) did not result in changes in symptom scores or 
temperature levels. After 2 ng/kg LPS on day 5, symptom scores were 1.6±2.4 with a peak 
temperature level of 36.8±0.6 oC (p<0.0001 and 0.045 respectively, compared to a symptom score 
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of 6.1±0.8 and a peak temperature level of 37.8±0.1oC  during the historical 2 ng/kg LPS 
experiment in subjects that are not tolerant to LPS, Figure 1).  
 
 
Figure 1: Clinical and inflammatory parameters.  
Clinical and inflammatory parameters of the LPS group (day 5, 2 ng/kg LPS) compared to a 
historical LPS tolerance group (5 consecutive days of 2 ng/kg LPS)201. Differences between days 
and groups were determined by two-way ANOVA with repeated measures and significant for all 
parameters. Data are expressed as meanSD. *indicates p<0.05.  
 
White blood cell counts increased up to 10.6±2x109/L after 0.2 ng/kg LPS on day 1 and 7.4±1.5x109/L 
after 2 ng/kg LPS on day 5 (p<0.0001, compared to day 1 of the historical 2 ng/kg LPS experiment, 
Figure 1). All plasma cytokines levels remained at baseline levels after the first administration of 
LPS (0.2 ng/kg), with a modest increase of levels on day 5 after 2 ng/kg LPS of TNFα 27±14 pg/ml, 
IL-6 222±120 pg/ml and IL-10 18±3 pg/ml (p<0.0001 for all cytokines compared to day 1 of the 
historical 2 ng/kg LPS experiment, Figure 1). The degree of tolerance obtained on day 5 with the 
present LPS dosing schedule was similar to our historical 2 ng/kg/day LPS experiment. 
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Complement activation 
On day 1, C3bc levels were 6.7±1.2 AU/mL before and 8.0±1.3 AU/mL after IR (p=0.1). TCC levels 
were 0.1±0.1 AU/mL before and 0.2±0.1 AU/mL after IR (p=0.3). 
 
Annexin A5 scintigraphy 
Data on annexin A5 targeting is presented in Figure 2. Although no difference in targeting 
between groups was observed, the control group showed significant less targeting compared to 
the LPS group at baseline, therefore delta targeting was calculated. The LPS group showed a 
delta 99mTc-annexin A5 targeting of 0.1±2.4% and -1.5±2.9% on the 1 and 4 hour scans respectively 
after 5 days of LPS administrations (p=0.98 and 0.61, respectively). The control group showed a 
delta annexin A5 targeting of -2.7±1.6% and -0.2±1.5% on  the 1 and 4 hour scan, without LPS 
treatment (p=0.1 and 0.9 respectively, Figure 2). In addition, subgroup analysis in subjects with an 
initial 99mTc-annexin A5 targeting of >10% (n=8) did not show a significant effect of LPS tolerance 
on annexin A5 targeting (p=0.7). Likewise, analysis with lag time between reperfusion and 
annexin A5 injections as a covariate did not reveal a significant effect of LPS tolerance on annexin 
A5 targeting (p=0.5). 
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Figure 2: Annexin A5 targeting between groups 
Filled bars represent the LPS group (n = 13), open bars represent the control group (n=10). Results 
are expressed as the percentage difference between 99mTc-annexin A5 targeting in the thenar 
region of the experimental hand and the control hand. No difference in annexin A5 targeting was 
observed between the LPS group and control group. Data are expressed as mean±SE. Data was 
compared using Wilcoxon’s signed rank test for differences between groups. ‘NS’ indicates no 
significant effect of treatment (LPS or placebo) within groups, on either the 1 or 4 hr post-
reperfusion scans.  
 
Discussion 
The present study demonstrates that in humans in vivo, administration of incremental dosages of 
LPS during 5 days induces profound endotoxin tolerance, indicated by the attenuated 
inflammatory response to “normally” pyrogenic doses of LPS on the fifth day associated with an 
abolished increase of circulating cytokines. More importantly, our study shows that LPS tolerance 
does not provide protection against mild IR injury, measured by 99mTc-annexin A5 targeting. In 
addition, we found no complement activation following the ischemic insult.  
These findings are in contrast with results from previous animal studies which consistently report 
that endotoxin tolerance also protects against IR injury77-85. In these animal experiments however, 
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ischemia is induced for a longer period and associated with more activation of inflammatory 
cascades. We therefore assume that the divergent severity of the ischemic insult accounts for the 
observed discrepancy. In our study on human volunteers, the ischemic stimulus was relatively 
mild, reflected by absent complement activation. Therefore, it cannot be ruled out that LPS 
tolerance protects against more severe ischemia, such as observed in major vascular and organ 
transplantation surgery256, procedures that are accompanied by severe complement activation. 
By using the same model of IR injury, we previously showed that the pharmacological modulation 
of the adenosine metabolism appears to be protective, as IR injury is prevented by ischemic 
preconditioning87, adenosine87, and dipyridamole90 whereas adenosine receptor antagonist 
caffeine prevents protection from ischemic preconditioning in healthy volunteers91 . This suggests 
that (in the absence of complement activation) these previously shown effects are mediated 
through one or several of the other IR injury pathways86. Therefore, based on the results of these 
studies and the present study, we can conclude that LPS tolerance does not protect against IR 
injury mediated through one of these other pathways not related to inflammation or activation of 
the complement system. Furthermore, in view of the reported activation of the inflammatory 
cascade with concomitant complement activation during more severe ischemia, it appears likely 
that LPS tolerance operates through downregulation of this pathway. 
The method used in the current study to detect IR injury has been validated in previous studies. 
We used 99mTc-annexin A5 scintigraphy of both hands after unilateral ischemic handgripping as a 
specific model to study the effect of endotoxin tolerance on IR injury in humans in vivo and as 
these interventions have also been demonstrated to limit myocardial ischemia-reperfusion injury 
in animal models257, IR-induced annexin targeting appears to be an accurate and relevant model 
to study IR injury in humans in vivo. Annexin A5 selectively binds to phosphatidylserine molecules, 
which are exposed on the outer membrane leaflet of affected cells immediately after an ischemic 
insult either as an early sign of apoptosis, or as a pathophysiological reversible event88;258. Binding 
of annexin A5 to these externalized molecules allows the detection of ischemia reperfusion injury 
by a gamma camera. It has not been studied in humans in vivo whether or not the IR-induced 
phosphatidylserine exposure is a rapidly reversible phenomenon. In a previous study, we have 
demonstrated a complete absence of annexin A5 targeting when the interval between 
reperfusion and annexin A5 administration was 1 hour87, suggesting that phosphatidylserine 
exposure is transient and reversible. Surprisingly, in the present study we observed a linear 
negative association between the lag time between reperfusion and annexin A5 injection and the 
final annexin A5 targeting, already during the first 5 minutes of reperfusion (data not shown). 
Thus, in this model of mild IR stress, timing of the 99mTc-annexin A5 injection is critical with a time 
window of less than 5 minutes after reperfusion to allow optimal visualization of IR-induced 
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phosphatidylserine exposition. Possible explanations for this short time window include rapid 
reversal of phosphatidylserine flip-flop and shedding of phosphatidylserine exposing membrane 
fractions. Regardless of its cause, the delay of annexin injection in this study could explain the 
lower targeting at baseline as compared with previous studies with this technique. Importantly, 
this does not explain the lack of effect of LPS tolerance on annexin targeting, since a post-hoc 
analysis of the subgroup of volunteers with initial annexin A5 targeting >10% and inclusion of lag 
time as co-variate, did not show LPS tolerance-mediated protection to IR injury either. Therefore, 
our negative findings indeed indicate the absence of any effect of LPS tolerance on the mild IR 
injury induced in this model. 
There is no apparent explanation for the considerably higher baseline level of annexin A5 
targeting in the LPS group compared to the time-control group. From the start of the study the 
experimental and analytical procedures were highly standardized, leaving little room for 
significant confounding. LPS-treated and control volunteers were studied in a random order and 
they all received the same dose of annexin A5. There were also no differences in workload 
between groups. Therefore we have to conclude that these differences at baseline are probably 
due to chance.  
In summary, endotoxin tolerance develops after 5 consecutive days of LPS administrations, but 
does not induce cross-tolerance against mild ischemia-reperfusion injury in humans. It appears 
likely that this lack of protection by LPS tolerance is due to the mild ischemic stimulus in our 
study, which did not induce activation of the complement system. We cannot exclude that LPS 
tolerance can limit IR injury following a more severe ischemic insult as observed during major 
vascular and organ transplantation surgery. 
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Chapter 7 
 
 
 
 
 
“Possible new markers of inflammatory-induced renal injury subside when 
endotoxin tolerance develops as measured by urine proteomics.” 
Draisma A, Heemskerk S, Bouw PWJM, Laarakkers C, van der Hoeven JG, Masereeuw R, 
Pickkers P. 
Abstract 
Purpose: Cytokines play an important role in the development of renal injury during sepsis. 
Because of its high mortality rate, early detection of inflammation-induced renal injury is of critical 
importance.  
Methods: We used Surface enhanced Laser Desorption/Ionization Time-of-Flight Mass 
Spectrometry (Seldi-TOF MS) to search for new biomarkers for early renal injury during acute 
systemic inflammation and after development of endotoxin tolerance in humans in vivo.  
Results: Repeated LPS administrations induced a diminished glomerular filtration rate of 33±7% 
(p=0.02) on day 2 and an increase in serum creatinine of 11±3% (p=0.002) on day 3, which was 
associated with the appearance of 15 peak intensities in the urinary protein profile including an 
increase in ß2-microglobuline levels (p=0.04) 6 hours after the first LPS administration. Four of the 
15 peak intensities on day 1 correlated with serum creatinine levels on day 3; 3950, 4445, 6723 and 
7735m/z (r=0.91, 0.97, 0.94, 0.87; p=0.03; 0.01; 0.02 and 0.05 respectively). With the development 
of LPS tolerance, renal function restored, reflected by a decrease in serum creatinine and ß2-
microglobuline levels to baseline (p=0.2 and 0.4 respectively, between day 1 and 5), and by 
attenuated peak intensities in the urinary protein profile (p<0.0001 for all 15 peak intensities).  
Conclusion:  Renal injury occurs during repeated endotoxemia and can be predicted by new 
urinary markers using proteome research. The four markers that correlated with the extent of 
renal injury may represent potential new biomarkers for renal injury and need further 
identification. The inflammation-induced renal injury subsided when LPS tolerance developed 
after 5 consecutive days of LPS administrations.  
 
Introduction 
Renal injury is a common clinical problem in the critically ill patient and is associated with poor 
outcome92;259. Recently, 2 large multicentre cohort studies reported the occurrence of renal injury 
in an estimated 30-40% of all patients admitted to the ICU260;261. Furthermore, critically ill patients 
who develop renal injury and require renal replacement therapy have mortality rates of 50-80%92.  
Sepsis has been identified as the most common cause of renal injury in intensive care units 
although the pathophysiology is not well understood. However in recent years, the emphasis has 
shifted from altered hemodynamics to a more aggravating role of pro-inflammatory cytokines, 
such as TNFα, IL-6 and IL1ß94-101. Nevertheless, clinical studies using anti-cytokine therapies failed 
to show a survival benefit in patients with sepsis94;262-264. Therefore, despite many advances in 
therapeutic and research techniques in the past 20 years fundamental changes in the outcome of 
patients with renal injury have not occurred. This limited progress may be related to many factors, 
including the lack of early diagnostic tests that indicate the onset of renal injury. Currently, the 
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diagnosis of renal injury is based on either the elevation of serum creatinine or the occurrence of 
oliguria whilst this is fraught with imprecision265.  
Since the introduction of functional genomics and proteomics, several new biomarkers have 
emerged104 with high sensitivity and specificity for detecting renal injury at an early stage. Of the 
various methods and platforms available, the Surface-Enhanced Laser Desorption/Ionization Time-
of-Flight Mass Spectrometry (Seldi TOF MS) technology has emerged as one of the preferred 
platforms for rapid urinary protein profiling266;267. This approach allows for rapid high throughput 
profiling of multiple urine samples, and detects low molecular weight biomarkers that are 
typically missed by other platforms, and even uncovers proteins bound to albumin. We recently 
established a Seldi-TOF MS method useful for the discovery of new urinary biomarkers after early 
stage kidney injury. This resulted in representative protein patterns whose joint action provide 
improved discrimination of mild kidney injury after a short ischemic period268. 
Endotoxin (lipopolysaccharide, LPS) is a glycolipid that constitutes the major portion of the 
outermost membrane of gram negative bacteria and when administered to healthy volunteers 
evokes a diverse spectrum of biological activities similar to that seen during early sepsis, including 
renal injury176;201. When healthy volunteers are challenged with repeated LPS administrations, a 
phenomenon called ‘endotoxin tolerance’ develops201. Interestingly, endotoxin tolerance 
provokes “cross-tolerance” against other forms of injury in animals, for example renal ischemia-
reperfusion injury84;85. However, whether LPS tolerance provides protection against 
inflammation-induced renal injury is a matter of debate. It was shown that instead of attenuated 
renal TNFα levels upon a LPS re-challenge, during repeated LPS administrations renal TNFα 
concentrations were about twice as high in the LPS preconditioned group compared to the LPS 
challenged naïve controls but still with less kidney injury85;105. Up to now, human studies are not 
available. 
The aim of the current study was to search for potential new early markers of renal injury during 
acute endotoxemia and to investigate whether renal injury can be ameliorated by the induction of 
LPS tolerance. 
 
Materials and methods 
Subjects:  
The study protocol was approved by the Ethics Committee of the Radboud University Nijmegen 
Medical Centre and complies with the Declaration of Helsinki including current revisions and the 
European Good Clinical Practice guidelines. Written informed consent was obtained from all study 
participants. Five male volunteers participated in the experiments (NCT 00246714). All volunteers 
had normal physical examinations, ECG and routine laboratory studies before start of the 
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experiment. Volunteers were not taking any prescription medications and they were negative for 
hepatitis B surface antigen and human immunodeficiency virus (HIV) infection 
 
Study design:  
Five subjects received iv bolus injections of 2 ng/kg/day Escherichia coli LPS for 5 consecutive days, 
with a 24 hour observation period on day 1 followed by a 6 hour period of observation on day 2-5. 
The subjects fasted overnight before the start of the experiment. Before each LPS administration 
the subjects were prehydrated with 1500 ml glucose/saline infusion164 and after LPS 
administration a continuous intravenous drip was started at 150 ml/hr during six hours.  
Endotoxin: 
U.S. Reference E.coli endotoxin (lot Ec-5, Center for Biologics Evaluation and Research, Food and 
Drug Administration, Bethesda, MD) was used in this study. Ec-5 endotoxin, supplied as a 
lypophilized powder, was reconstituted in 5 ml saline 0.9% for injection and vortex mixed for at 
least 5 minutes after reconstitution. The endotoxin solution was administered as a single 
intravenous bolus injection during 1 minute at a dose of 2 ng/kg of body weight. This dose of Ec-5 
endotoxin was pyrogenic and elicited subjective side effects in healthy non-tolerant male 
volunteers in our previous studies166;201;269. 
 
Hemodynamic and inflammatory parameters  
During the 5-day experiment, hemodynamic (heart rate and blood pressure) and inflammatory 
(temperature, C-reactive protein and cytokine levels) parameters were closely monitored. Heart 
rate (ECG) and mean arterial pressure (arterial catheter) were continuously monitored on day 1 
and day 5 and non-invasively on day 3. Temperature measurements were obtained every 30 
minutes after LPS administration from day 1 until day 5 using a tympanic thermometer (oC). C-
reactive protein levels were measured before each LPS administration during the 5-day 
experiment by use of routine laboratory techniques. Circulating levels of TNFα, IL-6 and IL-10 were 
determined before (t=0) and after (t=30, 60, 90 min, 2, 4, and 6 hrs) administration of LPS on day 
1 and 5 by use of the Luminex Assay (Bioplex-kits: BioRad Laboratories, Hercules, California USA) 
in accordance with manufacturers’ instructions. The lower limits of detection was for TNFα 36 
pg/ml; IL-6 8 pg/ml and for IL-10 8 pg/ml. 
 
Renal function 
Serum creatinine levels were measured before each LPS administration during the 5-day 
experiment by use of routine laboratory techniques. The glomerular filtration rate was calculated 
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by use of creatinine levels in urine samples (mmol/L) with the amount of urine (mL) and the serum 
creatinine levels (µmol/L) before, and during 3-hour periods after LPS administration on day 1 until 
day 5.  
 
Urine sample collection and preparation 
Freshly collected urine samples (before and until 6 hrs after LPS administrations) were briefly 
centrifuged (10 min, 2000 g) and stored with protease inhibitors270 in small aliquots at -80ºC to 
minimize  freeze-thaw cycles. A master pool reference sample of healthy volunteers was prepared 
by mixing together 50 urine samples containing 0.2 mmol creatinine each268.  
 
Seldi-TOF MS analysis 
We recently established a solid practical procedure for the preparation of urinary protein samples 
for downstream proteomic analysis268. We have compared urine samples from a defined group of 
intensive care unit patients with mild tubular injury after ischemia during coronary bypass graft 
surgery with those of healthy volunteers, and observed significant differences associated with 
early renal injury268. In the present study, a similar approach was used, in which urine samples 
were thawed, vortexed and diluted with ultraPURETM DNAse/RNAse free distilled water 
(Invitrogen, Breda, the Netherlands) to obtain constant creatinine concentrations (2.0 mmol/L). 
Subsequently, 250 µl urine was 10 times concentrated and desalted with centrifugal ultra-filtration 
(45-60 min, 13.000g 3 kD Microcon filters, Millipore, Billerica, USA).  
The preparation procedure was based on protocols from Ciphergen267;271 and described elsewhere 
in detail268. Briefly, we used an 8-spot weak cation-exchange chip (ProteinChip CM10; Ciphergen 
Biosystems, Fremont, CA). All spots were pretreated two times with 200µl binding buffer (0.1M 
ammonium acetate, pH 4.0) for 5 minutes on a shaking platform (500 rpm) in a bioprocessor. 
After pretreatment, 5 μl concentrated urine samples (100 nmol creatinine) were applied on the 
chip and incubated in the humid chamber for 30 min. Samples were removed with a pipette and 
spots were washed three times for 5 min with binding buffer (6µl). Spots were washed with 
distilled water and air dried for 10 min. Subsequently, 0.8 µl of a saturated solution of sinapinic 
acid in 0.5% (vol/vol) trifluoroacetic acid and 50% (vol/vol) acetonitrile, used as an energy-
absorbing matrix was applied to each spot surface, allowed to air-dry, and reapplied. The chip was 
analyzed in a PBS IIc Seldi mass spectrometer (Ciphergen Biosystems, Fremont, CA). Data were 
collected with standard operational settings, including starting laser intensity at 200, warming 
positions with 2 shots set at laser intensity 205, no warming shots included, high mass at 200 kDa, 
optimized from 1 kDa to 21 kDa in the low range and optimized from 20 kDa to 71 kDa in the 
middle range, detector sensitivity at 9. External mass calibration was performed with all in 1 
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protein standard II proteins (Ciphergen Biosystems). In the range of 3-20 kDa: hirudin BHVK (6964 
kDa), bovine cytochrome C (12230 Da), equine myoglobin (16951 Da). In the range of 20-70 kDa: 
bovine carbonic anhydrase (29023 Da), enolase for Saccharomyces cerevisiae (46671 Da) and 
bovine albumin (66433 Da). The timeline of every patient sample together with the masterpool is 
measured on the same chip in the same run. Inter-chip samples series were normalized by the 
masterpool. Masterpool samples were similar to that used previously268. Due to the standardized 
sample treatment and storage with a cocktail of protease inhibitors (in detail explained268), 
samples were stable for longer time. Obtained data were analyzed automatically using a minimal 
threshold peak of 30% of all spectra, a signal/noise first pass of 20 and a signal/noise second pass 
of 10. 
 
β2-microglobulin assay 
β2-microglobulin levels were measured with a non-competitive two-sided ELISA. The 
polyclonal rabbit anti-human β2-microglobulin was from DakoCytomation, Clostrup, Denmark. No 
protease inhibitors were added to this urine samples. Normal β2-microglobulin value in urine is < 
0.3 mg/L. 
 
 
Statistical analysis:  
Only clear peaks were selected and intensities of these manual detected peaks (Ciphergen 
ProteinChip Software 3.2.0) were exported to excel and corrected for masterpool intensities. A 
heatmap of these intensities was generated using the CIMminer algorithm 
(http://discover.nci.nih.gov/cimminer). Color-coded clustered image maps "heat maps" to 
visualize differences in protein expression profiles were generated using the CIMminer algorithm 
(). Statistical analysis with regard to the correlation between peak intensities and serum 
creatinine levels was performed by use of Graphpath Prism® (version 4.03 for Windows; 
Graphpath Software, San Diego, CA, USA) 
LPS-induced changes on different hemodynamic and inflammatory parameters between time 
points were tested for significance using ANOVA with repeated measures. Maximum levels of 
cytokines and ß2-microglobulin levels were tested for significance by use of the Wilcoxon’s signed 
rank test for non-parametric data and expressed as median levels with interquartile ranges. All 
other data is expressed as mean±SEM. A p <0.05 was considered statistically significant.  
In view of the explorative nature of this study, statistical analyses were not adjusted for multiple 
testing. 
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Results 
Baseline characteristics of the volunteers: 
The age, weight, height, heart rate and blood pressure of the volunteers were 211 years, 722 kg, 
1860.2 cm, 714 bpm and 1236/734 mmHg, respectively. 
 
Hemodynamic and inflammatory parameters 
Endotoxemia resulted in the expected and transient flu-like symptoms with a general increase in 
heart rate, temperature, C-reactive protein, pro-inflammatory cytokines (TNFα and IL-6) and anti-
inflammatory cytokine IL-10 with concomitant decrease in mean arterial pressure. After 5 
consecutive days of LPS administrations to induce LPS tolerance, all parameters measured were 
significantly attenuated indicating the development of LPS tolerance (difference between day 1 
and 5; p<0.001 for all parameters except mean arterial pressure p=0.015, Table 1). 
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Table 1: Hemodynamic and inflammatory parameters during endotoxemia and endotoxin tolerance  
Hemodynamic and inflammatory parameters of 5 healthy volunteers during 5 consecutive days of 
2 ng/kg LPS administrations to induce a LPS tolerant state. During the first and last day an arterial 
cannula registered mean arterial pressure (MAP) and heart rate continuously. On day 3 this was 
monitored non-invasively every half hour. Temperature levels were obtained every half hour by 
use of a tympanic thermometer. C-reactive protein levels were measured once a day before LPS 
administration and circulating cytokines were measured every hour on day 1 and 5, and before 
LPS administration on day 3. The response to LPS administration with regard to abovementioned 
parameters were tested for significance by use of ANOVA for repeated measures. Data are 
expressed as mean±SEM whereas the data concerning cytokine levels are expressed in median 
with interquartile range. “np” indicates not performed and * indicates p<0.05.  
 
Renal function 
Serum creatinine levels increased from 73±5 µmol/L before the fist LPS administration to a peak 
concentration of 82±6 µmol/L after 3 consecutive days of LPS administrations (p=0.01) which 
returned to baseline levels of 70±6 µmol/L on day 5 when LPS tolerance developed (p=0.2 
between baseline levels on day 1 compared to day 5, Figure 1). Glomerular filtration rate (GFR) 
measured every day decreased with 33±7% after 2 consecutive days of LPS administrations 
(p=0.02 between day 1 and 2) and returned to baseline levels on day 5, when LPS tolerance 
developed (p=0.18 between day 1 and 5).  
 
 
Figure 1: Serum creatinine levels (µmol/mL) and amount of urine produced by 5 healthy volunteers 
during 5 consecutive days of LPS administrations to induce a LPS tolerant state. Creatinine levels 
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were measured before each LPS administration and urine samples were collected 24hrs on the 
first day and 6 hrs after the following LPS administrations. The response of LPS administration 
with regard to maximum serum creatinine levels were tested for significance by use of Wilcoxon 
signed rank test. Data is expressed as mean±SEM. * indicates p<0.05 compared to day 1. 
 
Urine profiles by Seldi-TOF MS in individual urine samples  
Protein profiles of individual subjects showed peaks abundantly appearing in urine collected 6 
hours after the first LPS administration as compared to baseline and after LPS administration on 
day 5 (Figure 2).  
 
   
Figure 2: Color-coded clustered image maps or "heat maps" visualize differences in protein 
expression. Twenty peak intensities of the manual detected peaks within the 3-22 kDa range are 
shown generated in a heatmap. Red color means high intensities of the peaks and blue 
corresponds with low intensities. ‘S’ indicates subject and the number indicates the 5 different 
healthy volunteers. ‘a’=baseline day 1, ‘b’= 6 hours after the first LPS administration (day 1) and 
‘c’= 6 hours after the last LPS administration (day 5).  
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The abundance of urinary protein peaks is shown in Figure 3. In the range of 3-20kDa 15 out of 59 
automatically detected m/z values showed a significantly increase in peak intensities from 
baseline after the first LPS administration which returned to baseline levels after 5 consecutive 
days of LPS administrations (p<0.001 for all 15 measured peak intensities, Table 2). Four peak 
intensities measured on day 1, correlated significantly with the maximal raise in serum creatinine 
levels on day 3; 3950m/z (r=0.91, p=0.03), 4445m/z (r=0.97, p=0.01), 6723m/z (r=0.94, p=0.02) and 
7735m/z (r=0.88, p=0.05) depicted in Figure 4. To eliminate interindividual variabilities, we 
normalized the values and intensities for each individual measured at baseline. 
 
 
Figure 3A: Spectra of surface-enhanced laser desorption ionization time-of-flight mass 
spectrometry (Seldi-TOF MS) analysis of 5 volunteers of which peak intensities within the 3-22 kDa 
range are shown. ‘S’ indicates subject and the number indicates the 5 different healthy 
volunteers. ‘a’=baseline day 1, ‘b’= 6 hours after the first LPS administration (day 1) and ‘c’= 6 
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hours after the last LPS administration (day 5).The Seldi-TOF MS spectra show more peak 
intensities 6 hours after the first LPS administration (b) compared to baseline (a) and an 
attenuation of most peak intensities 6 hours after the 5th LPS administration when LPS tolerance 
developed (c).  
Figure 3B: Gel view of one volunteer (S.5) as in Figure 3A, also showing downregulation of most of 
the peak intensities after 5 consecutive days of LPS administrations when LPS tolerance 
developed.  
 
 
 
Table 2: Absolute levels of all 15 intensities with probable proteins 
Area under the curve generated data on all 15 intensities (m/z) which are detected in the urine 
proteome profile of 5 healthy volunteers before (t=0, day 1), 6 hours after the first and fifth LPS 
administration (t=0-6 day 1 and 5 respectively) with possible protein identification in the last row 
(http://www.nugo.org/nip/24000).  # indicates a significant (p<0.05) increase in peak intensity 
after the first LPS administration. Data was tested for significance by use of the one-way ANOVA 
and is expressed as mean±SEM. 
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Figure 4: Scatter plot of the 4 peak intensities (m/z) which significantly correlate to the delta raise 
in serum creatinine levels of 5 volunteers. Maximum levels of serum creatinine were found on day 
3 and data is tested for significance by use of Graphpath Prism 4 and expressed as r2 values. 
 
Urinary ß2-microglobulin levels 
LPS administration induced an increase in urinary ß2-microglobuline levels of 103[64-155]% 6 hours 
after LPS administration on day 1 (p=0.04) which returned to baseline levels 6 hrs after LPS 
administration of the 5th day, when LPS tolerance developed (p=0.35 between day 1 before LPS 
administration and 6 hours after the fifth LPS administration on day 5). 
 
 
Discussion 
The present work indicates the existence and the ability to detect subclinical renal injury during 
repeated experimental endotoxemia in humans at an early stage by urinary proteome 
investigations. More importantly, we found 4 peak intensities of unknown origin that correlated 
with the increase in serum creatinine levels 2 days later, and therefore may act as new potential 
biomarkers for inflammation-induced renal injury. During repeated LPS administrations, to induce 
LPS tolerance, renal protein loss subsided which may suggest that increased cytokine levels, 
present during acute endotoxemia, but not during LPS tolerance, are responsible for the tissue 
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injury observed during inflammation. However, this might illustrate a specific modification of the 
kidney function due to the phenomenon of LPS tolerance or could it be also observed after one 
single injection of LPS? 
Because of its high mortality rate, early detection and understanding the mechanisms of 
inflammation-induced renal injury is of critical importance. Up to now, the diagnosis of renal injury 
is either based on increase of serum creatinine levels or the presence of oliguria. Since serum 
creatinine levels can underestimate the extent of acute renal injury, the use of urinary proteome 
research seems promising. Moreover, by use of various biomarkers it has been shown that renal 
injury occurs in advance of any changed biochemical or clinical parameter. However, all 
biomarkers exert both advantages and shortcomings in predicting renal injury at an early stage 
and the ideal biomarker has not been discovered yet.  
Of possible clinical importance, multiple peak intensities were identified 6 hours after LPS 
administration in our experiments when serum creatinine levels were still unchanged. More 
importantly, we discovered 4 peak intensities of unknown origin which significantly correlate with 
the subsequent raise in serum creatinine levels.  
The question remains whether a single marker can fulfil the requirements to reliably detect a 
disease as early as possible. An alternative strategy is identification of several markers, which on 
their own do not present high specificity and sensitivity, but as a panel may work in concert and 
show a specific fingerprint that will help distinguish between the various types and pathogenesis 
of renal injury104;272.  
In the present study, we used a panel ranging from 3-20 kDa, as no significant LPS-induced peak 
levels were found in the 20-70 kDa range (data not shown). Furthermore, we did not find any of 
the peaks significantly altered in our previous study with coronary artery bypass graft-induced 
renal injury268. This suggests that indeed different pathologic mechanisms were triggered and it is 
likely that the abovementioned markers of renal injury are highly sensitive as experimental human 
endotoxemia and its systemic inflammatory response exerts a relatively mild and short insult on 
the kidneys.  
The biomarkers currently in use, e.g. α1-microglobulin, adenosine deaminase binding protein, 
cystatin C, renal tubular epithelial antigen-1, N-acetyl-ß-glucosaminidase, alanine-aminopeptidase, 
α/π-glutathione-S-transferase, γ-glutamyl transpeptidase, platelet activating factor, IL-18, kidney 
injury molecule-1 and Na/H exchanger isoform-3273 were not detected. Future research should be 
directed whether these biomarkers are associated with endotoxemia-induced renal injury.  
Due to the established properties of ß2-microglobulin274;275, with 99.9% reabsorption by cells of the 
proximal tubules after being filtered solely through the glomerulus, we used this established 
marker to estimate the effect of LPS and LPS tolerance on the kidney. ß2-microglobulin consists 
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of 99 amino acids with one disulfide bridge and has a molecular weight of 11.7 kDa. Production of 
ß2-microglobulin is very stable in individuals and its urinary excretion inversely relates to 
glomerular filtration rate275. The present study shows that ß2-microglobulin levels increased 
during renal injury and can be detected within the first 6 hours after LPS administration while 
serum creatinine levels remained unchanged within this time period. ß2-microglobulin levels tend 
to decrease over time resulting in cleaved ß2-microglobulin forms that were not detectable by 
available immunoassays274;276.  
There is mounting evidence that suggest that pro-inflammatory cytokines are also involved in the 
development of renal injury in septic patients94-101. However, data on whether LPS tolerance also 
protects against renal injury in humans are lacking, therefore the aim of the present study was to 
induce LPS tolerance in healthy volunteers to accomplish attenuated levels of pro-inflammatory 
cytokines by administration of LPS on 5 consecutive days and to monitor renal function by use of 
the urinary proteome. Indeed, LPS tolerance is associated with less renal injury adequately 
demonstrated by urinary proteome profiling. Whether the protective properties result from 
either an indirect effect through inflammatory changes on neutrophils and renovascular 
endothelial cell or from a direct effect on renal cytokine receptors remains unclear. 
Animal studies have shown that LPS tolerance protects against subsequent renal injury however 
the pathological mechanism appears to be different than expected85;105. In contrast to attenuated 
systemic TNFα levels measured in LPS tolerant animals, increased renal production of pro-
inflammatory cytokine TNFα was found. The finding of increased renal TNFα levels combined with 
less renal damage suggests that downregulation of renal TNFα receptors occurs277. Renal TLR-4 
expression was also measured and it appears that expression of this receptor was increased 
rather than downregulated during LPS tolerance, indicating a renal ‘stress response’, rather than 
reflecting a hyporesponsive state.105 Although in humans the mechanism is still unclear, our study 
demonstrates that repeated LPS administrations is associated with less renal injury.  
In conclusion, the present study shows that following the administration of LPS to humans, with 
urinary proteomics techniques it is possible to detect potential new markers that are associated 
with a subsequent increase in plasma creatinine. More importantly, four possible new biomarkers 
emerged with a positive correlation to serum creatinine levels, thereby underlining the role of 
biomarkers to forecast the approach of inflammation-induced renal injury at an early stage. 
During the development of LPS tolerance, urinary excretion of markers of renal injury subsides, 
and glomerular filtration rate normalizes.  
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“Endotoxin tolerance, mechanisms and clinical applicability” 
Draisma A, van der Hoeven JG, Pickkers P. 
Yearbook of critical care and emergency medicine 2009, p 51-58 
 
Introduction 
Lipopolysaccharide (LPS) is a glycolipid that constitutes the major portion of the outermost 
membrane of gram negative bacteria. LPS present in the bloodstream due to either dividing or 
dying bacteria in a septic patient or after intravenous administration of LPS to healthy volunteers, 
evokes an overwhelming spectrum of biological activities. LPS is considered one of the most 
powerful microbial stimulants of immune and non-immune cells. The immune system responds to 
LPS with a systemic production of pro- and anti-inflammatory cytokines, such as TNF, IL-6 and IL-
10, primarily aimed to eliminate invading pathogens and subsequently curtail the immune 
response. Although the pro-inflammatory cytokines are indispensable for the control of the 
growth and dissemination of the pathogen, excessive release of these cytokines, together with 
LPS-induced effects on endothelial cells, result in the clinical syndrome of septic shock and 
multiple organ failure. 
Tolerance to repeated administrations was a first noticed when typhoid vaccine was administered 
as a pyrogen to induce fever to slow the progress of Treponoma pallidum infection within the 
central nervous system. With repeated administrations the vaccine showed progressive loss of 
efficacy as a pyrogen, and an increase in dose was required to achieve the desired pyrogenic 
effect. In 1942 Favorite and Morgan administered purified LPS to humans for the first time and 
described the development of tolerance after repeated injections168. Furthermore, it was 
observed in the 1960s that animals receiving a low dose LPS had a markedly reduced mortality 
when challenged with a subsequent “lethal” injection of endotoxin. In the following years, 
endotoxin tolerance showed not only to provide protection against an subsequent identical insult 
with LPS, but also against other insults, specifically against ischemia-reperfusion injury, a 
phenomenon called ‘cross-tolerance’. This review will focus on the development of endotoxin 
tolerance and its effect on endothelial function in humans and the possible clinical applicability as 
cross-tolerance could protect against ischemia-reperfusion injury in certain patient groups. 
 
Mechanisms of endotoxin tolerance 
Toll-like receptors  
Toll like receptors (TLRs) recognize specific pathogen-associated molecular patterns. Up to now, 
10 members of the so called TLR family have been identified in humans. Various TLRs are involved 
in the recognition of different microbial products. Although TLRs do not exhibit specificity for a 
single microbial product, they are individually responsive to a limited group of molecules. Besides 
stimulation of TLR-4 with endotoxin, derived from the cell wall of Gram-negative bacteria, a wide 
variety of bacterial products, DNA and RNA viruses, fungi and protozoa play an important role 
through stimulation of other TLRs. For example, LPS and heat shock protein signal via TLR-4, 
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Gram positive peptidoglycan through TLR-1 and -2, TLR-3 is implicated in the recognition of viral 
double-stranded RNA, TLR-5 recognizes bacterial flagellin and single-stranded RNA viruses signal 
via TLR-7. Since the discovery of the various TLRs it is becoming more obvious that they act in 
concert in the signaling cascade following a specific ligand-specific stimulus. The resultant 
production and release of cytokines that occurs after TLR stimulation demonstrates a different 
spectrum per TLR. Also, the development of tolerance is not similar for each cytokine that is 
released, showing the complexity of this response. Interestingly, the development of tolerance 
after repeated exposure to LPS results not only in tolerance to subsequent TLR-4 stimulation 
both in vivo as well as in vitro, but also results in a diminished cytokine response after subsequent 
stimulation of TLR-2, -3 and -5 ex vivo127;129-131. In contrast, not following stimulation with a TLR-7 
agonist278, indicating that the development of tolerance is differentially regulated dependent on 
the specific TLR that is stimulated and the cytokine that is measured.  
 
Anti-inflammatory hypothesis and leukocyte reprogramming 
The mechanisms by which endotoxin tolerance develops is still not completely clear and during 
the last decades several pathophysiological pathways have been proposed (Table 1). The “anti-
inflammatory hypothesis” is based on the finding that endotoxin tolerance does not attenuate 
the release of different cytokines similarly resulting in attenuated levels of pro-inflammatory 
cytokines with concomitant increased levels of anti-inflammatory cytokines, resulting in the 
observed tolerance. Indeed, in vitro experiments show that LPS tolerance is associated with an 
increased expression of anti-inflammatory cytokines IL-1019;20 Il-1ra21 or TGFß21;22. However, the role 
of IL-10 has become controversial as numerous studies do not show enhanced expression of IL-10 
in whole blood or in animal in vivo studies. Finally, IL-10 knock-out mice show the dispensability of 
this anti-inflammatory cytokine in the development of endotoxin tolerance24.  
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 Table 1: An overview of used terms in describing the development of endotoxin tolerance with 
regard to pathophysiological pathways. In time, investigation of endotoxin tolerance has moved 
from soluble, secreted factors to the signal transduction machinery that resides on and inside of 
cells. Used abbreviations: SIRS: systemic inflammatory response syndrome: CARS: compensatory 
anti-inflammatory response syndrome, MARS: mixed antagonist response syndrome. 
 
The anti-inflammatory cytokine TGFß appears also to be involved in the development of LPS 
tolerance in previous in vitro and animal sepsis studies 21;22, as after administration of TGFß, 
animals become tolerant to LPS, whereas in animals that are infused with antibodies aimed to 
neutralize TGFß, no tolerance to LPS develops21. In humans, repeated infusions of LPS result in a 
diminished release of both pro- and anti-inflammatory cytokines such as TNFα, IL-6, IL-1ra and IL-
10 within 5 days, in contrast to LPS-induced circulating TGFß levels, which increase to the same 
extent after administration of LPS on day 5 compared to day 1201. These results indicate that TGFß 
may play a role in the development of LPS tolerance and that during this development production 
of TGFß is not downregulated in contrast to all other measured cytokines.  
Partly in accordance with the above, the investigation of endotoxin tolerance has moved from 
soluble, secreted factors to the signal transduction machinery that resides on and inside of cells. 
Alterations in signaling pathways and chromatin remodeling with the induction of LPS tolerance 
are referred to as “leukocyte reprogramming”56;57. Experiments show a reduced capacity of 
leukocytes from septic patients to produce pro-inflammatory cytokines while other (intra)cellular 
signaling pathways are unaltered (Table 2). Selection of different subpopulations of leukocytes 
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may also play a role in this phenomenon. Therefore, it is now clear that endotoxin tolerance is not 
synonymous with global downregulation of the immune response.   
 
 
Table 2: Alterations in signaling pathways and chromatin remodeling with the induction of LPS 
tolerance are referred to as “leukocyte reprogramming”. An overview of proposed mechanisms is 
presented during the development of endotoxin tolerance with regard to intra/extracellular 
changes. Used abbreviations: TLR: Toll like receptor, IRAK: IL-1 receptor associated kinase, Iκ-Bα: 
Inhibitory proteins, Erk: Extracellular signal-related kinase, MAP3K: Mitogen-activated protein 
kinase, NFκB: Nuclear factor kappa B. 
 
Endothelial function and microcirculation during LPS tolerance  
Whereas the endothelium was once regarded as the wall paper of blood vessels, an inert cell 
layer, it is now clear that the total opposite is true. During critical illness, e.g. sepsis, the 
endothelial cell can be viewed as both a victim as well as a perpetrator of the inflammatory 
response as it plays a central role in the (dys)regulation of vascular tone.  Hemodynamic 
instability with inadequate vasodilation combined with simultaneous presence of inadequate 
vasoconstriction in different vascular beds represents a typical characteristic of septic shock. This 
dysregulation of vascular tone in septic patients is the consequence of an attenuated 
vasoconstrictive response to catecholamines, while at the same time the endothelium-dependent 
vasodilatory response is also impaired. Production of iNOS with subsequent generated NO are 
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thought to be responsible as it has been observed that endothelial cells of blood vessel walls 
upregulate iNOS and subsequent huge amounts of NO cause systemic vasodilation108;109;279. In 
septic models, this excessive NO production also accounts for downregulation of physiologically 
essential endothelial NO-synthase (eNOS) leading to the observed attenuated endothelium-
dependent vasodilatory response112-114. 
The precise mechanism between inflammation and endothelial dysfunction is not completely 
understood. It is unclear whether LPS exerts a direct effect on endothelial function through 
activation of TLR-4 receptors that are present on endothelial cells 280, or that the LPS-induced 
cytokines or other inflammatory mediators are primarily responsible for endothelial dysfunction. 
The latter is supported by the fact that in humans Salmonella typhi vaccination is associated with 
short-term impairment of endothelium-dependent dilation in conduit and resistance vessels that 
parallels the inflammatory response210. Experimental human endotoxemia studies combined with 
forearm blood flow measurements demonstrate the presence of endothelial dysfunction during 
endotoxemia as the acetylcholine-induced vasodilatory response in the human forearm is 
attenuated during endotoxemia, whereas the vasodilatory response to sodium nitroprusside is 
unaffected113;166. Repeated LPS infusions during 5 consecutive days result in a marked attenuation 
of the acetylcholine-induced vasodilatory response on day 1, whereas this effect following LPS 
administration on day 5 is not present, associated with the diminished release of cytokines 
(Draisma et al. unpublished work). This suggests that LPS-induced cytokine production mediates 
the observed endothelial dysfunction, although downregulation of the TLR-4 receptor or altered 
intracellular signaling in the endothelial cell cannot be ruled out.  
Endothelial cell activation can also be measured by the release of von Willebrand factor, as this 
release is one of the first events that occur after the administration of endotoxin152. Repeated LPS 
administrations show peak levels of vWF 6 hours after LPS administration on day 1, but not on day 
5 which is another indication for the presence of endothelial dysfunction during endotoxemia 
which does not occur once LPS tolerance develops201. So, LPS-induced cytokine release results in 
activation of iNOS, leading to downregulation of eNOS and endothelial dysfunction, whereas 
these processes do not occur during LPS tolerance.  
The complex interplay between NO and LPS tolerance is also illustrated by the fact that selective 
iNOS inhibition abolishes the development of tolerance to stimulation with a TLR-5 agonist, but 
does not influence development of tolerance to either TLR-2 or -4 agonist stimulation278. 
In the last decade, the role of the microcirculation during systemic inflammation has become 
more clear. Near Infrared Spectroscopy (NIRS) and sidestream darkfield imaging (SDF) are 
noninvasive bedside techniques for continuous, real time monitoring of the microcirculation, and 
one of the most striking findings was the heterogeneity of microcirculatory flow during different 
128
disease states. More importantly, microvascular blood flow is more severely altered in 
nonsurvivors than in survivors of sepsis. Indeed, microcirculatory alterations improve rapidly in 
septic shock survivors but not in patients dying of multiple organ failure regardless whether shock 
resolves or not. Different patterns of microvascular alterations in septic shock patients could 
therefore characterize their outcome185. Interestingly, the increase of tissue oxygenation after 
local ischemia measured by (NIRS) is also related to the severity of the septic state and patient 
outcome191. It is observed that during experimental acute endotoxemia microvascular flow is 
decreased (SDF imaging) in addition to an attenuated endothelium-dependent ischemia-mediated 
increase in tissue oxygenation (NIRS) and an attenuated pharmacologically-induced endothelium-
dependent vasodilatory response to acetylcholine (venous occlusion plethysmography). In 
addition, these microvascular changes are not longer present after repeated LPS administrations, 
related to the development of LPS tolerance (Draisma et al. submitted work). 
 
Clinical applicability and therapeutic possibilities 
Cross-tolerance 
Although endotoxin has been used to induce tolerance against a subsequent identical stimulus, it 
has also been demonstrated that endotoxin provokes tolerance against other forms of injury, a 
phenomenon called ‘cross tolerance’. A vast amount of animal experiments demonstrate that 
pretreatment with endotoxin results in protection against hepatic77-80, pancreatic81, lung82;83 and 
renal ischemia-reperfusion (IR) injury84;85. In patients that will undergo an elective intervention 
during which a high risk of ischemia-reperfusion injury is expected, pretreatment with LPS to 
induce tolerance may improve their outcome. Major vascular surgery and elective organ 
transplantation are examples of patient groups that might benefit. However, whether this LPS 
tolerance-mediated protection against IR injury also exists in humans in vivo is unknown.  
It is possible to detect IR injury in humans in vivo with use of 99mTc annexin A5 scintigraphy as 
annexin A5 binds to negatively charged phosphatidylserine87. In general, the ischemia-induced 
injury results in a flip-flop of the phosphatidylserine molecules in the ischemic cell membranes 
allowing radiolabeled annexin A5 to bind this molecule and visualize this ischemia-induced injury 
through a 99mTc annexin A5 scintigraphy. As such, targeting of radiolabeled annexin A5 can be 
used to detect early and reversible ischemia-reperfusion injury in humans in vivo and 
pharmacological modulation of IR injury has been demonstrated90;91. Nevertheless, with use of 
this method, LPS tolerance does not provide protection against ischemia-induced injury (Draisma 
et al. unpublished work). This negative finding is associated with the lack of complement 
activation observed directly following reperfusion, suggesting that this IR model is too mild to 
induce an ischemia-induced  inflammatory response that could be down-regulated by the 
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presence of LPS tolerance. More severe ischemia, e.g. following myocardial infarction does result 
in an inflammatory response in humans281 suggesting that during these circumstances LPS 
tolerance may exert a protective effect. For this reason, it cannot be excluded that LPS tolerance 
provides protection against IR injury in humans in vivo, but apparently the IR injury must be 
severe enough to elicit an ischemia-induced inflammatory response. 
The previous described induction of LPS tolerance in humans in vivo was brought about by 
repeated injections of 2 ng/kg LPS during 5 consecutive days. As a consequence, volunteers 
experienced flu-like symptoms and fever during the first few days that subsided during the 
development of LPS tolerance. For cardiovascular compromised patients this would limit the 
clinical applicability. Of clinical importance, an incremental LPS dose protocol starting at 0.2 ng/kg 
LPS increasing to 2.0 ng/kg on day 4 and 5, results in an equal degree of LPS tolerance, but the 
subjects remain almost completely free of symptoms and no fever or relevant cardiovascular 
changes are observed. Therefore, this incremental LPS dose schedule will be easier applicable in 
clinical practice (Table 3). 
 
Table 3: Clinical, hemodynamic and inflammatory parameters comparing 2 different LPS 
administration protocols to develop LPS tolerance. In one group 2 ng/kg LPS was administrated 
daily for 5 consecutive days. In the other group an incremental dose protocol was used with 0.2 
ng/kg LPS on the first day, followed by 0.5 ng/kg on day 2; 1 ng/kg LPS on day 3; 2 ng/kg LPS on 
day 4 and 5. The symptom score consisted of backache, shivering, nausea, headache and muscle 
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ache. The volunteers were asked to score each of these complaints every 30 minutes after LPS 
administration from day 1 until 5 ranging from “not present” (score 0) up to “most severe ever” 
(score 5). The maximum score of each subject was used to calculate a group mean. Temperature 
levels were obtained every 30 minutes after LPS administration from day 1 until day 5 using a 
tympanic thermometer (oC). Heart rate and Mean arterial pressure data were obtained by use of 
an arterial cannula and therefore monitored continuously. Both groups developed LPS tolerance 
indicated by the attenuated levels of pro-inflammatory cytokine TNFα on day 5. After the first LPS 
administration, all displayed parameters are significantly more pronounced in xx group compared 
to the incremental group, whereas the development of LPS tolerance on day 5 was not different 
between the 2 groups, indicating that a similar degree of LPS tolerance was obtained associated 
with less symptoms in the incremental dose group, making this schedule easier applicable in 
clinical practice. 
 
Conclusions 
It is possible to induce endotoxin tolerance in humans in vivo by repeated LPS administrations 
associated with attenuated levels of most pro- and anti-inflammatory cytokines, with the 
exception of TGFß. Also, LPS tolerance is associated with less endotoxemia-induced endothelial 
dysfunction in humans in vivo. Whether or not LPS tolerance provides protection against 
ischemia-reperfusion injury in humans remains to be elucidated. In view of the fact that LPS 
tolerance can be easily and safely induced in humans, and its putative beneficial effects in certain 
patient groups, further research is warranted. 
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In summary 
 
 
In this thesis various aspects of acute endotoxemia and endotoxin tolerance in humans in vivo are 
investigated. The attenuated response to repeated endotoxin administrations is called endotoxin 
tolerance. Animal studies show that pretreatment with endotoxin followed by a normally lethal 
endotoxin dose does not result in death of the animal. Endotoxin tolerance is thought to not only 
protect against subsequent endotoxin administrations, but also against other forms of injury, e.g., 
ischemia-reperfusion injury.  
In this thesis we describe the development of endotoxin tolerance in humans in vivo. We 
specifically studied the potential beneficial effect of endotoxin tolerance on endothelial 
dysfunction, renal injury, microcirculatory changes and ischemia-reperfusion injury.  
 
Introduction 
Chapter 1 is an overview on endotoxin tolerance.  
Endotoxin (Lipopolysaccharide, LPS) is part of the outer membrane of gram-negative bacteria 
and is recognized by a specific receptor, the Toll-like receptor-4 (TLR-4) present on inflammatory 
cells. This interaction with its receptor initiates an inflammatory cascade with production of pro- 
and anti-inflammatory cytokines. Cytokines are essential for infection control, however when 
released in large quantities cytokines can also result in injury to organs.  
 
In the early 20th century, the pyrogenic effect of LPS was used for the treatment of syphilis, 
however during repeated administrations the same dosage of LPS resulted in less fever and the 
amount of LPS had to be increased to obtain the same pyrogenic effect. This represents the first 
description of endotoxin tolerance in humans. 
In the following years it was demonstrated that the development of endotoxin tolerance 
protected not only to a subsequent LPS challenge, but also to other forms of injury like ischemia-
reperfusion injury. Ischemia-reperfusion injury occurs after reperfusion of an organ deprived of 
blood flow. Both ischemia and the subsequent reperfusion may result in local injury. Animals 
pretreated with LPS before an ischemia-reperfusion experiment show less injury compared to 
animals that were not pretreated with LPS. Therefore, endotoxin tolerance appears to protect 
against ischemia-reperfusion injury, a phenomenon called cross tolerance.  
 
LPS has been administered to healthy volunteers for more than 100 years as a model for sepsis 
and is a controlled model for investigating the inflammatory response and its effect on different 
systems in the human body.  
In our experimental studies we administered LPS to healthy volunteers on 5 consecutive days to 
induce endotoxin tolerance. One hour after the first LPS administration, the volunteer 
134
experiences transiently flu-like symptoms like backache, shivering, headache, nausea and fever. 
Hemodynamic changes include increase in heart rate and temperature levels with decrease in 
blood pressure levels. During this period all measured cytokines, both pro- and anti-inflammatory 
cytokines increase. After the fifth LPS administration, the volunteer experiences none of the 
abovementioned alterations and nearly all cytokines are attenuated, indicating the development 
of endotoxin tolerance.   
 
Part A: Pathophysiology of endotoxin tolerance  
Chapter 2 describes the development of endotoxin tolerance in vitro. Before and after a single 2 
ng/kg LPS dose, blood samples drawn from healthy volunteers were stimulated in vitro not only 
with LPS (TLR-4 agonist), but also with ligands of other TLRs. We showed that a single LPS 
administration in humans results in the development of endotoxin tolerance after stimulation in 
vitro, but also in tolerance for other (TLR-3 and -5), but not all (TLR-2 and -7) TLR-agonists.  
Second, we investigated the effect of in vivo administration of the selective inducible NO synthase 
(iNOS) inhibitor aminoguanidine during acute endotoxemia on the development of endotoxin 
tolerance in vitro. The observed tolerance to TLR-4 stimulation was not influenced by selective 
iNOS inhibition, whereas TLR-3 stimulation after iNOS inhibition resulted in a restored 
Interleukine-10 (IL-10) response and development of tolerance to TLR-5 agonists was completely 
attenuated. These results indicate that the role of NO on the development of tolerance is 
complex and probably different for the various TLRs stimulated and resultant pro- and anti-
inflammatory cytokines released.   
 
Chapter 3 describes the development of endotoxin tolerance in humans in vivo after 5 
consecutive days of LPS administration. We specifically investigated the so called “anti-
inflammatory hypothesis” that postulates that the development of endotoxin tolerance is 
mediated through increased production of anti-inflammatory cytokine IL-10 most importantly, but 
also of transforming growth factor-ß (TGFß) and interleukine-1 receptor antagonist (IL-1ra). These 
anti-inflammatory cytokines are thought to be responsible for the downregulation of pro-
inflammatory cytokines (predominantly tumor necrosis factor-α, TNFα).  
Our experiments showed that after the first LPS administration all pro- and anti-inflammatory 
cytokines increase. However, after 5 consecutive days of LPS administration both pro- (TNFα, 
interleukine-6 IL-6) and anti- (IL-10, IL-1ra) inflammatory cytokines, with the exception of TGFß, are 
attenuated. These data may indicate that TGFß is an essential factor in the development of 
endotoxin tolerance, it also demonstrates that LPS tolerance observed in vivo in humans is not 
generalized to all anti-inflammatory cytokines. Therefore, our experiment does not support 
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animal studies showing that the anti-inflammatory cytokine IL-10 plays an important role in the 
development of endotoxin tolerance.  
 
Part B: Microcirculation and endothelial function  
Chapter 4 investigates the role of endotoxin tolerance on the development of microvascular 
dysfunction. During sepsis the microcirculation is affected resulting in compromised flow and 
decreased supply of oxygen and nutrients to organs which can potentially result in organ 
dysfunction. Using venous occlusion plethysmography, sidestream darkfield imaging and near-
infrared spectroscopy we showed that during acute human endotoxemia baseline microvascular 
flow is decreased and endothelial dysfunction is present. Endothelial dysfunction can be detected 
either by an attenuated endothelium-dependent ischemia-mediated increase in tissue 
oxygenation (measured by near infrared spectroscopy) or by an attenuated pharmacologically-
induced endothelium-dependent vasodilatory response to intrabrachial administered 
acetylcholine (measured by venous occlusion plethysmography). We demonstrated that the 
development of endotoxin tolerance after 5 consecutive days of LPS administration restored flow 
patterns and endothelial function. 
 
Chapter 5 describes the of the effect of the development of endotoxin tolerance on  endothelial 
dysfunction. Our experiments have shown endothelial dysfunction to be present after a single 
LPS administration as indicated by the attenuated vasodilatory response of the forearm 
circulation to administration of endothelial-dependent vasodilator acetylcholine while the 
vasodilatory response to endothelial-independent sodium nitroprusside remains present. Our 
experiments also showed that endothelial function can be restored by both the development of 
endotoxin tolerance associated with attenuated cytokine levels, and by the administration of the 
selective iNOS inhibitor aminoguanidine. Administration of aminoguanidine one hour after the 
first LPS administration (during peak levels of circulating cytokines) restored endothelial function 
which suggests that upregulation of iNOS is the main contributor in inflammation-induced 
endothelial dysfunction in humans in vivo.  
 
Part C: Cross-tolerance  
Chapter 6 investigates whether endotoxin tolerance protects against ischemia-reperfusion injury 
as was found in animal studies. These animal studies showed that pretreatment with LPS 
protected against ischemia-reperfusion injury in the pancreas, kidney, liver and lung. Previous 
experiments showed that ischemia-reperfusion resulted in a profound inflammatory response 
and this inflammatory response was thought to be partially responsible for the injury observed. 
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Therefore, attenuation of this inflammatory response, as observed during endotoxin tolerance, 
could protect against ischemia-reperfusion injury, however studies performed in humans are 
absent.  
 
In our model we induced ischemia-reperfusion in one arm with the other arm serving as a control. 
Ischemia was induced by inflating an upper arm blood pressure cuff for 10 minutes. After this 
period radiolabeled annexin A5 was administrated to allow ischemia-reperfusion injury to be 
visualized by use of a gamma camera. Annexin A5 binds to phosphatidylserine molecules which 
are present on the outer membrane as an early sign of apoptosis or reversible ischemia. The 
ischemia-reperfusion experiments were performed before the first LPS administration and 
repeated after 5 consecutive days of LPS administrations.  
We showed that endotoxin tolerance does not provide protection against mild ischemia-
reperfusion injury, measured by 99mTc-annexin A5 scintigraphy. It appears likely that lack of 
protection by endotoxin tolerance is due to the mild ischemic stimulus in our study, as the 
forearm circulation was occluded only for 10 minutes to induce transient ischemia. In addition, 
measurements of complement activation following the ischemic insult showed no activation of 
the complement cascade, which is another indication that either the stimulus used was too mild 
or possibly other pathways are involved. 
 
In Chapter 7 we investigated the possible protective effect of endotoxin tolerance with regard to 
the kidney. 
Organ failure during sepsis is not only caused by hemodynamic instability, but also by the 
activation of the inflammatory cascade. We demonstrate that subclinical renal injury occurs 
during repeated LPS administrations in humans as a small increase in serum creatinine levels was 
observed on day 3 that was no longer present after 5 days of LPS administration. Furthermore, 
we used urinary proteomics to search for markers to identify renal injury at an early stage. An 
example of such a marker is beta2-microglobuline, this protein was present in the urinary samples 
within 4 hours after the first LPS administration, while serum creatinine levels remained 
unchanged. In addition, we found 4 peak intensities of unknown origin which correlated 
significantly with the increase in serum creatinine levels on day 3 and therefore may act as 
potential biomarkers for inflammation-induced renal injury. During repeated LPS administrations, 
protein loss through the kidney subsided, including beta2-microglobuline levels, which suggests 
that endotoxin tolerance provides protection against inflammation-induced renal injury in 
humans.  
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Part D: Review 
Chapter 8 ends with an overview of the conducted experiments. Endotoxin tolerance provided 
protection against endothelial dysfunction, microcirculatory flow alterations and inflammation-
induced renal injury. In the future, endotoxin tolerance may be used in elective vascular or 
transplantation surgery to limit the complications related to disrupted microcirculatory flow and 
endothelial dysfunction. Human in vivo studies are warranted to explore this putative beneficial 
effect that represents a novel therapeutic possibility.  
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Summary in Dutch (Nederlandse samenvatting)  
 
In dit proefschrift worden een aantal aspecten van ‘endotoxinetolerantie’ bij de mens 
bestudeerd. Deze tolerantie houdt in dat het lichaam minder reageert op endotoxine indien dit 
herhaald wordt toegediend. Uit onderzoek bij dieren blijkt dat na herhaalde toediening van 
endotoxine een normaliter letale dosering niet langer meer tot de dood leidt. Induceren van 
endotoxinetolerantie bij de mens kan in sommige omstandigheden potentieel gunstige effecten 
hebben, waaronder bescherming tegen ischemie-reperfusieschade, bescherming van de 
microcirculatie en bescherming tegen het optreden van nierschade.  
 
Introductie 
Hoofdstuk 1 beschrijft endotoxine en endotoxinetolerantie in het algemeen.  
Endotoxine (lipopolysaccharide, LPS) is een deel van de buitenste laag van de celwand van een 
gram-negatieve bacterie. Endotoxine komt vrij als de bacterie dood gaat of zich vermenigvuldigt 
in het lichaam bij een ernstige infectie of bloedvergiftiging (sepsis). Als endotoxine vrijkomt, 
wordt het herkend door een bepaalde receptor, de Toll-like-4 receptor (TLR-4), welke zich bevindt 
op immuuncellen die verantwoordelijk zijn voor het opruimen van een bacteriën in het lichaam. 
Zo wordt een cascade in gang gezet die onder andere leidt tot productie van pro- en anti-
inflammatoire ontstekingseiwitten, cytokines genaamd. Deze cytokines helpen bij het doden van 
de bacteriën en perken de infectie in, maar aan de andere kant kan een overmatige productie van 
deze cytokines leiden tot schade aan organen en uiteindelijk eventueel zelfs tot de dood van de 
patiënt. 
 
Als er geen infectie is met een echte bacterie, maar gezuiverd endotoxine wordt toegediend leidt 
dit ook tot een ontstekingsreactie, omdat het lichaam (via de TLR-4) een bacterie denkt te 
herkennen. Het toedienen van endotoxine kan op deze manier worden gebruikt om aspecten van 
de ontstekingsreactie bij dier en mens te onderzoeken. 
In de dertiger jaren van de vorige eeuw werd koorts opgewekt middels de toediening van 
endotoxine, als deel van de therapie tegen syfilis. Al snel bleek dat na herhaalde toedieningen van 
LPS de koortsreactie steeds minder werd en er dus een hogere dosering endotoxine gegeven 
moest worden om dezelfde mate van temperatuurverhoging te bewerkstelligen. Dit was feitelijk 
het eerste voorbeeld van het ontwikkelen van endotoxinetolerantie bij de mens. 
Later bleek dat endotoxinetolerantie niet alleen beschermt tegen de gevolgen van een nieuwe 
endotoxinetoediening, maar ook tegen andere soorten schade, zoals ‘ischemie-
reperfusieschade’. Ischemie-reperfusieschade treedt op als een orgaan of weefsel na afsluiting 
van de bloedtoevoer opnieuw doorbloed wordt. Dit gebeurt bijvoorbeeld na een hartinfarct als 
na het verwijderen of oplossen van het stolsel in een kransslagader de doorbloeding van de 
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hartspier hersteld wordt. Niet alleen de ischemie maar ook de reperfusie zorgt voor lokale 
weefselschade. Bij dieren die voorafgaand aan het afsluiten van een bloedvat endotoxine 
toegediend hebben gekregen, is de ischemie-reperfusieschade sterk verminderd. 
Endotoxinetolerantie biedt dus bescherming tegen ischemie-reperfusieschade, een fenomeen dat 
‘kruistolerantie’ wordt genoemd.  
Al meer dan honderd jaar wordt endotoxine in onderzoeksverband toegediend aan gezonde 
vrijwilligers omdat het een gecontroleerde manier is om verschillende aspecten van ontsteking en 
de gevolgen ervan op diverse systemen in het menselijk lichaam te onderzoeken. Ongeveer een 
uur na het toedienen van de endotoxine ervaart de proefpersoon de maximale klachten zoals 
rillingen, hoofdpijn, rugpijn en misselijkheid en begint de hartfrequentie en lichaamstemperatuur 
op te lopen met een milde daling van de bloeddruk. In het bloed wordt na de endotoxine 
toediening een stijging gezien van alle pro- en anti-inflammatoire cytokines. Na ongeveer 20 
minuten is LPS uit het lichaam verdwenen terwijl de reactie op de endotoxine in het lichaam nog 
enige uren doorgaat. 
In ons onderzoek hebben wij gezonde vrijwilligers gedurende 5 opeenvolgende dagen 
endotoxine toegediend met de intentie endotoxinetolerantie te induceren. Na 5 dagen van 
endotoxinetoedieningen reageerden de proefpersonen niet meer zoals boven beschreven na de 
eerste toediening van endotoxine. Ook in het bloed lieten nagenoeg alle cytokines geen stijging 
meer zien na de 5e toediening van endotoxine, dit alles wijst op de ontwikkeling van 
endotoxinetolerantie.   
 
Deel A:  Mechanisme van endotoxinetolerantie 
Hoofdstuk 2 beschrijft de ontwikkeling van endotoxinetolerantie in vitro. Bloed, afgenomen van 
gezonde vrijwilligers voorafgaand en na een eenmalig toediening van endotoxine, werd in het 
laboratorium gestimuleerd met wederom endotoxine maar ook met liganden voor de andere Toll-
like receptoren, die bijvoorbeeld bacterieel DNA of virussen herkennen, om te onderzoeken of er 
ook ’kruistolerantie’ optreedt met andere TLR’s. Er werd aangetoond dat kruistolerantie 
aanwezig is voor bepaalde (TLR-3 en -5), maar niet alle TLR stimuli (TLR-2 en -7). 
Daarnaast werd de rol van NO bij het ontstaan van deze kruistolerantie onderzocht. Daarom werd 
bij de gezonde vrijwilligers een uur na een eenmalig endotoxinetoediening gestart met 
aminoguanidine, een selectieve remmer van het enzym induceerbare NO-synthase (iNOS). Dit 
leidde ertoe dat voor een bepaalde groep van de TLR-stimuli (TLR-5) de tolerantie werd 
opgeheven, terwijl voor andere TLR-stimuli het ontstaan van tolerantie niet beïnvloed werd. De 
rol van NO bij het ontstaan van tolerantie is complex en afhankelijk van de Toll-like receptor die 
wordt gestimuleerd en het cytokine dat wordt gemeten. 
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Hoofdstuk 3 beschrijft de ontwikkeling van endotoxinetolerantie bij gezonde vrijwilligers die 
gedurende 5 opeenvolgende dagen endotoxine krijgen toegediend. 
Wij onderzochten de hypothese dat endotoxinetolerantie ontstaat door een toegenomen 
productie van met name het anti-inflammatoire cytokine Interleukine-10 (IL-10), maar ook van 
Transforming growth factor-beta (TGFß) en Interleukine-1 receptor antagonist (IL-1ra). Onze 
experimenten tonen aan dat na de eerste toediening van LPS alle pro- en anti-inflammatoire 
cytokines stijgen, maar dat na 5 dagen LPS toediening een uitgesproken remming te zien is van 
zowel pro- als anti- inflammatoire cytokines met uitzondering van het anti-inflammatoire cytokine 
TGFß. Wellicht speelt TGFß derhalve een rol in de ontwikkeling van endotoxinetolerantie bij de 
mens in vivo. Anderzijds lijkt het anti-inflammatoire cytokine IL-10, dat van groot belang lijkt bij in 
vitro en dierexperimenteel onderzoek, bij de mens in vivo geen rol van betekenis te spelen.   
 
Deel B:  Microcirculatie en Endotheelcel dysfunctie 
In hoofdstuk 4 wordt beschreven hoe acute endotoxinemie en endotoxinetolerantie de 
microcirculatie beïnvloeden. Het is bekend dat tijdens sepsis de microcirculatie sterk verslechterd 
waarbij de bloeddoorstroming stagneert waarbij de zuurstof- en nutriëntbevoorrading in het 
gedrang komt naar de achterliggende organen. Met behulp van 3 verschillende methodieken 
(veneuze occlusie plethysmografie, sidestream dark-field imaging en near-infrared spectroscopie) 
toonden wij aan dat tijdens acute endotoxinemie (na 1 endotoxinetoediening) de 
bloeddoorstroming en reactiviteit afneemt in deze kleinste bloedvaten. Echter, na 5 herhaalde 
toedieningen van endotoxine waren de stroomsnelheden weer genormaliseerd en de reactiviteit 
van de bloedvatwand herstelde. Wij concludeerden dat het ontstaan van endotoxinetolerantie 
gepaard gaat met minder ontstekingsgerelateerde verstoring van de  microcirculatie.  
 
In hoofdstuk 5 wordt het effect van endotoxinetolerantie op endotheelceldysfunctie beschreven. 
Endotheelcellen vormen de binnenbekleding van bloedvaten en zijn voor een groot deel 
verantwoordelijk voor de wandspanning en daarmee de bloeddruk. Tijdens sepsis daalt, onder 
andere door toegenomen NO-productie, deze wandspanning en daarmee de bloeddruk. Hierdoor 
reageren patiënten ook minder op medicijnen die vaatvernauwend werken.  
Wij toonden aan dat na eenmalige endotoxinetoediening ‘endotheelceldysfunctie’ ontstaat. 
Endotheel-afhankelijke vaatverwijding was verminderd na een eenmalig toediening van 
endotoxine, terwijl de endotheel-onafhankelijke vaatverwijding intact bleef. 
Inductie van endotoxinetolerantie leidde tot een herstel van endotheelfunctie. Herstel kon ook 
worden bewerkstelligd door toediening van de iNOS-remmer aminoguanidine. Hierbij moet 
vermeld worden dat endotheelceldysfunctie niet optrad als aminoguanidine gegeven werd op het 
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moment dat de concentratie van verschillende cytokines het maximum had bereikt. Hiermee 
concluderen wij dat met name de door cytokines geïnduceerde NO-productie verantwoordelijk is 
voor het ontstaan van endotheelceldysfunctie tijdens inflammatie en niet de cytokines zelf.  
 
Deel C: Kruistolerantie 
In hoofdstuk 6 wordt onderzocht of endotoxinetolerantie leidt tot vermindering van ischemie-
reperfusieschade zoals beschreven bij dierexperimenteel onderzoek. De dierstudies laten zien dat 
een voorbehandeling met endotoxine beschermt tegen ischemie-reperfusieschade onder andere 
in de alvleesklier, nier, lever en long. Ischemie-reperfusieschade wordt voor een deel veroorzaakt 
door de inflammatiereactie. De door endotoxinetolerantie veroorzaakte onderdrukking van deze 
inflammatoire reactie na ischemie-reperfusie zou een verklaring kunnen zijn voor het ontstaan 
van kruistolerantie. Bij de mens is dit nooit eerder onderzocht.  
Wij maakten gebruik van een model waarin de gezonde vrijwilligers een ischemie-experiment 
ondergingen in één onderarm terwijl de andere onderarm als controle diende ter beoordeling van 
het effect. Ischemie werd opgewekt door opblazen van een bloeddrukmanchet om de bovenarm 
gedurende 10 minuten.  Met behulp van radioactief gelabelde annexine A5 is het mogelijk om 
middels een scan van beide handen de mate van ischemie-reperfusie schade zichtbaar te maken 
in de experimentele hand in vergelijking met de controle hand. Annexin A5 bindt aan 
phosphatidylserine moleculen aanwezig aan de buitenkant van een celmembraan direct na 
ischemie als teken van vroege celdood of nog reversibele ischemie. De ischemie-reperfusie 
experimenten werden voorafgaand aan en na 5 dagen endotoxinetoedieningen uitgevoerd, 
zodat bepaald kon worden of het ontstaan van endotoxinetolerantie effect had op de schade die 
ontstaat door ischemie-reperfusie. 
Wij toonden aan dat endotoxinetolerantie geen bescherming biedt tegen het ontstaan van 
ischemie-reperfusieschade. Uiteraard zijn de ischemie-reperfusie experimenten bij de mens vrij 
mild. Wij konden aantonen dat deze niet gepaard gingen met activatie van het 
complementsysteem als uiting van een ontstekingsreactie veroorzaakt door de ischemie-
reperfusie. Het ontbreken van een ontstekingreactie is mogelijk de verklaring van het feit dat 
endotoxinetolerantie geen gunstig effect heeft op ischemie-reperfusie schade in onze 
experimenten.  
Er is thans dus niet met zekerheid te zeggen dat endotoxinetolerantie niet beschermend werkt in 
situaties die gepaard gaan met meer uitgesproken zuurstoftekort, zoals bij grote vaatchirurgie of 
bij electieve orgaantransplantaties.  
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In hoofdstuk 7 wordt het beschermende effect van endotoxinetolerantie onderzocht met 
betrekking tot de nier.  
Orgaanschade tijdens sepsis wordt niet alleen veroorzaakt wordt door een verminderde 
doorbloeding van het orgaan, maar ook door de activatie van het immuunsysteem en de lokale 
inflammatie reactie. Tijdens onze endotoxinetolerantie-experimenten ontstaat een geringe en 
reversibele stijging van de creatininewaarden in het bloed op dag 3. Deze geringe nierschade is na 
5 dagen van endotoxine toedieningen weer volledig verdwenen.  
In deze experimenten onderzochten wij met behulp van proteomics ook naar de aanwezigheid 
van nieuwe markers van nierschade in de urine. Deze nieuwe markers kunnen een rol spelen bij de 
vroegdiagnostiek van nierschade bij sepsis. Een voorbeeld van een nierschademarker is ß2-
micoglobuline. Dit eiwit was na de eerste endotoxinetoediening al aantoonbaar in de urine terwijl 
de serum creatininespiegel als maat voor nierschade nog normaal was. Daarnaast vonden we op 
dag 1 van de endotoxinetoedieningen 4 andere eiwitten in de urine die een correlatie vertoonden 
met de ernst van de gemaakte nierschade gemeten op de 3e dag. Op de 5e dag waren deze 
eiwitten in de urine niet meer aantoonbaar. Endotoxinetolerantie lijkt derhalve een beschermend 
effect  tegen inflammatie-geinduceerde nierschade te bewerkstelligen.  
 
Deel D  Review 
Hoofdstuk 8 is een samenvatting van alle resultaten van onze experimenten in het licht van 
eerder onderzoek rondom endotoxinetolerantie. Endotoxinetolerantie resulteert in onze 
experimenten in een beschermend effect op endotheelceldysfunctie en bloeddoorstroming in de 
microcirculatie en verder lijkt het te beschermen tegen het optreden van nierschade dat ontstaan 
is door inflammatie. Bescherming tegen het ontstaan van schade ten gevolge van ischemie-
reperfusie konden we niet aantonen.  
In de praktijk zou dit betekenen dat een patiënt die een electieve grote vaatoperatie of 
orgaantransplantatie moet ondergaan, vooraf endotoxinetolerant gemaakt zou kunnen worden 
om postoperatief minder complicaties zoals dysfunctie van de  microcirculatie en 
endotheelfunctie door te maken.  
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